10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2013
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from ________________ to ________________

Commission file number: 333-148722

BOLDFACE GROUP, INC.

(Exact name of registrant as specified in its charter)

Nevada	02-0811868
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1309 Pico Blvd., Suite A, Santa Monica, CA	90405
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:  (310) 450-4501

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

Yes  x  No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x  No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  o  No x

As of February 14, 2014, there were 154,929,596 shares of the registrant’s common stock outstanding.

BOLDFACE GROUP, INC.

TABLE OF CONTENTS

		Page
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		1
PART I FINANCIAL INFORMATION		2
	CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2013 (UNAUDITED) AND JUNE 30, 2013	2
	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2013 AND 2012 (UNAUDITED)	3
	CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED DECEMBER 31, 2013 AND 2012 (UNAUDITED)	4
	NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)	5-27
ITEM 1.	FINANCIAL STATEMENTS	2
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	28
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK	36
ITEM 4.	CONTROLS AND PROCEDURES	36
PART II OTHER INFORMATION
ITEM 1.	LEGAL PROCEEDINGS	37
ITEM 1A.	RISK FACTORS	38
ITEM 2.	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS	45
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	45
ITEM 4.	MINE SAFETY DISCLOSURES	45
ITEM 5.	OTHER INFORMATION	45
ITEM 6.	EXHIBITS	45
SIGNATURES		46

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q for the quarter ended December 31, 2013 (this “Form 10-Q”) contains “forward-looking statements” (within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the Private Securities Litigation Reform Act of 1995) relating to the Company and its subsidiaries that are based on the beliefs of the Company’s management as well as information that is currently available to the Company’s management.  When used in this Form 10-Q, the words “may”, “will”, “believe”, “expects”, “anticipates”, “intends”, “estimates”, “projects”, “target”, “goal”, “plans”, “objective”, “should”, or similar expressions or variations on such expressions are intended to identify forward-looking statements. Such forward-looking statements include, in particular, projections about the Company’s future results and statements about its plans, strategies, business prospects, changes and trends in its business and the markets in which it operates.  All statements other than statements of historical fact are forward-looking statements.  There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from these forward-looking statements, including, but not limited to, the availability and pricing of additional capital to finance our operations, competition, material adverse changes in economic and industry conditions, retention and renewal of existing license agreements and entry into new license agreements.  Because these forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by any forward-looking statements. The Company does not undertake any obligation to publicly update any forward-looking statements.

1

PART I

FINANCIAL INFORMATION

ITEM 1.    FINANCIAL STATEMENTS

BOLDFACE GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

	December 31, 2013			June 30, 2013
	(UNAUDITED)
ASSETS
Current assets:
Cash and cash equivalents	$	26,431		$	388,892
Accounts receivable		9,199			100,087
Due from factor, net		244,970			164,090
Inventory (net of reserve of $200,000 and $365,772, as of December 31, 2013 and June 30, 2013, respectively)		2,049,503			1,948,908
Prepaid inventory		307,376			258,531
Prepaid expenses and other current assets		78,449			89,786
Current portion of prepaid royalty		8,055			378,960
Current portion of deferred financing costs, net		157,138			29,899
Total current assets		2,881,121			3,359,153
Property and equipment, net		617,414			669,033
Deferred financing costs, net		133,059			328,893
License acquisition costs		20,298			24,504
Total assets	$	3,651,892		$	4,381,583
LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities:
Accounts payable	$	3,642,532		$	2,481,852
Accrued expenses and other current liabilities		1,067,818			806,553
Current portion of convertible debt, net of debt discount ($596,021 and $116,524, as of December 31, 2013 and June 30, 2013, respectively)		589,312			23,476
Due to Gold Grenade, LLC (related party)		234,550			-
Total current liabilities		5,534,212			3,311,881
Long-Term Liabilities
Convertible debt, net of debt discount ($485,798 and $1,281,760, as of December 31, 2013 and June 30, 2013, respectively)		624,869			258,240
Derivative liability		527,606			1,660,440
Total Long-Term Liabilities		1,152,475			1,918,680
Total Liabilities		6,686,687			5,230,561
Commitments and Contingencies (Note 7)
Shareholders' deficit:
Preferred stock, $.001 par value, 10,000,000 shares authorized, zero issued and outstanding		-			-
Common stock, $.001 par value, 300,000,000 shares authorized, 155,829,276 and 155,301,468 shares issued as of December 31, 2013 and June 30, 2013 respectively		155,829			155,301
Treasury stock, at cost - 999,680 and 999,680 shares as of December 31, 2013 and June 30, 2013, respectively		(228,284	)		(228,284	)
Additional paid in capital		7,211,525			6,841,822
Accumulated deficit		(10,173,865	)		(7,617,817	)
Total shareholders' deficit		(3,034,795	)		(848,978	)
Total liabilities and shareholders' deficit	$	3,651,892		$	4,381,583

The accompanying notes are an integral part of these condensed consolidated financial statements

2

BOLDFACE GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – UNAUDITED

(in thousands)

	Six Months Ended						Three Months Ended
	31-Dec-13			31-Dec-12			31-Dec-13			31-Dec-12
Revenues
Gross revenues	$	3,520,976		$	1,753,812		$	1,968,962		$	1,753,812
Discounts		782,521			227,543			499,861			227,543
Revenues, net of discounts		2,738,455			1,526,269			1,469,101			1,526,269
Cost of Goods Sold
Cost of goods sold		1,900,211			794,396			1,143,141			794,396
Gross Profit		838,244			731,873			325,960			731,873
Operating expenses:
Selling expenses		350,516			341,778			253,513			341,778
Research and development		11,189			23,012			5,747			3,473
Royalty expense		396,334			322,809			176,597			161,404
Professional fees		667,705			608,723			245,443			571,326
General and administrative expenses		1,697,022			1,392,179			1,015,521			731,830
Depreciation and amortization expense		234,969			74,176			126,598			74,176
Product development fee - related party		500,000			412,700			230,000			210,000
Total Operating Expense		3,857,735			3,175,377			2,053,419			2,093,987
Loss from operations		(3,019,491	)		(2,443,504	)		(1,727,459	)		(1,362,114	)
Other (income) / expenses:
Interest expense, net of interest income		782,482			296,135			413,016			296,135
Derivative liability (gain) / loss		(1,245,925	)		346,627			(375,334	)		406,803
Net loss	$	(2,556,048	)	$	(3,086,266	)	$	(1,765,141	)	$	(2,065,052	)
Net loss per share attributable to common shareholders—basic and diluted	$	(0.02	)	$	(0.04	)	$	(0.01	)	$	(0.02	)
Weighted average number of common shares used in computing —basic and diluted		154,397,805			87,188,180			154,491,758			87,773,384

The accompanying notes are an integral part of these condensed consolidated financial statements

3

BOLDFACE GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – UNAUDITED

(in thousands)

	Six Months Ended			Six Months Ended
	December 31, 2013			December 31, 2012
Cash flows from operating activities:
Net loss	$	(2,556,048	)	$	(3,086,266	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation expense		327,606			289,279
Shares issued for services		42,625			-
Inventory reserves		200,000			-
Amortization of license acquisition costs		4,206			1,342
Amortization of deferred financing costs		130,659			62,523
Amortization of debt discount		495,559			52,704
Depreciation		234,969			11,652
Derivative liability gain		(1,245,925	)		346,627
Change in operating assets and liabilities:
Accounts receivable		90,888			(905,496	)
Due from factor, net		(80,880	)		-
Prepaid royalty		370,905			272,808
License acquisition costs		-			(8,902	)
Inventory		(300,595	)		(626,677	)
Prepaid expenses and other current assets		11,337			(98,528	)
Prepaid inventory		(48,845	)		(570,806	)
Accounts payable		1,160,680			996,984
Customer deposits		-			13,470
Accrued expenses and other current liabilities		261,265			347,134
Due to Gold Grenade, LLC		234,550			(108,475	)
Net cash used in operating activities		(667,044	)		(3,010,626	)
Cash flows from investing activities:
Acquisition of property and equipment		(183,351	)		(139,829	)
Net cash used in investing activities		(183,351	)		(139,829	)
Cash flows from financing activities:
Issuance of common stock, net of financing fees		-			771,235
Purchase of treasury stock and warrants		-			-
Proceeds from short term loans		-			1,335,000
Paydown of short term loans		-			(1,085,000	)
Factoring line of credit, net					536,144
Issuance of convertible debt		550,000			2,000,000
Payments for deferred financing fees in relation to convertible debt issuance		(62,065	)		(316,710	)
Net cash provided by financing activities		487,935			3,240,669
Net change in cash and cash equivalents		(362,461	)		90,214
Cash at beginning of period		388,892			71,532
Cash at end of period	$	26,431		$	161,746
Supplemental disclosures of cash flow information:
Cash paid during the year for:
Interest	$	59,161			210,228
Income Taxes		-			-
Non-cash financing activities:
Conversion of bridge notes and convertible debt		-			1,925,030
Contribution from shareholder of deferred financing cost		-			1,156,000
Other non-cash deferred financing fees from issuance of convertible debt		-			137,238
Fair value of conversion features and warrants issued in connection with equity and debt financing		113,091			5,203,574

The accompanying notes are an integral part of these condensed consolidated financial statements

4

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

NOTE 1.                         FORMATION AND NATURE OF BUSINESS

Organization

BOLDFACE Group, Inc. (“BLBK”) together with its wholly owned subsidiary BOLDFACE Licensing + Branding (“BLB” and collectively, the “Company”) was incorporated under the laws of the State of Nevada on July 9, 2007. On July 12, 2012, BOLDFACE Acquisition Corp., the Company’s wholly owned subsidiary, merged with and into BLB, with BLB remaining as the surviving entity (the “Merger”). As a result of the Merger, the Company acquired the business of BLB and has continued the existing business operations of BLB as the Company’s wholly owned subsidiary. In connection with the Merger, on August 14, 2012, the Company’s Board of Directors approved a change of the Company’s fiscal year end from September 30 to June 30.

For financial reporting purposes, the Merger represented a capital transaction of BLB or a “reverse merger” rather than a business combination, because the sellers of BLB effectively controlled the combined company immediately following the completion of the Merger. As such, BLB was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of BLB.

BLB was incorporated under the laws of the State of Nevada on April 26, 2012. BLB was founded by Ms. Nicole Ostoya, the Company’s Chief Executive Officer, President and a director, and Ms. Robin Coe-Hutshing, a principal shareholder of the Company. Ms. Ostoya and Ms. Coe-Hutshing are beauty industry veterans with over 40 years combined experience in the industry. BLB’s focus is on licensing top tier entertainment and designer brands for opportunities in the beauty, fragrance and personal care markets. BLB contracts to design, manufacture and sell branded color cosmetics, hair preparations, fragrances, home fragrances, skin care, beauty tools, and other beauty and personal care products in multiple channels of distribution.

To date, the Company has devoted its efforts to developing, marketing and selling its Kardashian Beauty™ brand in multiple retail channels, developing a line of products that will be marketed under its licenses with Mario Lopez and UGLYDOLL®, evaluating additional license agreements with additional celebrities and brands, and raising additional capital.

Basis of Presentation

The accompanying condensed consolidated financial statements as of December 31, 2013 and for the three and six month period ended December 31, 2012 are unaudited, but include all adjustments, consisting of normal recurring entries, which the Company’s management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of June 30, 2013 have been derived from the Company’s audited financial statements included in its Form 10-K for the year ended June 30, 2013 filed with the Securities and Exchange Commission (“SEC”) on October 15, 2013.

The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company’s audited financial statements in its Form 10-K for the year ended June 30, 2013. The Company’s operating results will continue to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

Going Concern and Liquidity

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  However, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to generate sufficient cash flow from its planned operations to meet its obligations on a timely basis, to raise additional equity and/or debt financing and through its factoring arrangements. In connection with the execution of its business plan, the Company anticipates additional increases in operating expenses and capital expenditures relating to: (i) payments under existing licenses, (ii) investments in inventory for our Kardashian Beauty™ brand; (iii) research and development costs associated with new product offerings, and (iv) management and consulting costs, as well as general administrative expenses, including the costs of being a public company. The Company intends to finance these expenses by raising additional capital and generating sufficient revenues to meet short-term and long-term operating requirements. If additional financings are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict its business operations. The Company currently does not have a specific plan of how it will obtain such funding; however, it anticipates that additional funding will be in the form of equity and/or debt financings and/or additional short-term borrowings. As such, these factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company continues to operate within its factoring agreement, which automatically renewed on November 21, 2013 for an additional one-year period.

The Company’s condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s auditors expressed substantial doubt about its ability to continue as a going concern in their audit report dated October 15, 2013, for the period ending June 30, 2013.

NOTE 2.                         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary BLB. All significant intercompany balances and transactions are eliminated in consolidation.

5

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Method of Accounting

The Company maintains its accounting records on the accrual method of accounting in conformity with GAAP. As of September 30, 2013, the Company reclassified the presentation of freight-out from cost of sales and has included the expense as a selling expense in the accompanying condensed consolidated statements of operations. As of December 31, 2013, the Company reclassified the presentation of commissions and fees from general and administrative expense and has included the expense as a selling expense in the accompanying condensed consolidated statements of operations.

Use of Estimates

In preparing the financial statements in conformity with GAAP, management makes estimates and assumptions that affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates on certain assumptions that it believes to be reasonable as of the reporting period, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most subjective and intricate estimates include inventory obsolescence reserves, certain accruals, returns and allowances and fair value calculations, including derivative liabilities and stock option expense.

Revenue Recognition

As required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable and collection is probable.

For the six months ended December 31, 2013, the Company achieved 46% of net revenues from international customers and 54% of net revenues from its domestic customers. For the three and six months ended December 31, 2012, the Company achieved 2% of net revenues from international customers and 98% of net revenues from its domestic customers.

For the three months ended December 31, 2013, the Company achieved 47% of net revenues from international customers and 53% of net revenues from its domestic customers.

The Company offers its customers a variety of sales and incentive programs, including discounts, allowances, coupons, slotting fees, and co-op advertising; such amounts are recorded as a reduction of revenue over the period in which revenue is recognized.

The Company reduced revenue in the amount of $782,520 and $227,543 for the six months ended December 31, 2013 and December 31, 2012, respectively, and such amounts are included in discounts in the accompanying condensed consolidated statement of operations.

The Company reduced revenue in the amount of $499,681 and $227,543 for the three months ended December 31, 2013 and December 31, 2012, respectively, and such amounts are included in discounts in the accompanying condensed consolidated statement of operations.

Fair Value Measurements

The Company’s financial instruments are primarily composed of cash, accounts receivable, factoring line of credit, accounts payable, and its convertible notes and warrants. The fair value of cash, restricted cash, accounts receivable, factoring line of credit, accounts payable and convertible notes closely approximates their carrying value due to their short maturities.

The valuation techniques utilized for the warrants and beneficial conversion feature of its convertible notes are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

The Company’s warrants and the beneficial conversion feature for its convertible notes are categorized within Level 3 of the fair value hierarchy. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company's accounting and finance department.

As of December 31, 2013, there were no transfers in or out of Level 3 from other levels.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

6

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Accounts Receivable

Accounts receivable balances represent payments due to the Company for previously recognized net sales, reduced by an allowance for doubtful accounts for balances, which are estimated to be uncollectible at December 31, 2013 and June 30, 2013, respectively. The Company grants credit terms in the normal course of business to its customers. The Company does not require collateral or other security to support credit sales. The allowance for doubtful accounts is determined based on historical experience and ongoing evaluations of the Company’s receivables and evaluations of the risks of payment. The allowance for doubtful accounts is recorded against accounts receivable balances when they are deemed uncollectible. When accounts are deemed significantly past due and uncollectible, the accounts receivable balances are written down for the amount deemed to be uncollectible. Recoveries of accounts receivable previously reserved are recorded in the consolidated statements of operations when received. As of December 31, 2013, all of the Company’s accounts receivable were deemed to be collectible. One customer accounted for 69% and 94% of outstanding accounts receivable as of December 31, 2013 and June 30, 2013, respectively.

Inventories

Inventories, which consist primarily of finished goods, include items which are considered salable or usable in future periods, and are stated at the lower of cost or market value, with cost being based on standard cost which approximates actual cost on a first-in, first-out basis. Costs include direct materials, direct labor and overhead (e.g., indirect labor, rent and utilities, depreciation, purchasing, receiving, inspection and quality control), and in-bound freight costs. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. During the six months ended December 31, 2013 and the twelve months ended June 30, 2013, the Company reserved $200,000 and $365,722, respectively, for write-offs. The inventory write-off as of June 30, 2013 was primarily due to the name change of its Kardashian Beauty™ brand, which forced the Company to destroy or mark for destruction finished goods and work-in-process. The inventory write-off reserve as of December 31, 2013 was for allowances related to liquidation of slower moving items and write-offs for obsolete inventory. Total inventories as of December 31, 2013 and June 30, 2013 were $2.050 million and $1.949 million, respectively.

Property and Equipment

Property and equipment as of December 31, 2013 consists of costs incurred by the Company in connection with installing display fixtures at certain key customer display rooms and retail stores. The display fixtures are being depreciated on a straight-line basis over two years, which approximates the estimated useful lives of such assets. Display fixtures maintained at customer display rooms and retail stores amounted to $617,414, net of accumulated depreciation, at December 31, 2013.

Depreciation expense amounted to $234,969 and $11,652 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is included in depreciation & amortization expense in the accompanying condensed consolidated statements of operations.

Depreciation expense amounted to $126,598 and $11,652 for the three months ended December 31, 2013 and December 31, 2012, respectively, and is included in depreciation & amortization expense in the accompanying condensed consolidated statements of operations.

Advertising

Advertising costs are expensed as incurred. Total advertising expenses amounted to $88,024 and $290,762 for the six months ended December 31, 2013 and December 31, 2012, respectively, and are included in general and administrative expenses in the accompanying condensed consolidated statements of operations. Total advertising expenses amounted to $53,394 and $100,181 for the three months ended December 31, 2013 and December 31, 2012, respectively, and are included in general and administrative expenses in the accompanying condensed consolidated statements of operations.

Selling Expenses and Commissions

Selling expenses are expensed as incurred. Total selling expenses amounted to $350,516 and $341,778 for the six months ended December 31, 2013 and 2012, respectively, and are included in operating expenses in the accompanying statements of operations. Total selling expenses amounted to $253,513 and $341,778 for the three months ended December 31, 2013 and 2012.

As of September 30, 2013, the Company reclassified the presentation of freight-out from cost of sales and has included the expense as a selling expense under operating expenses in the accompanying condensed consolidated statements of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Shipping expense is included in selling expense under operating expenses and amounted to $74,578 and $262,527 during the six months ended December 31, 2013 and December 31, 2012, respectively. Total shipping expense was $43,458 and $262,527 for the three months ended December 31, 2013 and 2012, respectively.

7

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Selling commissions are expensed as incurred. As of December 31, 2013, the Company reclassified the presentation of commissions and fees from general and administrative expenses and has included the expense as a selling expense under operating expenses in the accompanying condensed consolidated statements of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Total selling commissions amounted to $74,056 and $74,451 for the six months ended December 31, 2013 and 2012, respectively, and are included in selling expenses in the accompanying condensed consolidated statements of operations.  Total selling commissions amounted to $48,002 and $74,451 for the three months ended December 31, 2013 and 2012, respectively.

Deferred Financing Costs

Deferred financing costs represent fees paid in connection with obtaining short-term loans and convertible notes (see Notes 4, 5 and 6). These fees are amortized using a method that approximates the effective interest method over the term of the related financing.

As of December 31, 2013 and June 30, 2013, deferred financing costs of $290,197 and $358,792, respectively, net of accumulated amortization, are presented on the accompanying condensed consolidated balance sheets.

Amortization expense for deferred financing costs was $130,659 and $62,523 for the six months ended December 31, 2013 and 2012, respectively, is included in interest expense in the accompanying condensed consolidated statements of operations. Amortization expense for deferred financing costs was $69,075 and $62,523 for the three months ended December 31, 2013 and 2012, respectively, is included in interest expense in the accompanying condensed consolidated statements of operations.  The remaining deferred financing costs will be fully amortized by March 1, 2015.

Debt Discount

The Company records debt discounts in connection with raising funds through the issuance of convertible debt (see Note 5). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is charged to the statement of operations.

As of December 31, 2013 and June 30, 2013, convertible debt, net of unamortized debt discounts, was $1,214,181 and $281,716, respectively.

Amortization expense for debt discounts was $495,559 and $52,704 is included in interest expense in the accompanying condensed consolidated statements of operations for the six months ended December 31, 2013 and 2012, respectively. Amortization expense for debt discounts was $255,443 and $52,704 is included in interest expense in the accompanying condensed consolidated statements of operations for the three months ended December 31, 2013 and 2012, respectively. The remaining debt discounts will be fully amortized by March 1, 2015 (see Note 5).

Derivative Financial Instruments

GAAP requires derivative instruments embedded in convertible debt or equity instruments, to be bifurcated and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model, which management estimates to approximate the fair value using the Binomial Lattice Model. In assessing the debt instruments with characteristics of liability and equity, management determines if the convertible debt host instrument is conventional convertible debt and if there is a beneficial conversion feature. If the instrument is not considered conventional convertible debt, the Company will estimate the fair value of the embedded derivative instruments. The warrant liability is measured at fair value on a recurring basis using level 3 inputs (see Notes 5 and 6).

Financial Instruments and Concentrations of Business and Credit Risk

The Company’s financial instruments include cash and cash equivalents, convertible debt, a factoring line of credit, short-term loans, accounts payable and other current assets and liabilities.  The fair value of these instruments approximates their carrying value due to their relatively short maturities.  Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Customer concentrations also subject the Company to concentrations of credit risk.  The Company maintains cash balances that at times exceed amounts insured by the Federal Deposit Insurance Corporation.

8

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Three customers accounted for approximately 33%, 25% and 24% of the Company’s net revenues for the six months ended December 31, 2013. Three customers accounted for approximately 30%, 29% and 18% of the Company’s net revenues for the three months ended December 31, 2013. Three customers accounted for approximately 36%, 20% and 17% of the Company’s net revenues for the three and six months ended December 31, 2012.  

Accounts receivable for one customer represented 69% of the Company’s accounts receivable balance, prior to accrued discounts, as of December 31, 2013. Accounts receivable for one customer represented 94% of the Company’s accounts receivable balance as of June 30, 2013.

Three suppliers represented 33%, 15%, and 14% of the Company’s inventory purchases as of December 31, 2013.

The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area.

License Acquisition Costs

License acquisition costs represent legal fees paid in connection with obtaining the Company’s license agreements (see Note 3). These fees are amortized using the straight-line method over the term of each license agreement.

As of December 31, 2013 and June 30, 2013, license acquisition costs, net of amortization, were $20,298 and $24,504, respectively on the accompanying condensed consolidated balance sheets.

Amortization of license acquisition costs of $4,206 and $1,342 is included in depreciation and amortization expense in the accompanying condensed consolidated statements of operations for the six months ended December 31, 2013 and December 31, 2012. Amortization of license acquisition costs was $3,535 and $671 for the three months ended December 31, 2013 and December 31, 2012.

Estimated future license acquisition cost amortization expense is as follows:

Twelve month periods ending December 31,
2014	$	7,793
2015		7,793
2016		4,712
	$	20,298

Impairment of Long-Lived Assets

The Company evaluates long-lived assets and certain identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset.  In such cases, the carrying value of these assets are adjusted to their estimated fair value and assets held for sale are adjusted to their estimated fair value less selling expenses.  No impairment losses of long-lived assets or intangible assets were recognized for the six and three months ended December 31, 2013 and December 31, 2012.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date. The Company provides a valuation allowance against its deferred tax assets when circumstances indicate that it is no longer more likely than not that such assets will be realized.

9

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Net Loss Per Share

Basic net income / (loss) per share is computed by dividing net income / (loss) by the weighted average number of shares of common stock outstanding for the period. The Company’s potential dilutive shares, which include common stock options, common stock warrants and convertible debt have not been included in the computation of diluted net loss per share for all periods where there was a net loss as the result would be antidilutive. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share. Such potential shares of common stock consist of the following:

	As of December 31, 2013
Warrants		69,682,783
Stock options		17,780,000
Convertible Debt		33,764,706
		121,355,281

NOTE 3.                         PREPAID ROYALTIES

On July 11, 2012, the Company entered into a license agreement with an individual pursuant to which the Company (i) acquired the exclusive right to use the licensor’s image in connection with the development, production, distribution, advertisement, promotion and sale of products and (ii) the licensor agreed to provide certain ancillary services in connection with the marketing and promotion of the licensed products. The license agreement remains in effect through February 29, 2016.

During the term of the license agreement and as consideration for the grant of the license the Company has agreed to pay the licensor a royalty rate depending on the product sold on all net sales of all products during the contract term. In addition the Company has agreed to pay a guaranteed minimum royalty payment of $600,000 depending on the launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $100,000

· Contract period two: $225,000

· Contract period three: $275,000

As part of the license agreement, $100,000 was prepaid and is presented net of amortization of $100,000 under prepaid royalty as of December 31, 2013.

On April 25, 2013, the Company entered into a license agreement with an entity pursuant to which the Company (i) acquired the exclusive right to use the licensor’s image in connection with the development, production, distribution, advertisement, promotion and sale of products and (ii) the licensor agreed to provide certain ancillary services in connection with the marketing and promotion of the licensed products. The license agreement remains in effect through April 16, 2016.

During the term of the license agreement and as consideration for the grant of the license the Company has agreed to pay the licensor a royalty rate depending on the product sold on all net sales of all products during the contract term. In addition the Company has agreed to pay a guaranteed minimum royalty payment of $100,000 depending on the launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $33,333

· Contract period two: $33,333

· Contract period three: $33,334

10

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

As part of the license agreement, $10,000 was prepaid and is presented net of amortization of $1,945 under prepaid royalty as of December 31, 2013.

On May 9, 2012, the Company entered into a license agreement with three individuals pursuant to which the Company (i) acquired the exclusive right to use the licensors’ images in connection with the development, production, distribution, advertisement, promotion and sale of products and (ii) the licensors agreed to provide certain ancillary services in connection with the marketing and promotion of the licensed products. The license agreement remains in effect through November 30, 2016. The Company has the option to extend the term of the license agreement for an additional period of eighteen months.

During the term of the license agreement and as consideration for the grant of the license the Company has agreed to pay the licensors a single digit royalty depending on the product sold on all wholesale sales of all products during the contract term. In addition the Company has agreed to pay a guaranteed minimum royalty payment of $4,686,125 or $4,985,000 depending on the launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $1,000,000

· Contract period two: $925,000 or $1,000,000

· Contract period three: $1,188,625 or $1,285,000

· Contract period four: $1,572,500 or $1,700,000

In addition to the royalty payments and guaranteed minimum royalty payments, the Company granted the licensors warrants to purchase 10,000,000 common shares of the Company’s common stock on a cashless exercise basis.

As part of the license agreement, $1,000,000 was prepaid during period ended June 30, 2012 and is presented net of amortization of $1,000,000 under prepaid royalty as of December 31, 2013.

Contractual Obligations and Commitments:

The table below provides information concerning obligations of our contractual commitment as of December 31, 2013:

	Total		Less than 1 year		1 – 3 years		3 - 5 years		More than 5 years
License agreement obligations	$	7,417,125	$	1,185,278	$	3,389,722	$	2,842,125	$	0
Operating lease obligation	$	0	$	0	$	0	$	0	$	0
Total	$	7,417,125	$	1,185,278	$	3,389,722	$	2,842,125	$	0

NOTE 4.                         FACTORING AGREEMENTS AND SHORT - TERM LOANS

Factoring Agreements

Effective as of November 21, 2012, each of BLBK and BLB entered into a one-year Factoring Agreement (the “Factoring Agreements”) and Supply Agreement (the “Supply Agreements”) with Star Funding, Inc. Under the terms of the Factoring Agreements, the Company sells most of its trade receivables to the factor without recourse as to credit risk but with recourse for any claims by customers for adjustments in the normal course of business. The Company is able to borrow up to 80% of its factored receivables. Under the terms of the Supply Agreements, the Company is able to finance the purchases of its inventory.

For the six months ended December 31, 2013 and December 31, 2012, interest and commissions totaled approximately $59,907 and $36,765, respectively, under the Factoring Agreements and Supply Agreements. For the three months ended December 31, 2013 and December 31, 2012, interest and commissions totaled approximately $32,912 and $36,765, respectively, under the Factoring Agreements and Supply Agreements. Balances due from factor include outstanding accounts receivables from customers net of allowances for discounts and chargebacks, advances and interest due to factor. The Factoring Agreements and Supply Agreements limit the Company’s ability to: (i) incur additional debt, (ii) pay dividends or make distributions to its stockholders, (iii) incur liens that would rank senior in priority to, or pari passu with, the obligations under the Company’s the Factoring Agreements and Supply Agreements, (iv) sell certain assets, and (v) sell or otherwise dispose of any assets or rights of the Company or any of its subsidiaries, subject to certain exceptions. Substantially all of the Company’s assets are collateralized against the Factoring Agreements and Supply Agreements. The Company is continuing to operate under the existing Factoring Agreements and Supply Agreements until their renewal or cancellation, which automatically renewed on November 21, 2013 for an additional one-year period.

11

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Outstanding Factored Receivables	$	507,700
Less:
Advances and Deductions		(262,730	)
Unapplied Customer Credits		0
Due from Factor, Net	$	244,970

Short - Term Loans

During the six months ended December 31, 2012, the Company issued secured bridge loan promissory notes totaling in the aggregate $300,000 bearing interest at a rate of 10% per annum.

The promissory notes were issued in two installments:

· September 7, 2012 - $150,000, due by December 7, 2012

· September 25, 2012 - $150,000, due by December 25, 2012

As of March 28, 2013, the Company had re-paid the principal and accrued interest on all of the bridge loan promissory notes.

On November 9, 2012, the Company issued a short-term note in the principal amount of $60,000 to a stockholder of the Company bearing interest at an annual rate of 10%. As of December 21, 2012, the Company had re-paid the principal plus accrued interest on this promissory note.

On December 7, 2012, the Company issued a secured bridge loan promissory note totaling $100,000 bearing interest at a rate of 10% per annum. As of December 21, 2012, the Company has re-paid the principal plus interest on this promissory note.

On October 4, 2012, the Company entered into a Purchase Order Sale Agreement (the “PO Agreement”) with Solops LLC, under which it financed certain of its contracts of orders (or purchase orders) (the “Orders”), which represent amounts due from bona fide contracts for the sale and delivery of the Company’s goods to certain merchants, in the principal amount of $1,125,000. Pursuant to the PO Agreement, the Company sold the Orders to Solops for a purchase price of $875,000. Under the terms of the PO Agreement, Solops will receive $1,065,000 through a combination of the merchants’ payments under the Orders directly to Solops, the Company’s collection of accounts receivable under the Orders and resulting payments to Solops and/or any other payments made by the Company to Solops under the PO Agreement. Upon the full payment to Solops of $1,065,000, the PO Agreement will immediately terminate and Solops will convey, assign and deliver back to the Company the Orders and all of its rights thereunder. After such full payment is made, the Company will regain sole ownership of the Orders and it will not have any further obligations to Solops, and Solops will not have any further rights, with respect to the Orders or under the PO Agreement. As of November 21, 2012, the Company has re-paid its obligation under the PO Agreement.

NOTE 5.                         CONVERTIBLE DEBT OFFERINGS

August Convertible Notes Offering

On August 29, 2013, the Company issued senior secured convertible notes (the “August Convertible Notes”) with an original issue discount of 12% and a conversion price of $0.068 per share (the “August Conversion Price”) for gross proceeds of $616,000.  The term of the August Convertible Notes include an eighteen-month maturity period, with partial redemption beginning on September 1, 2014. The August Convertible Notes bear interest at a rate of 8% per annum, which is paid quarterly. Interest is payable in cash or at the Company’s option in shares of common stock, provided certain conditions are met, based on a share value equal to the lesser of (a) 90% of the average of the volume weighted average price (the “VWAP”) for the 20 consecutive trading days prior to the applicable interest payment date and (b) 100% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date less $0.01. Upon any Event of Default (as defined in the August Convertible Notes), the outstanding principal amount of each August Convertible Note, plus liquidated damages, interest, a premium of 30% and other amounts owing in respect thereof through the date of acceleration, shall become, at the noteholders’ election, immediately due and payable in cash.  Commencing five days after the occurrence of any Event of Default, the interest rate on each August Convertible Note shall accrue at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law.  The August Conversion Price is subject to  “full ratchet” and other customary anti-dilution protections.

As of February 14, 2014, with the timely filing of its Form 10-Q, the Company is in compliance with the covenants of the August Convertible Notes which require the timely filing of the Company’s periodic reports with the SEC. The August Convertible Notes limit the Company’s ability to (i) incur additional indebtedness, (ii) pay dividends or make distributions to its shareholders, (iii) incur liens that would rank senior in priority or pari passu to the August Convertible Notes, or (iv) sell or otherwise dispose of any assets or rights of the Company or its subsidiaries.

In connection with the issuance of the August Convertible Notes, warrants to purchase 9,058,824 shares of the Company’s common stock (“August Convertible Note Warrants”) were issued.  The August Convertible Note Warrants are exercisable for five years on a cashless basis. The August Convertible Note Warrants are exercisable at $0.082 per share and are subject to “weighted average” and other customary anti-dilution protections (see Note 6).

12

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

August Convertible Note Redemption

On September 1, 2014, October 1, 2014, November 1, 2014, December 1, 2014, January 1, 2015 and February 1, 2015, the Company is obligated to redeem an amount equal to $51,333 and on March 1, 2015, the Company is obligated to redeem an amount equal to $308,000 (plus accrued but unpaid interest, liquidated damages and any other amounts then owing in respect of the August Convertible Notes) (collectively, the “Periodic Redemption Amount”).  In lieu of a cash redemption and subject to the Company meeting certain equity conditions described in the August Convertible Notes, the Company may elect to pay the Periodic Redemption Amount in shares of its common stock based on a conversion price equal to the lesser of (a) $0.068 per share, subject to adjustments upon certain events, and (b) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable redemption date.

Debt Discounts

The fair value of the August Convertible Note Warrants and the corresponding Debt Conversion Feature, issued on August 29, 2013, totaling $113,091 is recorded as a debt discount in the accompanying consolidated condensed balance sheet as of December 31, 2013 and is amortized as interest expense in the accompanying condensed statements of operations over the term of the August Convertible Notes using the effective interest method (see Note 6).

Original Issue Discount

For certain convertible debt issue, the Company may provide the debt holder with an original issue discount. The August Convertible Notes were issued with an original issue discount of 12%. The original issue discount is recorded as debt discount, reducing the face amount of each August Convertible Note and is amortized to interest expense over the term of the August Convertible Notes.

August Convertible Note Face Value	$	616,000
Debt Discount
August Convertible Notes – Issued Warrant Derivative		87,264
Conversion Feature Derivative		25,827
Original Issue Discount		66,000
Total Debt Discount	$	179,091
Amortization of Debt Discount, as of December 31, 2013		(38,933	)
Debt Discount, Net	$	140,158
August Convertible Notes Carrying Value at December 31, 2013	$	475,842

Deferred Financing Costs

Transaction Fees

The Company paid $12,065, collectively, in legal fees to Gottbetter & Partners and Loeb & Loeb, and $50,000 in professional fees to the lead investor in the August Convertible Notes offering.

Legal fees and other fees associated with the August Convertible Notes offering	$	62,065
Total Deferred Financing Costs	$	62,065
Amortization of Deferred Financing Costs, as of December 31, 2013		(13,493	)
Deferred Financing Costs, Net, as of December 31, 2013	$	48,572

13

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

June Convertible Notes Offering

On June 20, 2013, the Company issued $1,500,000 senior secured convertible notes (the “June Convertible Notes”) with an original issue discount of 12%, and a conversion price of $0.068 per share (the “June Conversion Price”), for gross proceeds of $1,680,000.  The term of the June Convertible Notes includes an eighteen-month maturity period, with partial redemptions beginning on June 1, 2014. The June Convertible Notes bear interest at 8% per annum, which is paid quarterly beginning on November 1, 2013. Interest is payable in cash or at the Company’s option in shares of the Company’s common stock, provided certain conditions are met, based on a share value equal to the lesser of (a) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date and (b) 100% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date less $0.01.  Upon any Event of Default (as defined in the June Convertible Notes), the outstanding principal amount of the June Convertible Notes plus liquidated damages, interest, a premium of 30% and other amounts owing in respect thereof through the date of acceleration, shall become, at the holders’ election, immediately due and payable in cash.  Commencing five days after the occurrence of any Event of Default, the interest rate on the June Convertible Notes shall accrue at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law.  The June Conversion Price is subject to  “full ratchet” and other customary anti-dilution protections.

As of February 14, 2014, with the timely filing of its Form 10-Q, the Company is in compliance with the covenants of the June Convertible Notes which require the timely filing of the Company’s periodic reports with the SEC. The June Convertible Notes limit the Company’s ability to (i) incur additional indebtedness, (ii) pay dividends or make distributions to its shareholders, (iii) incur liens that would rank senior in priority or pari passu to the June Convertible Notes, or (iv) sell or otherwise dispose of any assets or rights of the Company or its subsidiaries.

In connection with the issuance of the June Convertible Notes, warrants to purchase 24,705,882 shares of the Company’s common stock (“June Convertible Note Warrants”) were issued. The June Convertible Note Warrants are exercisable for five years on a cashless basis. The June Convertible Note Warrants are exercisable at $0.082 per share and are subject to “weighted average” and other customary anti-dilution protections (see Note 6).

June Convertible Note Redemption

On June 1, 2014, July 1, 2014, August 1, 2014, September 1, 2014, October 1, 2014 and November 1, 2014, the Company is obligated to redeem an amount equal to $140,000 and on December 1, 2014, the Company is obligated to redeem an amount equal to $840,000 (plus accrued but unpaid interest, liquidated damages and any other amounts then owing in respect of the June Convertible Notes) (collectively, the “June Periodic Redemption Amount”).  In lieu of a cash redemption and subject to the Company meeting certain equity conditions described in the June Convertible Notes, the Company may elect to pay the June Periodic Redemption Amount in shares of its common stock based on a conversion price equal to the lesser of (a) $0.068 per share, subject to adjustments upon certain events, and (b) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable redemption date.

Debt Discounts

The fair value of the June Convertible Note Warrants and the corresponding Debt Conversion Feature, issued on June 20, 2013, totaling $1,423,177 is recorded as a debt discount in the accompanying condensed consolidated balance sheet as of December 31, 2013 and is amortized as interest expense in the accompanying condensed consolidated statements of operations over the term of the June Convertible Notes using the effective interest method (see Note 6).

14

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Original Issue Discount

For certain convertible debt issue, the Company may provide the debt holder with an original issue discount. The June Convertible Notes were issued with an original issue discount of 12%. The original issue discount is recorded to debt discount, reducing the face amount of each June Convertible Note and is amortized to interest expense over the term of the June Convertible Notes.

June Convertible Notes Face Value	$	1,680,000
Debt Discount
June Convertible Notes – Issued Warrant Derivative		752,126
Conversion Feature Derivative		491,051
Original Issue Discount		180,000
Total Debt Discount	$	1,423,177
Amortization of Debt Discount, as of December 31, 2013		(481,516	)
Debt Discount, Net	$	941,661
June Convertible Notes Carrying Value at December 31, 2013	$	738,339

Deferred Financing Costs

Transaction Fees

The Company paid Gottbetter Capital Markets (“GCM”) who acted as the sole placement agent for the June Convertible Notes offering a commission of 7.2% of the first $1,400,000 funds raised in the June Convertible Notes offering for a total payment of $100,000. In addition, GCM received five-year broker warrants to purchase approximately 1.9 million shares of the Company’s common stock at an exercise price of $0.082 per share (the “June Convertible Note Broker Warrants”). The June Convertible Note Broker Warrants are identical to the June Convertible Note Warrants in all material respects. The Company also paid $117,446 in legal fees to Gottbetter & Partners and $85,207 in professional fees to the lead investor in the June Convertible Notes offering.  The following table sets forth a summary of the fees and costs associated with the June Convertible Notes offering.

Placement agent and other fees associated with the June Convertible Notes offering	$	304,293
June Convertible Note Broker Warrants		60,886
Total Deferred Financing Costs	$	365,179
Amortization of Deferred Financing Costs, as of December 31, 2013		(123,554	)
Deferred Financing Costs, Net, as of December 31, 2013	$	241,625

December 2012 Convertible Notes Offering

On December 21, 2012 the Company issued senior secured convertible notes (the “Convertible Notes”).  The term of the Convertible Notes include an eight month maturity period and an annual interest rate of 12% which is accrued until payment or until the Convertible Notes are converted into equity. The Convertible Notes were issued at a price of $200,000 per unit, for total gross proceeds of $2,000,000 with an original issue discount of 0.2%.

The Convertible Notes are convertible at a per share conversion price of $0.25, which is subject to a one-time reset right (“Conversion Price Reset”) as well as “weighted average” and other customary anti-dilution protections (“Debt Conversion Feature”). The Conversion Price Reset will be available on the earlier of (the “Reset Date”) (i) the date of maturity of the 12% Notes or (ii) the completion of a subsequent financing by the Company of at least $5,000,000, if the closing price of the Company’s stock is less than $0.30 on the Reset Date. For (i) the conversion price after the reset will be equal to 70% of the 5-day VWAP immediately preceding the Reset Date. For (ii) the Conversion Price after the reset will be equal to 70% of 5-day VWAP immediately after the Reset Date.

In connection with the issuance of Convertible Notes, 8,000,000 five-year cashless exercise warrants (“Convertible Note Warrants”) were issued with “weighted average” and other customary anti-dilution protections. 4,000,000 Convertible Note Warrants are exercisable at $0.50 and 4,000,000 Convertible Note Warrants are exercisable at $1.00 (see Note 6 for further detail).

As of June 20, 2013, the Convertible Notes and the Convertible Note Warrants were converted into equity. The Convertible Notes were converted at a per share price of $0.07, as the Company’s stock price was less than $0.30 on the Reset Date, for 30,276,190 shares. The Convertible Note Warrants were converted into 7,000,000 shares of the Company’s common stock.

Debt Discounts

Convertible Note Warrants and Debt Conversion Feature

The fair value of the Convertible Note Warrants and the Debt Conversion Feature, issued as of December 21, 2012, totaling $1,353,720 was recorded as a debt discount in the accompanying balance sheet and was amortized as interest expense in the accompanying statement of operations over the term of the Convertible Note using the effective interest method (see Note 6 for further detail). As of June 30, 2013, the full value of this debt discount had been amortized as a result of the conversion of the Convertible Notes and Convertible Note Warrants into equity.

15

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Deferred Financing Costs

Transaction Fees

The Company paid Aegis Capital Corp. (“Aegis”), who acted as the sole placement agent for the Convertible Notes Offering a commission of 10% of the funds raised in the Convertible Notes Offering and a 3% non-accountable reimbursement of its expenses, for a total payment of $406,900, which is recorded as a deferred financing cost in the accompanying balance sheet.

The Company incurred additional fees of $96,556 for legal and escrow agent fees in connection with the Convertible Notes Offering, which are recorded as a deferred financing cost in the accompanying balance sheet.

Convertible Note Broker Warrants

In addition, Aegis received five-year warrants (the “Convertible Note Broker Warrants”) to purchase 1,600,000 shares of the Company’s common stock. The Convertible Note Broker Warrants were issued with “weighted average” and other customary anti-dilution protections. The Convertible Note Broker Warrants are identical to the Convertible Note Warrants in all material respects, except that they are exercisable at $0.25. As of June 20, 2013, the Convertible Note Broker Warrants were considered converted into 1,440,000 shares of common stock based on the same conversion terms as the Convertible Note Warrants. The Convertible Note Broker Warrants were valued at approximately $137,238 based on a Black-Scholes model (see Note 6 for further detail).

Third Party Share Sale

The Convertible Note holders were sold 4,000,000 free trading shares by non-affiliated, third party shareholders of the Company at par value. Although the Company was not a party to the sale of these shares by third party shareholders, per FASB ASC Topic 718, the fair value of this non-affiliated third party transaction is recognized by the Company as a deferred financing cost of the Convertible Note transaction. Additionally, the Company will provide no reimbursement or compensation to the selling shareholders of the 4,000,000 free trading shares. As such, the Company does not anticipate recognizing any further expenses in relation to this third-party transaction. The fair value of this third party transaction of $1,156,000 is recorded under deferred financing costs in the accompanying balance sheet.

NOTE 6.                         DERIVATIVE LIABILITY

As of December 31, 2013, the Company had reserved 69,682,783 shares of common stock for issuance upon exercise of the Company’s outstanding warrants. The Company had reserved 33,764,706 shares of common stock for issuance upon exercise of the Company’s outstanding convertible debt as of December 31, 2013.

In connection with the June and August Convertible Notes offerings, the Company entered into an Amendment and Waiver Agreement (collectively, the “Amendment Agreement”) the holders of substantially all of the securities issued in connection with the Company’s Bridge Notes (as defined below), PPO Units (as defined below), short-term loans and PPO and Bridge Broker Warrants (as defined below) with the holders (collectively, the “Holders”) pursuant to which the Company reduced the exercise prices of all of its outstanding Series A, Series B, Series C, Series D and Series E common stock purchase warrants (collectively, the “Warrants”) as follows: the exercise price per share of the Series A warrants that had an initial exercise price of $0.25 was reduced to $0.01; the exercise price per share of the Series B warrants that had an initial exercise price of $0.50 was reduced to $0.015; the exercise price per share of the Series C warrants that had an initial exercise price of $1.00 was reduced to $0.03; and the exercise price per share of the Series D and Series E warrants that had an initial exercise price of $0.25 was reduced to $0.01. As the triggering event for the re-pricing of the warrants was the June Convertible Notes offering, the effect of the reduction in the respective exercise prices was reflected in the June 30, 2013 statement of operations and accompanying balance sheet.

In consideration of the exercise price reductions, the Holders agreed to permanently waive all past and future exercise price and share number anti-dilution adjustment provisions that would otherwise be triggered by share issuances by the Company at prices less than the purchase, exercise or conversion price of any securities acquired by the Holders in the offerings or underlying any of such securities.

Bridge Notes

Upon the completion of the Merger, $1,925,030 in bridge notes (the “Bridge Notes”) converted into PPO Units. The holders of the Bridge Notes received 7,700,120 five-year bridge warrants (the “Bridge Warrants”), each exercisable to purchase one share of the Company’s Common Stock. 3,850,060 of the Bridge Warrants were originally exercisable at $0.25 per share (the “Series A Warrants”) and 3,850,060 of the Bridge Warrants (the “Series B Warrants”) were originally exercisable at $0.50 per share. As of August 29, 2013, the Series A warrants were modified to be exercisable at $0.01 per share and the Series B warrants were modified to be exercisable at $0.015 per share. Except as to exercise price, the Bridge Warrants are identical, in all material respects to the Investor Warrants (as defined below).

Licensor Warrants

The Company also issued to the certain licensors warrants to purchase an aggregate of 10,000,000 shares of the Company’s common stock for a term of ten years at an original exercise price of $0.24 per share (the “Licensor Warrants”). The exercise price and number of shares of common stock issuable upon exercise of the Licensor Warrants may be adjusted in certain circumstances including stock splits and stock dividends (but excluding future issuances of the Company’s equity securities, regardless of whether or not such issuance is for no consideration or for consideration per share less than $0.24). The Licensor Warrants are exercisable on a cashless basis at any time prior to their expiration. Except as otherwise described herein, the Licensor Warrants are identical in all material respects to the Investor Warrants. On May 8, 2013, the Company reduced the exercise price of the Licensor Warrants to $0.12 in consideration of value received.

16

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Private Placement Offering

Concurrently with the closing of the Merger, the Company completed an initial closing of a private placement offering (the “Offering”) wherein 500,000 units (the “PPO Units”) were sold, at a price of $0.25 per PPO Unit, for a total cash consideration of $125,000. Each PPO Unit consists of one share of the Company’s common stock and a warrant to purchase one share of the Company’s common stock (the “Investor Warrants”). The Investor Warrants are exercisable for a period of five years at a purchase price of $1.00 per share of the Company’s common stock. If at any time during the two year period following the closing of the Offering the Company issues additional shares of common stock for consideration per share of less than $0.25 (the “Reduced Price”), then the Company agreed to issue to the investors in the Offering, concurrently with such issue and without any additional consideration from the investors, a number of additional shares of the Company’s common stock and Investor Warrants equal to the difference between (A) the purchase price of the PPO Units being subscribed for divided by the Reduced Price and (B) the number of shares of the Company’s common stock included in the units being subscribed for in the subsequent offering. In addition, on July 12, 2012, the Company effected the conversion of $1,925,030 in Bridge Notes. The Bridge Notes were converted into 7,700,120 PPO Units and 7,700,120 five-year Investor Warrants each exercisable to purchase one share of the Company’s common stock. As of August 29, 2013, the Investor Warrants were modified to be exercisable at $0.03 per share.

On July 20, 2012, the Company completed the second closing of the Offering through the sale of 124,000 PPO Units (for aggregate gross proceeds of $31,000) consisting of 124,000 shares of common stock and 124,000 five-year Investor Warrants with an exercise price of $1.00.

On July 31, 2012, the Company completed the third closing of the Offering through the sale of 1,639,920 PPO Units (for aggregate gross proceeds of $409,980) consisting of 1,639,920 shares of common stock and 1,639,920 five-year Investor Warrants with an exercise price of $1.00.

On August 24, 2012, the Company completed the fourth closing of the Offering through the sale of 500,000 PPO Units (for aggregate gross proceeds of $125,000) consisting of 500,000 shares of common stock and 500,000 five-year Investor Warrants with an exercise price of $1.00.

On September 10, 2012, the Company completed the fifth closing of the Offering through the sale of 80,000 PPO Units (for aggregate gross proceeds of $20,000) consisting of 80,000 shares of common stock and 80,000 five-year Investor Warrants with an exercise price of $1.00.

On December 6, 2012, the Company completed the sixth closing of the Offering through the sale of 600,000 PPO Units (for aggregate gross proceeds of $150,000) consisting of 600,000 shares of common stock and 600,000 five-year Investor Warrants with an exercise price of $1.00.

On December 10, 2012, the Company completed the seventh closing of the Offering through the sale of 200,000 PPO Units (for aggregate gross proceeds of $50,000) consisting of 200,000 shares of common stock and 200,000 five-year Investor Warrants with an exercise price of $1.00.

On December 12, 2012, the Company completed the eighth closing of the Offering through the sale of 100,000 PPO Units (for aggregate gross proceeds of $25,000) consisting of 100,000 shares of common stock and 100,000 five-year Investor Warrants with an exercise price of $1.00.

On February 8, 2013, the Company completed the ninth closing of the Offering through the sale of 200,000 PPO Units (for aggregate gross proceeds of $50,000) consisting of 200,000 shares of common stock and 200,000 five-year Investor Warrants with an exercise price of $1.00.

As of August 29, 2013, the Investor Warrants, aggregating to 11,664,040 warrants, or the “Series C” Warrants, were modified to be exercisable at $0.03 per share.

In connection with the July 12, 2012 PPO closing, the Company issued an aggregate of 656,010 five year broker warrants with an exercise price of $0.25 per share. Effective as of December 31, 2013, 119,962 broker warrants have been cancelled with the repurchase of 999,680 shares. In connection with the July 20, 2012, July 31, 2012, August 24, 2012, and September 10, 2012 closings, the Company issued an aggregate of 187,514 five-year broker warrants with an exercise price of $0.25 per share. In connection with the December 6, 2012, December 10, 2012, and December 12, 2012 closings, the Company issued an aggregate of 72,000 five-year broker warrants with an exercise price of $0.25 per share. In connection with the February 8, 2013 closing, the Company issued 16,000 five-year broker warrants with an exercise price of $0.25 per share. As of August 29, 2013, the broker warrants, aggregating to 851,549 warrants, were modified to be exercisable at $0.01 per share.

17

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Short - Term Loans

In connection with two short-term notes that were issued on September 7, 2012 and an additional short-term note that the Company issued on September 24, 2012, for an aggregate principal amount of $300,000, the Company issued 1,200,000 warrants to holders of these notes (the “Series D Warrants”). These warrants are exercisable for a period of five years at a purchase price of $0.25 per share of the Company’s common stock. These warrants contain certain anti-dilution and other customary terms.

On March 28, 2013, in connection with a repayment of a short-term shareholder note, the Company issued an additional 150,000 five-year warrants to the holder to compensate the holder as the shareholder note was past due. The fair value of the warrants was $9,482 using a Black-Scholes model with the following assumptions: expected volatility of 70%, risk free interest rate of 0.83%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and debt discount on the balance sheet.  These warrants are exercisable for a period of five years at a purchase price of $0.25 per share of the Company’s common stock. These warrants contain certain anti-dilution and other customary terms.

As of August 29, 2013, the Series D warrants were modified to be exercisable at $0.01 per share.

Convertible Note Warrants

In connection with the Convertible Note offering on December 21, 2012, the Company issued 8,000,000 Convertible Note Warrants. 4,000,000 Convertible Note Warrants were exercisable at $0.50 and 4,000,000 Convertible Note Warrants were exercisable at $1.00.

The fair value of the warrants at issuance was estimated at $686,192 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and debt discount on the balance sheet.

Convertible Note Broker Warrants

In connection with the Convertible Note offering, the Company issued 1,600,000 Convertible Note Broker Warrants. 800,000 Convertible Note Broker Warrants are exercisable at $0.50 and 800,000 Convertible Note Warrants are exercisable at $1.00.

The fair value of the warrants at issuance was estimated at $137,238 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

Debt Conversion Feature

The Convertible Note offering on December 21, 2012 included a Debt Conversion Feature (see Note 5).

The fair value of the Debt Conversion Feature was estimated, using Level 3 inputs, at $663,528 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry.  

June and August Convertible Note Warrants

In connection with the June Convertible Note offering on June 20, 2013, the Company issued 24,705,882 June Convertible Note Warrants, which are exercisable at $0.082 and contain weighted average anti-dilution protections.

The fair value of the warrants at issuance was estimated at $752,126 using a Black-Scholes valuation model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and debt discount on the balance sheet.

In connection with the August Convertible Note offering on August 29, 2013, the Company issued 9,058,824 August Convertible Note Warrants, which are exercisable at $0.082 and contain weighted average anti-dilution protections.

The fair value of the warrants at issuance was estimated at $85,293 using a Black-Scholes valuation model with the following assumptions: expected volatility of 65%, risk free interest rate of 1.9%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded as a debt discount on the balance sheet.

June Convertible Note Broker Warrants

In connection with the June Convertible Note offering on June 20, 2013, the Company issued 1,912,195 Convertible Note Broker Warrants. The Convertible Note Broker Warrants are exercisable at $0.082.

The fair value of the warrants at issuance was estimated at $60,886 using a Black-Scholes valuation model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

18

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Founder Warrants

In connection with the acquisition of the Third License on April 17, 2013, the Company issued 2,500,000 warrants. The warrants are exercisable at $0.13.

The fair value of the warrants at issuance was estimated at $210,349 using a Black-Scholes valuation model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

Consultant Warrants

On April 8, 2013, the Company issued 500,000 five-year warrants with an exercise price of $0.25 to a consultant, engaged effective as of the same date for consulting services to the Company. The warrants shall vest ratably in arrears over six 30-day periods beginning on April 8, 2013, with one-sixth of the warrants vesting on each successive thirtieth day following April 8, 2013, subject to the termination of the consulting agreement prior thereto.

The fair value of the warrants at issuance was estimated at $42,625 using a Black-Scholes valuation model with the following assumptions: expected volatility of 65%, risk free interest rate of 1.57%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

Debt Conversion Feature

The June and August Convertible Note offerings included a Debt Conversion Feature (see Note 5).

The fair value of the Debt Conversion Feature of the June 20, 2013 closing was estimated, using Level 3 inputs, at $491,051 using a Black-Scholes model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of eighteen months and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry.

The fair value of the Debt Conversion Feature of the August 29, 2013 closing was estimated, using Level 3 inputs, at $25,827 using a Black-Scholes model with the following assumptions: expected volatility of 65%, risk free interest rate of 1.9%, expected life of eighteen months and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry.

Fair Value Measurement

The fair value at issuance of those warrants granted during the quarter ended September 30, 2012 was estimated at $3,788,687 using a Black-Scholes model with the following assumptions: expected volatility of 70%, risk free interest rate of 0.83%, expected life of 5.0 – 10.0 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The fair value at issuance of those warrants granted during the quarter ended December 31, 2012 was $888,596 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of 0.8 - 5.0 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The fair value at issuance of those warrants granted during the quarter ended March 31, 2013 was estimated at $297,716 using a Black-Scholes model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.005%, expected life of 5.0 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

19

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

The fair value at issuance of those warrants granted during the quarter ended June 30, 2013 was estimated at $1,067,196 using a Black-Scholes model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of eighteen months to 10 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The fair value at issuance of those warrants granted during the quarter ended September 30, 2013 was estimated at $155,716 using a Black-Scholes model with the following assumptions: expected volatility of 65%, risk free interest rate of 1.57% -1.90%, expected life of eighteen months to five years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The Company’s warrant liability was valued at December 31, 2013 using a Black-Scholes valuation model with the following assumptions: expected volatility of 80%, risk free interest rate of 2.1%, expected life of fourteen months – 10 years, based upon the term of the warrant or convertible note, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty industry. The following table is a roll forward of the fair value of the warrant liability:

	December 31,  2013			June 30, 2013
Beginning Balance	$	1,660,440		$	0
Issuance of Warrants		113,091			7,252,283
Repurchase / Exercise / Cancellation of Warrants		0			(179,884	)
Change in fair value		(1,245,925	)		(5,411,959	)
Ending Balance	$	527,606		$	1,660,440

The fair value of the Company’s outstanding warrants and derivative instruments was estimated at $527,606 and $1,660,440 as of December 31, 2013 and June 30, 2013. The (gain) / loss in the fair value of the warrants of $(1,245,925) and $346,627 for the six months ended December 31, 2013 and December 31, 2012, respectively, was recognized as a (gain) / loss in the derivative liability section on the accompanying condensed consolidated statement of operations. The (gain) / loss in the fair value of the warrants was $(375,334) and $406,803 for the three months ended December 31, 2013 and December 31, 2012, respectively.

NOTE 7.                         COMMITMENTS AND CONTINGENCIES

License Agreements

On May 9, 2012, the Company entered into a licensing agreement with the Licensors (see Note 3 for further detail).

During the term of the licensing agreement the Company has agreed to pay a guaranteed minimum royalty payment of $4,686,125 or $4,985,000 depending on launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $1,000,000

· Contract period two: $925,000 or $1,000,000

· Contract period three: $1,188,625 or $1,285,000

· Contract period four: $1,572,500 or $1,700,000

20

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

On July 11, 2012, the Company entered into the Second License (see Note 3). The Company agreed to pay a guaranteed minimum royalty payment of $600,000 depending on launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $100,000

· Contract period two: $225,000

· Contract period three: $275,000

On April 25, 2013, the Company entered into a licensing agreement with the Third Licensor (see Note 3). The Company agreed to pay a guaranteed minimum royalty payment of $100,000 depending on launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $33,333

· Contract period two: $33,333

· Contract period three: $33,334

Operating Lease

On May 8, 2012, the Company executed a one-year operating lease for its corporate office commencing on May 15, 2012 at a monthly rent payment of $1,785 per month. Total rent expense related to this operating lease was $10,710 and $10,620 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is included in general and administrative expenses in accompanying statement of operations. Total rent expense related to this operating lease was $5,355 for each of the three months ended December 31, 2013 and December 31, 2012. As of December 31, 2013, the lease has expired and the Company is renting the office space on a month-to-month basis.

On January 7, 2013, the Company executed a five-month operating lease for storage commencing on January 1, 2013 at a monthly rent payment of $1,500 per month. Total rent expense related to this operating lease was $9,000 and $0 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is included in general and administrative expenses in accompanying statement of operations. Total rent expense related to this operating lease was $4,500 and $0 for the three months ended December 31, 2013 and December 31, 2012, respectively. As of December 31, 2013, the storage space lease has expired and the Company is renting the space on a month-to-month basis.

Litigation

In the normal course of business, the Company may become involved in various legal proceedings. Except as described below, management knows of no pending or threatened legal proceeding to which they are or will be a party and which, if successful, might result in a material adverse change in our business, properties or financial condition.

On November 19, 2012, an action entitled Chroma Makeup Studio, LLC. v. BOLDFACE Group, Inc. and BOLDFACE Licensing + Branding was filed in the United States District Court for the Central District of California, Western Division (the “Court”). Chroma Makeup Studio, LLC (“Chroma”) alleged that the Company’s use of the term Khroma, including the marks Khroma Beauty and Khroma Beauty By Kourtney, Kim and Khloe (the “Khroma Beauty Marks”), for cosmetics is infringing upon Chroma's rights in its Chroma mark. The Complaint included claims for trademark infringement under the Lanham Act and unfair competition under applicable California law. The Court set a tentative trial date of April 22, 2014. The parties also agreed to pursue private mediation in an attempt to resolve the disputed issues in this case. On November 7, 2013, following private mediation, the parties agreed to settle the action and are currently negotiating the terms of a written settlement agreement. On December 11, 2013, the Company entered into a settlement agreement and mutual general release (the “Settlement Agreement”) with Chroma to settle any and all claims between the Company and Chroma. Pursuant to the terms of the Settlement Agreement, the parties have agreed that the terms of the Settlement Agreement are to remain confidential.  Pursuant to the terms of the Settlement Agreement, and with no admission of any liability, the Company has agreed to pay Chroma a cash amount over a period of one year commencing on December 31, 2013 and ending on December 31, 2014. The total cash amount that the Company has agreed to pay Chroma is lower than the amount the Company reserved for any payments to be made in connection the dispute.

21

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

On November 30, 2012, BLB filed a complaint for a declaratory judgment in the United States District Court for the Central District of California, Western Division entitled BOLDFACE Licensing + Branding v. By Lee Tillett, Inc. (“Tillett”). BLB’s complaint requests a declaration from the Court that (1) BLB’s use of the Khroma term, including the Khroma Beauty marks does not infringe on Tillett’s rights in its Kroma trademark, and (2) BLB’s two pending trademark applications for Khroma Beauty marks should be allowed to register with the USPTO. On January 9, 2013 Tillet filed an answer and counterclaims for (1) trademark infringement, (2) false designation of origin, (3) trademark infringement, and (4) unfair competition pursuant. In addition to BLB, Tillett's Counterclaims are made against the following additional parties: Kims a princess Inc., 2Die4Kourt Inc., Khlomoney Inc., and individuals Kim Kardashian, Kourtney Kardashian, and Khloe Kardashian (collectively, the "Kardashian Parties"). In March 2013, Tillet obtained a preliminary injunction enjoining BLB’s use of the Khroma Beauty mark. BLB appealed the injunction and moved for a stay in the Ninth Circuit. As a result, the injunction was stayed until May 31, 2013. The Ninth Circuit ruled on the Company’s motion on June 7, 2013 granting Tillett’s application and ruling that the preliminary injunction would be effective as of June 7, 2013. By the time the stay expired, BLB had already changed the name of its mark from Khroma Beauty by Kourtney, Kim and Khloe to Kardashian Beauty. On August 9, 2013, BLB and the Kardashian Parties filed a joint motion to dismiss the appeal. On August 2, 2013, the parties participated in mediation in an attempt to settle the case but were unable to do so. The Court set a tentative trial date of April 22, 2014.

On October 28, 2013, Tillett filed a motion to amend its counterclaim to add Gold Grenade, LLC as a counter-defendant and two additional claims: conspiracy and common law trademark infringement.  The Company and the Kardashian Parties have filed an answer to Tillett’s motion.  On November 18, 2013, the Court denied Tillett’s motion to amend its counterclaim.

The Company filed a motion for summary judgment, contending that Tillett could not prove that it suffered any damages based on the conduct of the BLB. On December 6, 2013, the Court issued an order to show cause re: contempt and sanctions against BLB based on allegations that BLB had distributed Khroma labeled product after the effective date of the preliminary injunction. As part of that order, the Court took off calendar the pending summary judgment motion and all remaining trial and pre-trial dates. The parties filed briefs regarding the alleged contempt and an evidentiary hearing was held on January 9, 2014, after which the Court took the matter under submission. As of the date of this filing, no ruling has been issued.

Based on the expressed willingness of BLB to settle the cases and the likely cost to continuing litigation, the Company has accrued for total settlement costs of less than $700,000 for any potential settlement offers.

Registration Agreement

As of December 31, 2013, the Company had 300,000,000 shares of common stock authorized. As of December 31, 2013, the Company had 155,829,276 shares issued and 155,591,438 shares outstanding.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are not entitled to receive dividends unless declared by the Company's Board of Directors.

PPO Offering Registration Rights

In connection with the Merger and Offering (as defined in Notes 1, 4 and 7), the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with each of the investors participating in the Offering. Under the Registration Rights Agreement, as amended, the Company committed to file a registration statement on Form S-1, or other applicable form (the “Registration Statement”), covering the resale of (i) the Company’s common stock underlying the Bridge Warrants (as defined in Note 6), (ii) common stock underlying the PPO Units (as defined in Note 6) sold or to be sold in the Offering, and (iii) common stock underlying the Investor Warrants (as defined in Note 6) (including securities issued in the Offering as a result of the conversion of the Bridge Notes (as defined in Note 6), but not common stock that is issuable upon exercise of the broker warrants issued to the placement agent for the Offering) (collectively, the “Registrable Securities”) no later than October 29, 2012 (the “Filing Date”), and to use commercially reasonable efforts to cause the Registration Statement to become effective no later than 150 days after it is filed (the “Effectiveness Date”). As of the date of this Quarterly Report the Company has not filed the Registration Statement with the SEC. The Company agreed to use its commercially reasonable efforts to maintain the effectiveness of the Registration Statement for at least one year from the date the Registration Statement is declared effective by the SEC or for such shorter period ending on the earlier to occur of (i) until Rule 144 of the Securities Act is available to investors with respect to all of their Registrable Securities or (ii) the date when all of the Registrable Securities registered thereunder shall have been sold.

22

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

The Company will be liable for liquidated damages at the rate of 1% of the purchase price per PPO Unit paid by each investor for the Registrable Securities then held by such investor for each full period of 30 days for which the Company fails to file the registration statement by the Filing Date or if the Company fails to have the Registration Statement declared effective by the Effectiveness Date (each, a “Registration Event”), until such failure is cured. The payment amount shall be prorated for partial 30-day periods. The aggregate penalty accrued with respect to each investor may not exceed 10% of the original purchase price paid by such investor. However, if a Registration Event occurs (or is continuing) on a date more than one year after July 12, 2012 or the final closing of the Offering, liquidated damages shall be paid only with respect to that portion of the Registrable Securities that cannot then be immediately resold in reliance on Rule 144. If the Company fails to pay any partial liquidated damages or refund pursuant in full within seven days after the date payable, the Company will pay interest thereon at a rate of 8% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the holder of the PPO Unit.

In December 2006, the FASB issued guidance on accounting for registration payment arrangements. This guidance specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement, should be separately recognized and measured in accordance with FASB guidance on accounting for contingencies. This guidance further clarifies that a financial instrument subject to a registration payment arrangement should be accounted for in accordance with GAAP without regard to the contingent obligation to transfer consideration pursuant to the registration payment arrangement. The Company applied the recognition and measurement provisions of the FASB guidance to the registration rights associated with the Registration Rights Agreement.

The Amendment Agreements also provided for a waiver of all penalties incurred by the Company under the terms of the PPO registration rights agreement as a result of the Company’s failure to timely file and effect the registration for resale of the private placement securities.

Aegis Convertible Note Offering Registration Rights

In connection with two closings of convertible note offerings in December 2012 and March 2013, the Company also entered into a registration rights agreement with the Investors (the “Convertible Note Registration Rights Agreement”). Under the terms of the Convertible Note Registration Rights Agreement, the Company committed to file a registration statement on Form S-1, or other applicable form, covering the resale of (i) the Common Stock underlying the Warrants and (ii) the Common Stock underlying the Notes (collectively, the “Convertible Note Registrable Securities”) within 45 days from the final closing of the Offering (the “Filing Date”), and to use its commercially reasonable efforts to cause the registration statement to become effective no later than 90 days after it is filed (the “Effectiveness Date”).

The Company agreed to use its commercially reasonable efforts to maintain the effectiveness of the registration statement for at least one year from the date the registration statement is declared effective by the SEC or for such shorter period ending on the earlier to occur of (i) until Rule 144 of the Securities Act of 1933, as amended (the “Securities Act”), is available to Investors with respect to all of their Convertible Note Registrable Securities or (ii) the date when all of the Convertible Note Registrable Securities registered thereunder shall have been sold. The Company will be liable for monetary penalties equal to 0.5% of the purchase price per Unit paid by such Investor for the Convertible Note Registrable Securities then held by each investor for each full period of period of 30 days if the Company fails to file the registration statement by the Filing Date or if the Company fails to use its reasonable efforts to have the registration statement declared effective by the Effectiveness Date until such failure is cured. The payment amount shall be prorated for partial 30-day periods. The maximum aggregate amount of payments to be made by the Company as the result of such failures, whether by reason of a filing deadline failure, effectiveness deadline failure or any combination thereof, shall be an amount equal to 6% of the purchase price per Unit paid by such Investor for the Convertible Note Registrable Securities held by such Investor at the time of the first occurrence of such failure to file with, or to have the registration statement be declared effective by, the United States Securities and Exchange Commission (the “SEC”).

23

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Moreover, no such payments shall be due and payable with respect to any Convertible Note Registrable Securities that the Company is unable to register due to limits imposed by the SEC’s interpretation of Rule 415 under the Securities Act. The holders of any Convertible Note Registrable Securities removed from the registration statement as the result of a Rule 415 comment or other comment from the SEC shall have “piggyback” registration rights for the shares of Common Stock underlying the Convertible Note Registrable Securities, until such shares can be sold without limitation under Rule 144, with respect to any registration statement filed by the Company following the effectiveness of the registration statement which would permit the inclusion of these shares.

During the period ended December 31, 2013, the Company has recorded total liabilities of $206,381 in accrued expenses on the accompanying condensed consolidated balance sheet associated with the above registration rights.

NOTE 8.                         EQUITY TRANSACTIONS

On December 31, 2013, the Company issued 337,838 shares of common stock to a board member per the compensation package of said board member, fair valued at $6,250.

NOTE 9.                         STOCK COMPENSATION EXPENSE AND FAIR VALUE MEASUREMENT

In July 2012, the Company's Board of Directors adopted the 2012 Stock Option and Incentive Plan (the "2012 Equity Incentive Plan"). The 2012 Equity Incentive Plan provides for the grants of incentive and non-qualified stock options, restricted stock and other equity awards to employees, officers, directors, consultants and advisors of the Company. Provisions such as vesting, repurchase and exercise conditions, and limitations are determined by the Board of Directors on the grant date. There are 20,000,000 shares of the Company’s Common Stock reserved for issuance under its 2012 Equity Incentive Plan.

As of December 31, 2013, the Company has issued an aggregate of 17,780,000 common shares for future issuance upon exercise of outstanding and future grants of common stock options and future issuances of restricted stock awards pursuant to the Company's 2012 Equity Incentive Plan.

Effective as of July 12, 2012 the Company issued 4,600,000 stock options under its 2012 Equity Incentive Plan to the Company’s CEO, a consultant and the Chairman of the Board of Directors; 3,600,000 of which have a five-year term and 1,000,000 of which has a ten-year term. All of the options are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.24 per share. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the Merger, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date. As of December 31, 2013, 1,000,000 options have been forfeited.

Effective as of August 15, 2012 the Company issued 400,000 stock options under its 2012 Equity Incentive Plan to certain of the Company’s employees and consultants. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.24 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date. As of December 31, 2013, 2,500 options have been forfeited.

Effective as of November 21, 2012 the Company issued 500,000 stock options under its 2012 Equity Incentive Plan to the Company’s newly appointed director. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.24 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

24

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

Effective as of March 28, 2013 the Company issued 500,000 stock options under its 2012 Equity Incentive Plan to the Company’s newly appointed director. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.17 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of April 8, 2013 the Company issued 500,000 stock options under its 2012 Equity Incentive Plan to the Company’s newly appointed director. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.14 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of June 28, 2013 the Company issued 50,000 stock options under its 2012 Equity Incentive Plan to two of the Company’s directors pursuant to the Company’s board compensation package, effective as of March 15, 2013. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.05 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of July 12, 2013 the Company issued 11,400,000 stock options under its 2012 Equity Incentive Plan to the Company’s CEO and a consultant. The options have a five-year term. All of the options are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.06 per share. Such options, which will vest annually at a rate of 33% beginning on the first anniversary of the grant date, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of August 15, 2013 the Company issued 1,357,500 stock options under its 2012 Equity Incentive Plan to certain of the Company’s employees and consultants. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.05 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

As of December 31, 2013, 1,527,500 stock options had been forfeited.

25

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model. The expected life assumption is based on the estimated forfeiture rate. Expected volatility is based on a blend of the volatility of the Company and similar public entities in the beauty industry. The risk-free interest rate is the yield currently available on U.S. Treasury five-year and seven-year zero-coupon issues approximating the expected term used as the input to the Black-Scholes model. FASB accounting guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods as options vest, if actual forfeitures differ from those estimates. During the six months ended December 31, 2013, because substantially all of the Company's stock option grants vest annually, stock-based employee compensation expense includes the actual impact of forfeitures. No stock options are exercisable as of December 31, 2013. The relevant inputs used to determine the value of the stock option grants is as follows:

	Number of options outstanding		Weighted average risk-free rate			Expected life in years		Expected  volatility			Expected  dividends
July 12, 2012		3,600,000		0.83	%		3.5		70	%		0	%
August 15, 2012		397,500		0.83	%		6.0		70	%		0	%
November 21, 2012		500,000		0.95	%		6.0		60	%		0	%
March 28, 2013		0		1.005	%		6.0		55	%		0	%
April 8, 2013		500,000		1.685	%		6.0		55	%		0	%
June 28, 2013		25,000		1.685	%		6.0		55	%		0	%
July 12, 2013		11,400,000		1.715	%		3.5		65	%		0	%
August 15, 2013		1,357,500		1.860	%		6.0		65	%		0	%
Total		17,780,000

The fair value of the Company’s outstanding options issued to non-employees was $27,119 as of December 31, 2013. These options were valued at December 31, 2013 using a Black-Scholes model with Level 3 inputs. Expected volatility was based on the volatility of similar public entities in the beauty industry.

As a result, share-based compensation expense totaled $315,106 and $289,279 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is recorded in general and administrative expenses. Share-based compensation expense totaled $161,803 and $159,131 for the three months ended December 31, 2013 and December 31, 2012, respectively.

NOTE 10.                      INCOME TAXES

The Company did not incur any income tax expense for the three and six months ended December 31, 2013. At December 31, 2013, $2,746,569 of federal and state net operating losses were available to the Company to offset future taxable income, which will expire in 2033. Given the short history of the Company and the uncertainty as to the likelihood of future taxable income, the Company has recorded a 100% valuation reserve against the anticipated recovery from the use of the net operating losses created at the inception or generated thereafter. The Company will evaluate the appropriateness of the valuation allowance on an annual basis and adjust the allowance as considered necessary.

The Company’s effective tax rate differs from the federal statutory rate of 34% primarily due to the impact of state income taxes and the valuation allowance recorded against its deferred tax assets.

	December 31, 2013
Statutory rate		34.0	%
State income taxes		6.0	%
Permanent differences		(15.7	)%
Valuation allowance		(21.4	)%
Other		(2.7	)%
Total		0.0	%

26

BOLDFACE GROUP, INC.

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE INTERIM PERIOD ENDED DECEMBER 31, 2013

(UNAUDITED)

The principal components of deferred tax assets and (liabilities) are as follows as of December 31, 2013 and June 30, 2013 on a tax effected basis:

	December 31, 2013			June 30, 2013
Net operating losses carryforward	$	2,159,286		$	2,002,842
Start-up costs and fixed assets, net of amortization		120,011			60,005
Property and equipment		126,955			56,270
Stock based compensation		340,217			192,786
Gross deferred taxes	$	2,746,569		$	2,311,903
Valuation allowance		(2,746,569	)		(2,311,903	)
Net deferred taxes	$	-		$	-

The Company follows the provisions of FASB ASC Subtopic 740-10-65-1, Income Taxes. As of December 31, 2013 and June 30, 2013, respectively, the Company did not recognize any liability for unrecognized tax benefits.

Section 382 of the Internal Revenue Code can limit the amount of net operating losses, which may be utilized if certain changes to a company’s ownership occur. While the Company underwent a shift in ownership in 2013 as defined by Section 382 of the Internal Revenue Code, the Company has not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code, it may incur limitations in the future if there is a change in ownership.

The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at December 31, 2013. There are no income tax examinations currently in process and as of the date of this report.

NOTE 11.                      RELATED PARTY TRANSACTIONS

The Company entered into a consulting agreement with Gold Grenade, LLC (“Gold Grenade”), a related entity co-owned by two of the shareholders to receive product development services. As of December 31, 2013 and December 31, 2012, $234,550 and $149,898, respectively, was due to Gold Grenade. For the six months ended December 31, 2013 and December 31, 2012, the Company incurred approximately $500,000 and $412,700 respectively, in product development fees payable to Gold Grenade. For the three months ended December 31, 2013 and December 31, 2012, the Company incurred approximately $230,000 and $210,000 respectively, in product development fees payable to Gold Grenade. The agreement is to remain in effect unless either party desires to cancel the agreement.

NOTE 12.                      SUBSEQUENT EVENTS

None.

27

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

BOLDFACE Group, Inc. (“BGI” and, together with its wholly-owned subsidiary BOLDFACE Licensing + Branding (“BLB”), the “Company”, “we”, “us” or “our”) is a celebrity beauty licensing and branding company focused on acquiring top-tier entertainment, celebrity and designer brands for opportunities in the beauty, personal care, home and fragrance markets. We contract to design, manufacture and sell branded color cosmetics, hair preparations, fragrances, home fragrances, skin care, beauty tools and other beauty products in multiple channels of distribution.  We currently own the brand Kardashian Beauty™, and have licensed the right to use the Mario Lopez brand to develop and distribute products in the male fragrance and men’s grooming categories and the UGLYDOLL® brand to develop and distribute products in the personal care category. Our vision for our Kardashian Beauty™ brand is to offer luxury products at affordable prices through mass retail channels. We have secured distribution of Kardashian Beauty™ products in over 5,100 points of distribution with retail partners, including, among others, CVS, ULTA Beauty, Duane Reade™, Fred Meyer®, meijer®, and Ricky’s NYC, and are currently in active discussions with other retailers to distribute Kardashian Beauty™ products.

RECENT DEVELOPMENTS – RESULTS OF OPERATIONS

Overview

During the quarter ended December 31, 2013, we achieved top-line gross and net revenue of $1.969 million and $1.469 million, respectively compared to $1.754 million and $1.526 million for the quarter ended December 31, 2012.  During the quarter ended December 31, 2013, we continued to work on the expansion of our Kardashian Beauty™ brand through securing additional international points of distribution as well as developing seasonal and core-line products that we believe are both unique and high-quality; thereby, building on our strategy of bringing luxury products at an affordable price for distribution to mass retailers. We also continued to work on the development of our lines of products that will be branded under our Mario Lopez and UGLYDOLL® licenses.

Kardashian Beauty™ License

We had net revenues of $2.738 million and a gross margin of 31% from our Kardashian Beauty ™ license for the six months ended December 31, 2013 compared $1.526 million and a gross margin of 48% for the six months ended December 31, 2012.  Our gross margin as of December 31, 2013 was impacted by the name change of our Kardashian Beauty ™ brand due to the re-labeling efforts and associated costs to update our products as well as a reserve for inventory liquidation and write-offs for slow moving inventory. The Kardashian Beauty™ brand currently consists of four categories of products: eyes (38 SKUs), lips (40 SKUs), face/body (24 SKUs), and nails (46 SKUs). Since inception, we have garnered over 139 million media impressions for the Kardashian Beauty™ brand in print and online media channels.  We have secured distribution for the Kardashian Beauty™ brand in over 5,100 points of distribution with U.S. retail partners, including, among others, CVS, ULTA Beauty, Duane Reade™, Fred Meyer®, meijer®, and Ricky’s NYC. We have also secured international distribution relationships in the European Union, Middle East, Australia and South Africa.

We had net revenues of $1.469 million and a gross margin of 22% from our Kardashian Beauty ™ license for the three months ended December 31, 2013 compared $1.526 million and a gross margin of 48% for the three months ended December 31, 2012. Our net revenues for the three months ended December 31, 2013 represented 54% of the revenues for the six months ended December 31, 2013 primarily due to sales of seasonal items as well as improving our in-stock position for our core items in the quarter. Our gross margin for the three months ended December 31, 2013 was negatively impacted by an inventory reserve of $0.200 million for inventory liquidations as well as seasonal items that have a lower gross margin as compared to our core line.

Mario Lopez License

We are currently in the product development phase for the products that will be branded under our Mario Lopez license.  We expect to complete development and launch our product line by the end of 2014.  Accordingly, no revenue was generated from our Mario Lopez license for the three and six months ended December 31, 2013 and December 31, 2012.

UGLYDOLL® License

We are currently in the product development phase for the products that will be branded under our UGLYDOLL® license.  We expect to complete development and launch our product line by the end of 2014.  Accordingly, no revenue was generated from our UGLYDOLL® license for the three and six months ended December 31, 2013 and December 31, 2012.

28

FACTORING AND SUPPLY AGREEMENTS

Effective as of November 21, 2012, the Company and BLB each entered into a (i) Factoring Agreement, dated as of October 17, 2012 (the “Factoring Agreements”), with Star Funding, Inc. (“Star Funding”) pursuant to which Star Funding provides financing, on a discretionary basis, against our purchase orders, accounts, contract rights and other obligations for the payment of money, and (ii) Supply Agreement, dated as of October 17, 2012 (the “Supply Agreements”), with Star Funding pursuant to which Star Funding provides to us, on a discretionary basis, factoring and financial accommodations to enable the Company to purchase cosmetics and related products (collectively, the “Goods”).  Each of the Factoring and Supply Agreements is for an initial term of one year, subject to automatic one-year renewals or early termination as provided therein.

Under the Factoring Agreements, Star Funding has agreed to purchase certain of our accounts receivable. We agreed to pay Star Funding a factoring commission of between 1.0% and 1.5% of the gross amount of each account receivable subject to the Factoring Agreements, depending on the total gross amounts of account receivables purchased and the actual duration of the selling terms. As of December 31, 2013, $0.245 million was due from factor.

The financing under the Supply Agreements may be made via direct payment to the Company’s suppliers, issuance of letters of credit and/or advances to the Company.  Under the Supply Agreements, the Company is required to pay Star Funding an amount equal to 5.0% per month of all Expenses (as such term is defined in the Supply Agreements) associated with the purchase of any Client-Assembled Goods (as such term is defined in the Supply Agreements), and (b) 2.0% of all Expenses associated with the purchase of any Pre-Assembled Goods (as such term is defined in the Supply Agreements) for the initial 30-day period, provided that such fee shall be reduced to 1.0% for each subsequent 15-day period until the date on which all of the Expenses have been paid in full in cash under the Supply Agreements. As of December 31, 2013, $0 was outstanding under the Supply Agreements.

MERGER WITH BOLDFACE LICENSING + BRANDING

On July 12, 2012, our wholly-owned subsidiary, BOLDFACE Acquisition Corp. (“Acquisition Corp.”), merged with and into BLB, with BLB remaining as the surviving entity (the “Merger”). As a result of the Merger, each outstanding share of BLB common stock was cancelled and converted into 200 shares of our common stock resulting in the issuance of an aggregate of 20,000,000 shares to former BLB stockholders. As part of the Merger, we also issued 5,000,000 shares of our common stock to stockholders of BLB in proportion to their ownership of shares of BLB common stock, in connection with the execution of the License Agreement with Pez-Mar, Via Mar Productions Inc., a corporation wholly owned by Mario Lopez, dated as of July 11, 2012.

The Merger Agreement, dated as of July 12, 2012 (the “Merger Agreement”), executed in connection with the Merger contained customary representations, warranties and covenants of the Company and Acquisition Corp. The Merger Agreement provides for a post-closing adjustment in an aggregate amount of up to 1,000,000 additional shares of our common stock issuable pro rata to BLB’s pre-Merger stockholders for any breach of the Merger Agreement by us that is discovered during the two-year period following the closing date. The Merger Agreement also provided that 5% of the 20,000,000 shares of our common stock (the “BLB Escrowed Shares”) that BLB’s pre-Merger stockholders received in the Merger in exchange for shares of BLB common stock be held in escrow for any breach of the Merger Agreement by BLB that is discovered during the two-year period following July 12, 2012 pursuant to the terms of an Escrow Agreement, dated as of July 12, 2012, among us, the pre-Merger stockholders of BLB, and Gottbetter & Partners, LLP, as Escrow Agent. As of the date of this report, no breaches of the Merger Agreement have occurred.

In connection with the Merger, for a period of 24 months from the closing date except in certain limited circumstances, our officers, directors, key employees and holders of 10% or more of our common stock, calculated after giving effect to the Merger, who received shares of our common stock in connection with the Merger, agreed to “lock-up”, not sell or otherwise transfer or hypothecate directly or indirectly, or effect or agree to effect any short sale of, any of their shares of our common stock received in connection with the Merger.

29

In connection with the closing of the Merger, we issued warrants to purchase 10,000,000 shares of our common stock (the “Licensor Warrants”) to the licensors under the Kardashian Beauty™ license agreement.  The warrants are exercisable for a term of ten years.  The warrants were originally exercisable at $0.24 per share. Subsequently, we agreed with the warrant holders to lower the exercise price of the warrants to $0.12 per share.

For financial reporting purposes, the Merger represented a capital transaction of BLB or a “reverse merger” rather than a business combination, because the sellers of BLB effectively controlled the combined company immediately following the completion of the Merger. As such, BLB was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of BLB.

CAPITAL EXPENDITURES

As of December 31, 2013, we incurred capital expenditures of $0.183 million, which consisted of fixtures at certain key customer retail stores and display rooms.

RESULTS OF OPERATIONS

Revenues

We generated net revenues from operations of $2.738 million and $1.526 million for the six months ended December 31, 2013 and December 31, 2012, respectively. Net sales were generated from the successful launch of our Kardashian Beauty™ brand and securing retail points of distribution domestically and international distribution relationships.

We generated gross and net revenues from operations of $1.969 million and $1.469 million for the three months ended December 31, 2013. We generated gross and net revenues of $1.754 million and $1.526 million for the three months ended December 31, 2012, respectively. Our gross revenues for the three months ended December 31, 2013 improved over the three months ended December 31, 2012 as a result of sales of our core line in addition to seasonal items in the period ended December 31, 2013 as compared to only seasonal items in most points of distribution for the three months ended December 31, 2012, which were partially offset by an increase in discounts and reserves for discounts in the three months ended December 31, 2013.

Cost of Goods Sold

Cost of goods sold was $1.900 million and $0.794 million for the six months ended December 31, 2013 and December 31, 2012, respectively, or 69% and 52% of net revenues over the same period. The cost of goods sold includes direct materials, labor, overhead, and in-bound freight costs. As of December 31, 2013, we reclassified the presentation of freight-out from cost of sales and have included the expense as a selling expense in the accompanying statement of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Cost of goods sold also includes a reserve of $0.200 million and $0 for the six months ended December 31, 2013 and December 31, 2012 for inventory write-offs and write-downs.

Cost of goods sold was $1.143 million and $0.794 million for the three months ended December 31, 2013 and December 31, 2012, respectively, or 78% and 52% of net revenues over the same period. As compared to the prior period, the cost of goods sold during the period ended December 31, 2013 was negatively impacted by relabeling costs of our Kardashian Beauty™ line and reserves for inventory liquidation.

Operating Expenses

We incurred operating expenses from operations for the six months ended December 31, 2013 and 2012 of $3.858 million and $3.175 million, respectively. Our operating expenses primarily consisted of general and administrative expenses, selling expenses, professional fees, depreciation and amortization expense and product development fees paid to a related party. The increase in our operating expenses is due to the increase in royalty expense, general and administrative expense, depreciation and amortization expense related to our fixtures in customer locations, and product development fees to a related party. Our general and administrative expense for the six months ended December 31, 2013 was increased over the prior year primarily due to an increased reserve for penalties and settlements for our ongoing litigation (see Note 7 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q).

We incurred operating expenses from operations for the three months ended December 31, 2013 and 2012 of $2.053 million and $2.094 million, respectively. Our operating expenses for the three months ended December 31, 2013 were improved over the three months ended December 31, 2012 due to lower professional fees and selling expenses, primarily due to lower freight-out costs, offset by higher product development fees and increased general and administrative expense as a result of reserves for penalties and settlements as discussed above.

Losses from Operations

We incurred operating losses of $3.019 million and $2.444 million for the six months ended December 31, 2013 and 2012, respectively. The main components of the recorded operating loss during both periods were general and administrative expenses, professional fees, depreciation and amortization expense and product development fees paid to a related party.

Our operating loss for the three months ended December 31, 2013 and 2012 was $1.727 million and $1.362 million, respectively. Our operating loss for the three months ended December 31, 2013 was primarily impacted by our gross margin of 22% for the three months ended December 31, 2013 as compared to 48% for the three months ended December 31, 2012.

Other (Income) / Expense

We incurred other (income) / expenses for the six months ended December 31, 2013 and 2012 of $(0.463) million and $0.643 million, respectively. Our other (income)/expense for the three months ended December 31, 2013 and 2012 was $0.038 million and $0.703 million, respectively.  Our other (income) / expense primarily consisted of non-cash interest expense and derivative liability gains.

30

Net Losses

We incurred net losses in the amounts of $2.556 million and $3.086 million, of $0.02 and $0.04 per basic and diluted share for the six months ended December 31, 2013 and 2012, respectively, primarily due to our losses from operations and net interest expense, offset by a non-cash derivative liability gain.

Our net loss for the three months ended December 31, 2013 and 2012 was $1.765 million and $2.065 million, respectively, primarily due to our losses from operations, which were driven by higher cost of goods and increased general and administrative expense as a result of reserves for penalties and settlements partially offset by lower selling expenses as compared to the three months ended December 31, 2012.

LIQUIDITY AND CAPITAL RESOURCES

As of December 31, 2013, we had cash and cash equivalents of $0.026 million compared to $0.389 million as of June 30, 2013. We had negative working capital of $2.653 million at December 31, 2013 compared to positive working capital $0.047 million, including $0.589 million and $0.023 million of current portion of convertible debt net of debt discounts, at December 31, 2013 and June 30, 2013, respectively. The change is attributable to investments in inventory as we continue to grow the Kardashian Beauty™ brand, an increase in due from factor and an increase in short term debt due to our recent financings.

As of December 31, 2013, our total assets were $3.652 million, our total shareholders’ deficit was $3.035 million and our total liabilities were $6.687 million compared to $4.382 million in total assets, $0.849 million in shareholders’ deficit and $5.231 million in total liabilities as of June 30, 2013.

As of December 31, 2013, our assets were comprised of $0.254 million in accounts receivable and due from factor, $2.357 million in inventory and prepaid inventory, and $0.290 million in deferred financing costs. Our total liabilities were comprised primarily of $3.643 million in accounts payable, $1.068 million in accrued expenses and other liabilities, $0.528 million in long-term liabilities related to the value of our derivative instruments, and debentures in the net amount of $1.214 million.

As of June 30, 2013, our assets were comprised of $0.264 million in accounts receivable and due from factor, $2.207 million in inventory and prepaid inventory, $0.379 million in prepaid royalty, and $0.359 million in deferred financing costs. Our total liabilities were comprised primarily of $2.482 million in accounts payable and $1.660 million in long-term liabilities related to the value of our derivative instruments, debentures in the net amount of $0.282 million and accrued expenses of $0.807 million.

We have limited cash reserves and need a substantial amount of capital to implement our business plan. To date, we have financed our operations from proceeds generated by the private placement of equity and convertible debt instruments and through our factoring line of credit. In connection with our business plan, management anticipates continuing to have operating expenses and capital expenditures relating to: (i) payments under existing licenses, (ii) investments in inventory for our Kardashian Beauty™ brand; (iii) research and development costs associated with new product offerings, and (iv) management and consulting costs, as well as general administrative expenses, including the costs of being a public company. We intend to finance these expenses by raising additional capital and generating sufficient revenues to meet our short-term and long-term operating requirements. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations. We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the form of equity and/or debt financing and/or additional short-term borrowing.

Net Cash Used in Operating Activities

During the six months ended December 31, 2013, we used net cash in operating activities of $0.667 million related to losses in net income and investments in inventory offset primarily by increases in accounts payable and accrued expenses. We spent $3.011 million for operating activities during the six months ended December 31, 2012 in relation to our net loss as well as investments in inventory and prepaid inventory, increases in accounts receivable for the launch of our Kardashian Beauty™ line, which were partially offset by increases in accounts payable and accrued expenses.

Net Cash Used in Investing Activities

Net cash used in investing activities was $0.183 million and $0.140 million during the six months ended December 31, 2013 and December 31, 2012. Net cash used in investing activities was attributable to the acquisition of property and equipment.

31

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $0.488 million and $3.241 million during the six months ended December 31, 2013 and December 31, 2012.  Net cash provided by financing activities for the six months ended December 31, 2013 was primarily attributable to a convertible note we issued to an existing investor. Net cash provided by financing activities for the six months ended December 31, 2012 was attributable to short term loans and proceeds from convertible debt.

GOING CONCERN

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  However, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to generate sufficient cash flow from its planned operations to meet its obligations on a timely basis and ultimately attain profitability. The Company’s ability to continue as a going concern is also dependent upon its ability to obtain additional equity and/or debt financing or ability to generate sufficient revenue to cover its operating expenses. Additional financing may not be available upon acceptable terms, or at all.

To date, the Company has financed its operations from the proceeds generated from the private placement of equity, convertible debt instruments as well as through its factoring arrangements. In connection with the execution of its business plan, the Company anticipates additional increases in operating expenses and capital expenditures relating to: (i) payments under existing licenses, (ii) investments in inventory for our Kardashian Beauty™ brand; (iii) research and development costs associated with new product offerings, and (iv) management and consulting costs, as well as general administrative expenses, including the costs of being a public company. The Company intends to finance these expenses by raising additional capital and generating sufficient revenues to meet short-term and long-term operating requirements. If additional financings are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict its business operations. The Company currently does not have a specific plan of how it will obtain such funding; however, it anticipates that additional funding will be in the form of equity and/or debt financings and/or additional short-term borrowings. As such, these factors raise substantial doubt as to the Company’s ability to continue as a going concern.

The Company’s condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s auditors expressed substantial doubt about its ability to continue as a going concern in their audit report dated October 15, 2013, for the period ending June 30, 2013.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The presentation of our financial statements are impacted by the accounting policies used and the estimates and assumptions made by management during their preparation. A complete listing of these policies is included in Note 2 – Summary of Significant Accounting Policies of the notes to our unaudited condensed consolidated financial statements for the six months ended December 31, 2013 included elsewhere in this Form 10-Q. Below, we have identified the accounting policies that are of particular importance in the presentation of our financial statements, results of operations and cash flows, and which require the application of significant judgment by management.

Use of Estimates

In preparing our financial statements in conformity with generally accepted accounting principles in the United States (“GAAP”), management makes estimates and assumptions that affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates include the fair value of warrant liabilities, debt discount and the ability to realize deferred tax assets. Actual results could differ from these estimates.

Revenue Recognition

As required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification   (“ASC”) Topic 605, Revenue Recognition, we expect to recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable and collection is probable.

We offer our customers a variety of sales and incentive programs, including discounts, allowances, coupons, slotting fees, and co-op advertising; such amounts are recorded as a reduction in revenue over the period in which revenue is recognized. We expensed $0.783 million and $0.228 million for the six months ended December 31, 2013 and 2012, respectively, and such amounts are included in discounts in the accompanying statement of operations. We expensed $0.500 million and $0.228 million for the three months ended December 31, 2013 and 2012, respectively, and such amounts are included in discounts in the accompanying statement of operations.

32

Fair Value Measurements

Our financial instruments are primarily composed of cash, accounts receivable, factoring line of credit, accounts payable, and its convertible notes and warrants. The fair value of cash, restricted cash, accounts receivable, factoring line of credit, accounts payable and convertible notes closely approximates their carrying value due to their short maturities.

The valuation techniques utilized for the warrants and beneficial conversion feature of its convertible notes are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

We utilize observable market inputs (quoted market prices) when measuring fair value whenever possible. Our warrants and the beneficial conversion feature for its convertible notes are categorized within Level 3 of the fair value hierarchy. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company's accounting and finance department.

As of December 31, 2013, there were no transfers in or out of Level 3 from other levels.

Cash and Cash Equivalents

We consider all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Accounts Receivable

Accounts receivable balances represent payments due to us for previously recognized net sales, reduced by an allowance for doubtful accounts for balances, which are estimated to be uncollectible at December 31, 2013 and June 30, 2013, respectively. We grant credit terms in the normal course of business to its customers and do not require collateral or other security to support credit sales.

The allowance for doubtful accounts is determined based on historical experience and ongoing evaluations of our receivables and evaluations of the risks of payment. The allowance for doubtful accounts is recorded against accounts receivable balances when they are deemed uncollectible. When accounts are deemed significantly past due and uncollectible, the accounts receivable balances are written down for the amount deemed to be uncollectible. Recoveries of accounts receivable previously reserved are recorded in the consolidated statements of operations when received. One customer accounted for 69% and 94% of outstanding accounts receivable as of December 31, 2013 and June 30, 2013, respectively. As of December 31, 2013, all of our accounts receivable balances were deemed to be collectible.

Inventories

Inventories include items which are considered salable or usable in future periods, and are stated at the lower of cost or market value, with cost being based on standard cost which approximates actual cost on a first-in, first-out basis. Costs include direct materials, direct labor and overhead (e.g., indirect labor, rent and utilities, depreciation, purchasing, receiving, inspection and quality control), and in-bound freight costs. We periodically review the value of items in inventory and provide write-downs or write-offs of inventory based on our assessment of market conditions Write-downs and write-offs are charged to cost of goods sold.

During the six months ended December 31, 2013 and the period ended June 30, 2013, we reserved $0.200 million and $0.366 million, respectively, for write-offs. During the three months ended December 31, 2013 and the period ended June 30, 2013, we reserved $0.200 million and $0.366 million, respectively, for write-offs.

The inventory write-off as of June 30, 2013 was primarily due to the name change of our Kardashian Beauty ™ brand, which forced the Company to destroy or mark for destruction finished goods and work-in-process. Total inventories as of December 31, 2013 and June 30, 2013 were $2.050 million and $1.949 million, respectively.

Property and Equipment

Fixed assets as of December 31, 2013 consisted of costs incurred by us in connection with installing display fixtures at certain key customer display rooms and retail stores. The display fixtures are being depreciated on a straight-line basis over two years, which approximates the estimated useful lives of such assets. Display fixtures maintained at customer display rooms and retail stores amounted to $0.617 million, net of accumulated depreciation, at December 31, 2013. Depreciation expense amounted to $0.235 million and $0.012 million for the six months ended December 31, 2013, and is included in depreciation & amortization expense in the accompanying statements of operations. Depreciation expense for the three months ended December 31, 2013 and 2012 amounted to $0.127 million and $0.012 million for the three months ended December 31, 2013, and is included in depreciation & amortization expense in the accompanying statements of operations.

Advertising

Advertising costs are expensed as incurred. Total advertising expenses amounted to $0.088 million and $0.291 million for the six months ended December 31, 2013 and 2012, respectively, and are included in general and administrative expenses in the accompanying statement of operations. Total advertising expenses amounted to $0.053 million and $0.100 million for the three months ended December 31, 2013 and December 31, 2012, respectively. Our advertising expenses in the three and six months ended December 31, 2013 were lower than the prior period due to the reduced spend on print advertising and photo shoot expenses during the current period.

33

Selling Expenses and Commissions

Selling expenses are expensed as incurred. Total selling expenses amounted to $0.351 million and $0.342 million for the six months ended December 31, 2013 and 2012, respectively. Total selling expenses amounted to $0.254 million and $0.342 million for the three months ended December 31, 2013 and 2012.  As of September 30, 2013, the Company reclassified the presentation of freight-out from cost of sales and has included the expense as a selling expense under operating expenses in the accompanying statement of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Shipping expense is included in selling expense under operating expenses and amounted to $0.075 million and $0.263 million during the six months ended December 31, 2013 and December 31, 2012, respectively. Total shipping expense was $0.043 million and $0.263 for the three months ended December 31, 2013 and 2012, respectively. Our shipping expense for the three months ended December 31, 2012 was significantly impacted due to one-time airfreight costs for outbound shipments.

Selling commissions are expensed as incurred. As of December 31, 2013, the Company reclassified the presentation of commissions and fees from general and administrative expenses and has included the expense as a selling expense under operating expenses in the accompanying condensed consolidated statements of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Total selling commissions amounted to $0.074 million for each of the six months ended December 31, 2013 and 2012, respectively, and are included in selling expenses in the accompanying statement of operations. Total selling commissions amounted to $0.048 million and $0.074 million for the three months ended December 31, 2013 and 2012, respectively. Our selling commissions for the three months ended December 31, 2013 were lower over the prior period as a result of a different mix of our sales from domestic versus international sales where we do not pay a sales commission as well as increased discounts in the three months ended December 31, 2013.

Deferred Financing Costs

Deferred financing costs represent fees paid in connection with obtaining short-term and long-term loans (see Notes 4 and 5 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q). These fees are amortized using a method that approximates the effective interest method over the term of the related financing.

In connection with an offering of debentures that closed in August 2013, we paid $50,000 to the investor in the offering and $12,064 in legal fees, collectively, to Loeb & Loeb and Gottbetter & Partners.

In connection with an offering of debentures that closed in June 2013, we paid Gottbetter Capital Markets (“GCM”) who acted as the sole placement agent for the offering a commission of 7.2% of the first $1,400,000 funds raised in the offering for a total payment of $100,000. We also issued 1.9 million five-year warrants to GCM on the same terms as the warrants offered to the investors in the offering, with an exercise price of $0.082. In addition, we paid $117,446 in legal fees to Gottbetter & Partners and $85,207 in professional fees to the lead investor in the offering.

As of December 31, 2013 and June 30, 2013, deferred financing costs of $0.290 million and $0.359 million, respectively, net of accumulated amortization, are presented on the accompanying balance sheet. Amortization of deferred financing costs of $0.131 million and $0.063 million for the six months ended December 31, 2013 and 2012, respectively, is included in interest expenses in the accompanying statement of operations. Amortization expense for deferred financing costs was $0.069 million and $0.063 million for the three months ended December 31, 2013 and 2012, respectively.  The remaining deferred financing costs will be fully amortized by March 1, 2015.

Debt Discount

We may record debt discounts in connection with raising funds through the issuance of convertible debt (see Note 5 and 6 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.

As of December 31, 2013 and June 30, 2013, convertible debt, net of unamortized debt discounts, was $1.214 million and $0.282 million, respectively. Amortization of debt discounts of $0.496 million and $0.053 million is included in interest expense in the accompanying statement of operations for the six months ended December 31, 2013 and 2012, respectively. Amortization expense for debt discounts was $0.255 million and $0.053 million for the three months ended December 31, 2013 and 2012, respectively. The remaining debt discounts will be fully amortized by March 1, 2015. See Note 5 and 6 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q.

Derivative Financial Instruments

GAAP requires derivative instruments embedded in convertible debt or equity instruments, to be bifurcated and measured at their fair value for accounting purposes. In determining the appropriate fair value, we use the Black-Scholes option-pricing model, which we estimate to approximate the fair value using the Binomial Lattice model. In assessing the debt instruments with characteristics of liability and equity, management determines if the convertible debt host instrument is conventional convertible debt and if there is a beneficial conversion feature. If the instrument is not considered conventional convertible debt, we estimate the fair value of the embedded derivative instruments. The warrant liability is measured at fair value on a recurring basis using level 2 inputs (see Notes 5 and 6 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q).

As of December 31, 2013, we had reserved 69,682,783 shares of common stock for issuance of common stock upon exercise of our outstanding warrants.

As of December 31, 2013, the fair value of all warrants issued was estimated at $0.528 million. The gain/(loss) in the fair value of the warrants of $1.246 million and $(0.347) million for the six months ended December 31, 2013 and 2012, respectively, was recorded in the long-term liability section of the balance sheet and recorded as a gain in the derivative liability section on the statement of operations. The gain/(loss) in the fair value of the warrants was $0.375 million and $(0.407) million for the three months ended December 31, 2013 and 2012, respectively.

34

Financial Instruments and Concentrations of Business and Credit Risk

Our financial instruments include cash and cash equivalents, factoring lines of credit, convertible debt, accounts payable, other current assets and liabilities, and short-term loans. The fair value of these instruments approximates their carrying value due to their relatively short maturities.

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We may maintain cash balances that at times may exceed amounts insured by the Federal Deposit Insurance Corporation. Three customers accounted for approximately 33%, 25% and 24% of the Company’s net revenues for the six months ended December 31, 2013. Three customers accounted for approximately 30%, 29% and 18% of the Company’s net revenues for the three months ended December 31, 2013. Three customers accounted for approximately 36%, 20% and 17% of the Company’s net revenues for the three and six months ended December 31, 2012.

Accounts receivable for one customer represented 69% of the Company’s accounts receivable balance, prior to accrued discounts, as of December 31, 2013. Accounts receivable for one customer represented 94% of the Company’s accounts receivable balance as of June 30, 2013.

We have not experienced any losses in these accounts and believe we are not exposed to any significant credit risk in this area.

License Acquisition Costs

License acquisition costs represent legal fees paid in connection with obtaining our license agreements (see Note 3 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q). These fees are amortized using the straight-line method over the term of each license agreement.

As of December 31, 2013 and June 30, 2013, license acquisition costs, net of amortization, were $20,298 and $24,504, respectively on the accompanying condensed consolidated balance sheets.

Amortization of license acquisition costs of $4,206 and $1,342 is included in depreciation and amortization expense in the accompanying condensed consolidated statements of operations for the six months ended December 31, 2013 and December 31, 2012. Amortization of license acquisition costs was $3,535 and $671 for the three months ended December 31, 2013 and December 31, 2012.

Impairment of Long-Lived Assets

We evaluate long-lived assets and certain identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset. In such cases, the carrying value of these assets is adjusted to their estimated fair value and assets held for sale are adjusted to their estimated fair value less selling expenses. No impairment losses of long-lived assets or intangible assets were recognized for the six months ended December 31, 2013.

Income Taxes

We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We provide a valuation allowance against our deferred tax assets when circumstances indicate that it is no longer more likely than not that such assets will be realized. As we provided a full valuation allowance against our deferred tax assets, there was no net impact on net loss or net loss per share as of December 31, 2013.

Section 382 of the Internal Revenue Code can limit the amount of net operating losses, which may be utilized if certain changes to a company’s ownership occur. While the Company underwent a shift in ownership in 2013 as defined by Section 382 of the Internal Revenue Code, the Company has not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code, it may incur limitations in the future if there is a change in ownership.

Net Loss Per Share

Basic net income / (loss) per share is computed by dividing net income / (loss) by the weighted average number of shares of common stock outstanding for the period. Our potential dilutive shares, which include common stock options, common stock warrants and convertible debt have not been included in the computation of diluted net loss per share for all periods where there was a net loss as the result would be antidilutive. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

There have been no recently issued accounting pronouncements that impact us.

INFLATION

The effect of inflation on our revenues and operating results has not been significant.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements.

35

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended December 31, 2013, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the Exchange Act. Based on this evaluation, because of the identification of the material weakness described below, management concluded that as of December 31, 2013 our disclosure controls and procedures were ineffective.

As reported in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, our management identified a control deficiency relating to inadequate accounting resources. Management believes that this material weakness is primarily due to the limited number of accounting personnel. To mitigate the effects of this deficiency, we rely heavily on the use of external consultants.

Subject to the availability of funds, we plan to hire additional personnel with financial accounting expertise to further support our current accounting personnel. If and when implemented, our internal accounting personnel will be responsible for performing regular internal audits of the Company’s disclosure controls and procedures, internal control over financial reporting and performing other financial functions.

Management believes that hiring additional accounting personnel who have financial expertise and knowledge will result in a much more knowledgeable accounting staff. Additional accounting personnel will also ensure the proper segregation of duties and provide more checks and balances and better enable us to deal with any personnel losses within our accounting staff. We believe this will greatly decrease any disclosure control and procedure issues we may encounter in the future.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the most recent fiscal quarter ended December 31, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

36

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We may, from time to time, be a party to litigation that arises in the normal course of our business operations.  Except as set forth below, there are no legal proceedings, governmental actions, administrative actions, investigations or claims pending against us or that we are a party to that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

On November 19, 2012, an action entitled Chroma Makeup Studio LLC. v. BOLDFACE Group, Inc. and BOLDFACE Licensing + Branding was filed in the United States District Court for the Central District of California, Western Division. Chroma Makeup Studio LLC (“Chroma”) alleged that our use of the Khroma mark, alleged that our use of the term Khroma, including the marks Khroma Beauty and Khroma Beauty By Kourtney, Kim and Khloe (the “Khroma Beauty Marks”), infringes upon Chroma’s rights in its Chroma mark. The complaint included claims for trademark infringement under the Lanham Act and unfair competition under applicable California law. On December 5, 2012, Chroma filed a motion for preliminary injunction to enjoin our use of the Khroma Beauty Marks, including the promotion and sale of products offered under such marks during the pendency of the litigation. On January 23, 2013, the court denied Chroma’s motion. Prior to deciding the motion, the court ordered the parties to appear at a scheduling conference on March 25, 2013 to discuss the proposed pretrial discovery plan and address other pretrial issues. The scheduling conference occurred on March 25, 2013, and the court issued a scheduling order setting November 18, 2013 as the end of the discovery period, January 6, 2014 as the deadline to file dispositive motions, and a tentative trial date of April 22, 2014. On December 11, 2013, following private mediation, the parties entered into a settlement agreement and mutual general release (the “Settlement Agreement”) with Chroma to settle any and all claims between the Company and Chroma.  Pursuant to the terms of the Settlement Agreement, the parties have agreed that the terms of the Settlement Agreement are to remain confidential.

Pursuant to the terms of the Settlement Agreement, and with no admission of any liability, the Company has agreed to pay Chroma a cash amount over a period of one year commencing on December 31, 2013 and ending on December 31, 2014. The total cash amount that the Company has agreed to pay Chroma is lower than the amount the Company reserved for any payments to be made in connection the dispute.

On November 30, 2012, we filed a complaint for a declaratory judgment in the United States District Court for the Central District of California, Western Division entitled BOLDFACE Licensing + Branding v. By Lee Tillett, Inc. BLB’s complaint requests a declaration from the court that (1) BLB’s use of the Khroma term, including the marks Kardashian Khroma and Khroma Beauty By Kourtney, Kim and Khloe (the “Khroma Marks”), does not infringe on By Lee Tillett, Inc.’s (“Tillett”) rights in its Kroma mark, and (2) BLB’s two pending trademark applications for the Khroma Marks should be allowed to register with the United States Patent and Trademark Office (“USPTO”). On January 9, 2013, Tillett filed an answer and counterclaims for (1) trademark infringement, (2) false designation of origin, (3) trademark infringement, and (4) unfair competition under applicable California law. In addition to BLB, Tillett’s counterclaims are made against BGI and Kimasprincess Inc., 2Die4Kourt Inc., Khlomoney Inc., Kim Kardashian, Kourtney Kardashian and Khloe Kardashian (the “Kardashian Parties”).

BLB and the Kardashian Parties filed an answer to Tillett’s counterclaims on February 11, 2013, and Tillett contemporaneously filed a motion for preliminary injunction to enjoin the Company’s use of the Khroma   Marks. The Court heard the motion on March 11, 2013, and granted the motion after finding that Tillett had demonstrated a likelihood of success on its trademark infringement claim and related claims, and a likelihood of irreparable harm in the absence of injunctive relief. In the order granting the injunction, the Court enjoined BLB and its affiliates from making, promoting, or selling any goods or services using the Khroma trademark, although it did not prohibit the Company’s retailers from selling the Khroma products already in their inventories. On March 20, 2013, BLB filed an ex-parte application for clarification of the court’s order granting the motion and setting forth the terms of the injunction. With its application, BLB submitted a proposed order that would limit the scope of the injunction to the United States only, and make clear that it was not intended to apply to overseas sales or promotion. BLB ex-parte application is still pending and the Court has not yet issued a ruling or set a hearing date.

37

The Court ordered counsel for the parties to appear for a scheduling conference on March 25, 2013, following which the Court filed a preliminary scheduling order setting November 18, 2013 as the last day of the parties’ discovery period, January 6, 2014 as the deadline to file dispositive motions, and a tentative trial date of April 22, 2014. Following the scheduling conference, the discovery period opened and the parties exchanged requests for documents and information. BLB and the Kardashian Parties served their respective objections and responses to Tillett’s discovery requests on April 29, 2013. The parties have entered into a stipulated protective order concerning the production of confidential, proprietary, and private information during the discovery process.

In response to the injunction issued by the court, the Company filed a notice of appeal with the Ninth Circuit Court of Appeals (the “9th Circuit”) on March 15, 2013 to overturn the district court’s March 11, 2013 decision. The Company filed its opening brief with the 9th Circuit on April 19, 2013. On March 18, 2013, the Company also filed a motion to stay with the 9th Circuit, requesting a stay of the injunction during the pendency of the Company’s appellate case. The 9th Circuit ruled on the Company’s motion on June 7, 2013 granting Tillett’s application and ruling that the preliminary injunction would be effective as of June 7, 2013

On October 28, 2013, Tillett filed a motion to amend its counterclaim to add Gold Grenade, LLC as a counter-defendant and two additional claims: conspiracy and common law trademark infringement.  The Company and the Kardashian Parties have filed an answer to Tillet’s motion.  On November 18, 2013, the Court denied Tillet’s motion to amend its counterclaim.

The Company filed a motion for summary judgment, contending that Tillett could not prove that it suffered any damages based on the conduct of the BLB. On December 6, 2013, the Court issued an order to show cause re: contempt and sanctions against BLB based on allegations that BLB had distributed Khroma labeled product after the effective date of the preliminary injunction. As part of that order, the Court took off the calendar the pending summary judgment motion and all remaining trial and pre-trial dates. The parties filed briefs regarding the alleged contempt and an evidentiary hearing was held on January 9, 2014, after which the Court took the matter under submission. As of the date of this filing, no ruling has been issued.

Based on the existing status of the two actions, our management believes it has adequately reserved for these matters such that there would not be a material effect on future financial statements.

ITEM 1A.            RISK FACTORS

An investment in shares of our common stock is highly speculative and involves a high degree of risk.  We face a variety of risks that may affect our operations or financial results and many of those risks are driven by factors that we cannot control or predict.  Before investing in our common stock you should carefully consider the following risks, together with the financial and other information contained in this Form 10-Q.  If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be materially adversely affected.

RISKS RELATED TO THE COMPANY

We have a limited operating history.

Our wholly-owned operating subsidiary, BLB, was incorporated on April 26, 2012.  BLB has a limited operating history in an industry characterized by changing consumer preferences, evolving industry standards and frequent introductions of new products and services.  As of December 31, 2013, BLB had acquired three licenses: (i) the Kardashian Beauty™ license, (ii) the Mario Lopez license and (iii) the UGLYDOLL® license.

The Company expects to acquire additional celebrity and designer brand licenses although no assurance can be given that the Company will be able to do so. Our limited operating history, and our dependence on a limited number of licenses and the uncertainty surrounding our ability to acquire additional licenses may have a material adverse effect on our business, results of operations and financial condition.

38

Our operating results are unpredictable and are expected to fluctuate in the future.

Our operating results are unpredictable and are expected to fluctuate in the future as a result of a number of factors, many of which may be beyond our control. As a result, operating results for any period should not be relied upon as an indication of our future performance.  The following factors may affect our operating results:

·           our ability to deliver products in a timely manner and in sufficient volumes;

·           our ability to recognize product trends;

·           our loss of one or more significant distributors or customers;

·           the introduction of successful new products by our competitors;

·           our inability to maintain or increase awareness and recognition of our brands; and

·           adverse media reports on the use of our products.

Because our business is constantly evolving, our historical operating results may not be useful in predicting our future operating results.

Our working capital is limited and we may need additional financing to continue our operations.

As of December 31, 2013, we had negative working capital of $2.653 million, which includes the current portion of amortized debt discounts of $0.596 million.  We require substantial working capital to fund our operations, and additional capital will be necessary for the Company to continue its operations. If we are unable to obtain financing in the amounts required and on acceptable terms, or at all, or raise additional capital, we will need to significantly reduce the scope of our operations, which may have a material adverse effect on our business, results of operations and financial condition.

If unknown liabilities should arise in connection with the Merger and the split-off of our wholly-owned subsidiary BOLDFACE Split Corp., we may be required to divert cash from other business purposes to discharge such liabilities, which may have a material adverse effect on our business, results of operations and financial condition.

In connection with the Merger, we split off (the “Split-Off”) our wholly-owned subsidiary, BOLDFACE Split Corp., a Nevada corporation (“Split Corp.”). The Split-Off was accomplished through the exchange of 189,781,000 shares of our common stock held by Noah Levinson for all of the issued and outstanding shares of common stock of Split Corp.  All of our assets and liabilities immediately following the Merger, excluding any assets and liabilities of BLB assumed in the Merger, were transferred to Split Corp.

Although we transferred certain assets and liabilities relating to our pre-merger shell operations in connection with the Merger and the Split-off, there can be no assurance that such transfer will release us of all such liabilities.  If Split Corp. does not pay such liabilities or unknown liabilities arise, we may be required to divert cash from other business purposes to discharge such liabilities, which may have an adverse effect on our current business, results of operation and financial condition.

Our failure to manage our growth could place a significant strain on our operational and financial resources.

Our growth has placed a significant strain on our operational and financial resources and has placed significant demands on our current management and personnel.  In order to manage growth, we will be required to expand existing operations, particularly with respect to product development and marketing, and to improve existing, and implement new, operational and financial systems, procedures and controls.

We have experienced a significant strain on our resources because of difficulties in hiring and retaining skilled personnel necessary to support our business and the continued development of our financial and information management systems.  Difficulties we may encounter in dealing successfully with the above risks could adversely affect our operations. We cannot offer any assurance that our current personnel, systems, procedures and controls will be adequate to support our future operations or that management will be able to identify, hire, train, retain, motivate and manage required personnel.  A failure to manage our growth effectively could have a material adverse effect on our business, results of operations and financial condition.

39

Our success depends on our key personnel and our ability to attract and retain qualified personnel.

Our success depends on our ability to retain our key personnel including our Chief Executive Officer and Chief Financial Officer.  The unexpected loss of one or more of our key employees could adversely affect our business.  Our success also depends on our ability to identify, attract, hire, train, motivate, and retain other highly qualified personnel.  We may not be successful in attracting, assimilating or retaining qualified personnel in the future, and our failure to do so could adversely affect our business.

Our success depends on our ability to execute our business strategy. If we are unable to raise additional capital, our ability to fully implement our business strategy will be limited.

Our ability to implement our business strategy is dependent upon a number of factors, including our ability to:

● develop high-quality brands in connection with our current licenses;

● establish, maintain and increase our product sales and market share, and strengthen the recognition of our brands;

● implement appropriate product mix and pricing strategies and realize the anticipated benefits from these strategies;

● realize efficiencies across our supply chain, marketing processes, sales model and organizational structure;

● effectively manage our inventory and implement initiatives to reduce inventory levels, including the potential impact on cash flows and obsolescence;

● acquire additional celebrity and designer brand licenses; and

● secure short and long-term financing at attractive rates.

There can be no assurance that any of these initiatives will be successfully and fully executed in the amounts or within the time periods that we expect.

We rely on a limited number of customers for a substantial portion of our sales, and the loss of or a material reduction in purchase volume by any of these customers would adversely affect our sales and results of operations.

For the three and six months ended December 31, 2013, three customers accounted for approximately 77% and 83%, respectively, of our net revenues.  Our largest customer for the three and six months ended December 31, 2013, accounted for 29% and 33%, respectively, of our sales.  The loss of any of our major customers, a significant reduction in purchases by any major customer, or, any serious financial difficulty of a major customer, would have a material adverse effect on our sales and results of operations.

We are currently defendants in one pending trademark infringement action.  If we are unable to successfully defend against or settle these actions, our business, financial condition and results of operations may be materially adversely affected.

On November 30, 2012, we filed a complaint for a declaratory judgment in the United States District Court for the Central District of California, Western Division entitled BOLDFACE Licensing + Branding v. By Lee Tillett, Inc. BLB’s complaint requests a declaration from the Court that (1) BLB’s use of the Khroma Marks does not infringe on Tillett’s rights in its Kroma mark, and (2) BLB’s pending trademark applications for the Khroma Marks should be allowed to register with the USPTO. On January 9, 2013, Tillett filed an answer and counterclaims for (1) trademark infringement, (2) false designation of origin, (3) trademark infringement, and (4) unfair competition under applicable California law. In addition to BLB, Tillett’s counterclaims are made against the following additional parties: BGI and the Kardashian Parties.  The parties are currently in the discovery phase, and the court has set a tentative trial date of April 22, 2014.

40

If we are unable to settle these actions or successfully defend against these actions, our business, financial condition and results of operations may be materially adversely affected.

For additional disclosure relating to these actions, please see Item 1 “Legal Proceedings” contained elsewhere in this Form 10-Q.

There is substantial doubt about our ability to continue as a going concern.

In its audit report, dated October 15, 2013, for the period ending June 30, 2013, Friedman LLP, our former independent registered public accounting firm, expressed substantial doubt about our ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  However, our ability to continue as a going concern is dependent upon our ability to generate sufficient cash flow from our planned operations to meet our obligations on a timely basis and ultimately attain profitability. Our ability to continue as a going concern is also dependent on our ability to raise additional capital or obtain additional financing and our ability to generate sufficient revenue to cover our operating expenses. Additional financing may not be available upon acceptable terms, or at all.

To date, we have financed our operations from proceeds generated by the private placement of equity and convertible debt instruments and through our factoring line of credit. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) payments under existing licenses, (ii) investments in inventory for our Kardashian Beauty™ brand; (iii) research and development costs associated with new product offerings, and (iv) management and consulting costs, including the cost of being a public company. We intend to finance these expenses by raising additional capital and generating sufficient revenues to meet our short-term and long-term operating requirements. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations. We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the form of equity and/or debt financing and/or additional short-term borrowing. As such, these factors raise substantial doubt about our ability to continue as a going concern.

As of December 31, 2013, our management determined that certain disclosure controls and procedures were ineffective, which could result in material misstatements of our financial statements.

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. As of December 31, 2013, our management determined that some of our disclosure controls and procedures were ineffective due to weaknesses in our financial closing process.

When our resources permit, we intend to implement remedial measures designed to address the ineffectiveness of our disclosure controls and procedures, including (i) hiring additional individuals with accounting, auditing and financial reporting experience, (ii) segregating our internal and external financial reporting among a larger finance and accounting staff, (iii) implementing more specific segregation of our accounting software and (iv) providing historical information more timely.  We have also adopted and implemented written procedures to document retailer purchase orders, inventory buying, product discounts and product transition flow, invoice review, cash and expense management, as well as an analyses of our cost of goods sold.  If these remedial measures are insufficient to address the ineffectiveness of our disclosure controls and procedures, or if material weaknesses or significant deficiencies in our internal controls are discovered or occur in the future, we may fail to meet our future reporting obligations on a timely basis, our consolidated financial statements may contain material misstatements, and we may be required to restate our prior period financial results.

41

We can give no assurance that the measures we plan to take in the future will remediate the ineffectiveness of our disclosure controls and procedures or that any material weaknesses will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting or adequate disclosure controls and procedures.  In addition, even if we are successful in strengthening our disclosure controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our consolidated financial statements.

Upon completion of our offering of 8% original issue discount senior secured convertible debentures (the “Debentures”) and related warrants, we incurred significant debt obligations. The terms of the Debentures impose significant operating and financial restrictions on us and our subsidiaries, which may materially and adversely affect our business.

As of December 31, 2013, we had total debt, prior to debt discounts, of approximately $2.296 million under the Debentures, plus accrued interest of approximately $0.031 million. In connection with the sale of the Debentures, the investors who purchased our 12% secured convertible notes in December 2012, March 2013 and April 2013 in an aggregate principal amount of $3.380 million converted all of their 12% secured convertible notes (including accrued and unpaid interest thereon) into shares of our common stock.

The terms of the Debentures and the Factoring Agreements and the Supply Agreements and related agreements we entered into with Star Funding, Inc. impose significant operating and financial restrictions on us, which limit our ability, among other things, to:

· incur additional indebtedness;

· pay dividends or make distributions to our shareholders;

· incur liens that would rank senior in priority to, or pari passu with, the obligations under the Debentures; and

· sell or otherwise dispose of any assets or rights of the Company or any subsidiary, subject to certain exceptions.

·           These restrictions may affect our ability to operate our business, including, among other things:

· making it more difficult for us to satisfy our obligations with respect to the Debentures and our other indebtedness;

·           limiting our ability to obtain additional financing to fund future working capital, capital expenditures, strategic acquisitions or other general corporate requirements;

·           requiring a substantial portion of our cash flows to be dedicated to debt service payments instead of other purposes;

·           limiting our financial flexibility in planning for and reacting to changes in the industry in which we compete;

·           placing us at a disadvantage compared to other, less leveraged competitors; and

·           increasing our cost of borrowing.

42

We may not be able to generate a sufficient amount of cash flow to meet our debt service obligations, including the Debentures and the Chroma Settlement.

Our ability to make scheduled payments or to refinance our debt obligations with respect to the Debentures, the Chroma Settlement, and our other indebtedness depends on our financial and operating performance, which, in turn is subject to certain financial, competitive, business and other factors which may be beyond our control.  If our cash flow and capital resources are insufficient to fund our debt service obligations, including the Debentures, and our other commitments, we could face substantial liquidity problems and may be forced to reduce or delay scheduled expansions and capital expenditures, sell material assets or operations, obtain additional capital or restructure our debt.

In addition, we cannot assure you that our operating performance, cash flow and capital resources will be sufficient for payment of our debt in the future.  Any refinancing of our indebtedness could be at higher interest rates and may require us to comply with more restrictive covenants which could further restrict our business operations.  In the event that we are required to dispose of material assets or operations or restructure our debt to meet our debt service obligations, we cannot provide assurance that we could effect any of these actions on a timely basis, on commercially reasonable terms or at all, or that these actions would be sufficient to repay our debt service obligations.

If we cannot make scheduled payments on our debts, we will be in default and, as a result, our debt holders could declare all outstanding principal and interest to be due and payable and we could be forced into bankruptcy or liquidation.

RISKS RELATED TO OUR BUSINESS

The beauty business is highly competitive, and if we are unable to compete effectively, our results of operations could suffer.

We face vigorous competition from companies throughout the United States and the world, including multinational consumer product companies.  Most of these competitors have greater resources than we do and may be able to respond to changing business and economic conditions more quickly than us.  Competition in the beauty business is based on the pricing of products, innovation, perceived value, service to the consumer, promotional activities, advertising, special events, new product introductions, e-commerce and m-commerce initiatives and other activities.  It is difficult for us to predict the timing and scale of our competitors’ actions in these areas.  Our ability to compete also depends on the continued strength of our brands, our ability to attract and retain key talent and other personnel and the efficiency of our manufacturing channels and distribution networks.  If we are unable to compete effectively, our results of operations could suffer.

A general economic downturn or sudden disruption in business conditions may affect consumer purchases of discretionary items and the financial strength of customers that are retailers, which could adversely affect our financial results.

Consumer spending is affected by a number of factors, including general economic conditions, inflation, interest rates, energy costs, and consumer confidence generally, all of which are beyond our control.  Consumer purchases of discretionary items tend to decline during recessionary periods, when disposable income is lower. A decline in consumer purchases of discretionary items may impact sales of our products and our customers that are retailers.  A downturn in the economies in which we expect to sell our products or a sudden disruption of business conditions in those economies could adversely affect our sales and profitability.

Our failure to effectively anticipate and respond to market trends and changes in consumer preferences could have a material adverse effect on our business, financial condition and results of operations.

Our success depends in large part on our ability to anticipate, gauge and react in a timely and effective manner to changes in consumer spending patterns and preferences for beauty and other consumer products that we market and sell.  We must continually work to develop, produce and market new products, maintain and enhance the recognition of our brands, achieve a favorable mix of products, and refine our approach as to how and where we market and sell our products.  Although we devote effort and resources to analyzing and responding to consumer spending patterns and preferences, consumer spending patterns and preferences are difficult to predict and can change rapidly.  If we are unable to anticipate and respond to trends in the market for beauty and other consumer products and changing consumer demands, our business, results of operations and financial condition may be materially and adversely affected.

43

Furthermore, material shifts or decreases in market demand for our products could result in an inability to sell our products in sufficient quantities or at anticipated prices.  In addition, shifts and decreases in market demand for our products could result in increased product returns by our customers and excess inventory levels.  To the extent that we experience any of these risks, it may have a material adverse effect on our business, financial condition and results of operations.

An increase in product returns could negatively impact our operating results and profitability.

We permit the return of damaged or defective products and accept limited amounts of product returns in certain instances. While such returns have historically been nominal and within management’s expectations and the provisions established, future return rates may differ from those experienced in the past. Any significant increase in damaged or defective products or expected returns could have a material adverse effect on our operating results for the period or periods in which such returns are realized.

Our success depends, in part, on the quality and safety of our products.

Our success depends, in part, on the quality and safety of our products.  If our products are found to be defective or unsafe, or if they otherwise fail to meet our consumers’ standards, our relationships with our customers or consumers could suffer, the appeal of one or more of our brands could be diminished, and we could lose sales and become subject to liability claims, any of which could result in a material adverse effect on our business, results of operations and financial condition.

A disruption in operations or our supply chain could adversely affect our business and financial results.

As we are a company engaged in the manufacture (through third-party manufacturers) and distribution of beauty products, our operations are subject to the risks inherent in manufacturing and distribution activities, including industrial accidents, environmental events, strikes and other labor disputes, disruptions in supply chain or information systems, loss or impairment of key manufacturing sites, product quality control, safety, licensing requirements and other regulatory issues, as well as natural disasters and other external factors over which we have little or no control.  If such an event were to occur, it could have an adverse effect on our business, results of operations and financial condition.

Our success depends upon market awareness of our brands.

Development and awareness of the Company will depend largely on our success in creating recognition of the brands we manufacture and distribute. If our distributors and customers, and ultimately our consumers, do not perceive us as a company that manufactures and distributes high-quality affordable beauty products, we may be unsuccessful in promoting and maintaining our brands. Our business is significantly dependent on our licenses with celebrities and designer brands.  In addition, our ability to successfully market, promote and sell our products is tied, to a certain extent, to the popularity of our celebrity licensors.  Any negative publicity associated with our celebrity licensors could affect our ability to market and distribute our products.

To attract and retain customers and consumers and to promote and maintain a competitive position, we may find it necessary to increase our marketing, networking, and advertising budgets and otherwise to increase substantially our financial commitment to creating and maintaining brand loyalty among distributors, customers and consumers. We will continue to devote substantial financial and other resources to increase and maintain the awareness of our brands.  However, we cannot offer any assurance that our efforts will be successful and our inability to increase and maintain awareness of our brands could have a material adverse effect on our business, financial condition and results of operations.

44

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

Equity Transactions

On December 31, 2013, the Company issued 337,338 shares of common stock, fair valued at $6,250, to a board member as compensation for serving on the Board of Directors of the Company.  The foregoing securities were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Description
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*†	The following materials from the Company’s Quarterly Report on Form 10-Q for the six months ended December 31, 2013 formatted in XBRL (extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of December 31, 2013 (unaudited) and June 30, 2012, (ii) Condensed Consolidated Statements of Operations for the three and six months ended December 31, 2013 and 2012 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2013 and 2012 (unaudited) and (iv) Notes to Interim Condensed Consolidated Financial Statements

* Filed herewith.

† Pursuant to Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of such section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

45

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 14, 2014

BOLDFACE Group, Inc.
By:	/s/ Nicole Ostoya
Name:	Nicole Ostoya
Title:	Chief Executive Officer and President

BOLDFACE Group, Inc.
By:	/s/ Ashumi Shippee
Name:	Ashumi Shippee
Title:	Chief Financial Officer

46

EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Nicole Ostoya, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the quarter year ended December 31, 2013 of BOLDFACE Group, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 14, 2014	/s/ Nicole Ostoya
	Nicole Ostoya, Chief Executive Officer and President

EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ashumi Shippee, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the quarter year ended December 31, 2013 of BOLDFACE Group, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 14, 2014	/s/ Ashumi Shippee
	Ashumi Shippee, Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended December 31, 2013 of BOLDFACE Group, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nicole Ostoya, Chief Executive Officer and President of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.  A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: February 14, 2014	/s/ Nicole Ostoya
	Nicole Ostoya, Chief Executive Officer and President

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended December 31, 2013 of BOLDFACE Group, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ashumi Shippee, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.  A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: February 14, 2014 /s/ Ashumi Shippee

XML

Equity Transactions (Details) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2013 Board [Member]
Equity Transactions (Textual)
Commons stock issued to a board member for services, Shares			337,838
Fair value of commons stock issued to a board member for services	$ 5,912	$ 6,060	$ 6,250

XML

Convertible Debt Offering (Details) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Schedule of convertible debt discount
Convertible Note Face Value			$ 258,240
Debt Discount
Amortization of Debt Discount, as of December 31, 2013	255,443	52,704	495,559	52,704
Convertible Notes Carrying Value, at December 31, 2013	624,869		624,869
June Convertible Note [Member]
Schedule of convertible debt discount
Convertible Note Face Value			1,680,000
Debt Discount
Convertible Notes - Issued Warrant Derivative			752,126
Conversion Feature Derivative			491,051
Original Issue Discount			180,000
Total Debt Discount			1,423,177
Amortization of Debt Discount, as of December 31, 2013			(481,516)
Debt Discount, Net			941,661
Convertible Notes Carrying Value, at December 31, 2013	738,339		738,339
August Convertible Note [Member]
Schedule of convertible debt discount
Convertible Note Face Value			616,000
Debt Discount
Convertible Notes - Issued Warrant Derivative			87,264
Conversion Feature Derivative			25,827
Original Issue Discount			66,000
Total Debt Discount			179,091
Amortization of Debt Discount, as of December 31, 2013			(38,933)
Debt Discount, Net			140,158
Convertible Notes Carrying Value, at December 31, 2013	$ 475,842		$ 475,842

XML

Income Taxes (Tables)

6 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

	December 31, 2013
Statutory rate		34.0	%
State income taxes		6.0	%
Permanent differences		(15.7	)%
Valuation allowance		(21.4	)%
Other		(2.7	)%
Total		0.0	%

Schedule of Deferred Tax Assets and (liabilities)

	December 31, 2013			June 30, 2013
Net operating losses carryforward	$	2,159,286		$	2,002,842
Start-up costs and fixed assets, net of amortization		120,011			60,005
Property and equipment		126,955			56,270
Stock based compensation		340,217			192,786
Gross deferred taxes	$	2,746,569		$	2,311,903
Valuation allowance		(2,746,569	)		(2,311,903	)
Net deferred taxes	$	-		$	-

XML

Income Taxes (Details)	6 Months Ended
	Dec. 31, 2013
Summary of Company's effective tax rate reconciliation
Statutory rate	34.00%
State income taxes	6.00%
Permanent differences	(15.70%)
Valuation allowance	(21.40%)
Other	(2.70%)
Total	0.00%

XML

Derivative Liability (Details Textual) (USD $)	1 Months Ended	0 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended		0 Months Ended	3 Months Ended		6 Months Ended						0 Months Ended	3 Months Ended		6 Months Ended						0 Months Ended		1 Months Ended	3 Months Ended			6 Months Ended	12 Months Ended		1 Months Ended			0 Months Ended		1 Months Ended	0 Months Ended					1 Months Ended	0 Months Ended			1 Months Ended					0 Months Ended	6 Months Ended	0 Months Ended		1 Months Ended						6 Months Ended			1 Months Ended			0 Months Ended
	Aug. 29, 2013	Jul. 12, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2012 Minimum [Member]	Jun. 30, 2013 Minimum [Member]	Dec. 31, 2012 Minimum [Member]	Dec. 31, 2013 Minimum [Member]	Dec. 31, 2013 Minimum [Member] Series Warrant [Member]	Dec. 31, 2013 Minimum [Member] Series B Warrrant [Member]	Dec. 31, 2013 Minimum [Member] Series C Warrrant [Member]	Dec. 31, 2013 Minimum [Member] Series D Warrrant [Member]	Dec. 31, 2013 Minimum [Member] Series E Warrrant [Member]	Sep. 30, 2012 Maximum [Member]	Jun. 30, 2013 Maximum [Member]	Dec. 31, 2012 Maximum [Member]	Dec. 31, 2013 Maximum [Member]	Dec. 31, 2013 Maximum [Member] Series Warrant [Member]	Dec. 31, 2013 Maximum [Member] Series B Warrrant [Member]	Dec. 31, 2013 Maximum [Member] Series C Warrrant [Member]	Dec. 31, 2013 Maximum [Member] Series D Warrrant [Member]	Dec. 31, 2013 Maximum [Member] Series E Warrrant [Member]	Apr. 08, 2013 Warrant [Member]	Sep. 30, 2012 Warrant [Member]	Apr. 30, 2013 Warrant [Member]	Jun. 30, 2013 Warrant [Member]	Mar. 31, 2013 Warrant [Member]	Dec. 31, 2012 Warrant [Member]	Dec. 31, 2013 Warrant [Member]	Jun. 30, 2013 Warrant [Member]	Jun. 30, 2012 Warrant [Member]	Aug. 29, 2013 Warrant [Member] Series C Warrrant [Member]	Dec. 31, 2013 Convertible Debt [Member]	Jun. 30, 2013 Convertible Debt [Member]	Jun. 20, 2013 Convertible Debt [Member] Level 2 [Member]	Dec. 21, 2012 Convertible Debt [Member] Level 2 [Member]	Aug. 29, 2013 Convertible Debt [Member] Level 2 [Member]	May 08, 2013 Licensors Warrants [Member]	Jun. 30, 2012 Licensors Warrants [Member]	Feb. 08, 2013 Broker Warrants [Member]	Dec. 06, 2012 Broker Warrants [Member]	Jul. 12, 2012 Broker Warrants [Member]	Aug. 29, 2013 Broker Warrants [Member]	Dec. 10, 2012 Broker Warrants [Member]	Dec. 12, 2012 Broker Warrants [Member]	Sep. 10, 2012 Broker Warrants [Member]	Aug. 24, 2012 Broker Warrants [Member]	Jul. 31, 2012 Broker Warrants [Member]	Jul. 20, 2012 Broker Warrants [Member]	Dec. 31, 2013 Broker Warrants [Member]	Jun. 30, 2013 Broker Warrants [Member]	Dec. 21, 2012 Convertible Note Warrants[ [Member]	Dec. 31, 2013 Convertible Note Warrants[ [Member]	Dec. 21, 2012 Convertible Note Broker Warrants [Member]	Jun. 30, 2012 Convertible Note Broker Warrants [Member]	Aug. 29, 2013 Convertible Note Broker Warrants [Member]	Mar. 28, 2013 Convertible Note Broker Warrants [Member]	Jun. 20, 2013 August Convertible Note Offering [Member]	Mar. 28, 2013 Short-term Note [Member]	Sep. 24, 2012 Short-term Note [Member] Notes	Sep. 07, 2012 Short-term Note [Member] Notes	Dec. 31, 2013 Initial Closing [Member] Convertible Debt [Member]	Jun. 30, 2013 Initial Closing [Member] Convertible Debt [Member]	Dec. 31, 2013 Initial Closing [Member] Convertible Debt [Member] Series C Warrrant [Member]	Jul. 20, 2012 Second Closing [Member] Private Placement Offering [Member]	Jul. 31, 2012 Third Closing [Member] Private Placement Offering [Member]	Aug. 24, 2012 Fourth Closing [Member] Private Placement Offering [Member]	Sep. 10, 2012 Fifth Closing [Member] Private Placement Offering [Member]	Dec. 06, 2012 Sixth Closing [Member] Private Placement Offering [Member]	Dec. 10, 2012 Seventh Closing [Member] Private Placement Offering [Member]	Dec. 12, 2012 Eighth Closing [Member] Private Placement Offering [Member]	Feb. 08, 2013 Ninth Closing [Member] Private Placement Offering [Member]
Derivative Liability (Textual)
Common stock reserved for future issuance																																	69,682,783				33,764,706
Number of common stock repurchase																																																							999,680
Number of warrants cancelled																																																						119,962
Amount of bridge loan converted in to Private Placement Offering		$ 1,925,030																																																																	$ 1,925,030
Warrant exercisable term																																										10 years	10 years	5 years	5 years	5 years		5 years	5 years	5 years	5 years	5 years	5 years										5 years	5 years		5 years			5 years	5 years	5 years	5 years	5 years	5 years	5 years	5 years
Number of bridge warrants received by bridge holder		7,700,120
Number of bridge note warrants exercisable at $0.25 per share		3,850,060
Number of bridge note warrants exercisable at $0.50 per share		3,850,060
Per share price of 3,850,060 Bridge Warrants		$ 0.25					$ 0.01
Per share price of another 3,850,060 Bridge Warrants		$ 0.50					$ 0.015
Warrants, exercise price	0.082												0.01	0.015	0.03	0.01	0.01					0.25	0.50	1	0.25	0.25	0.25											0.082				0.12	0.24																				0.25	0.25				0.03
Number of common stock purchase due to issuance of warrants																											500,000																10,000,000
Sale price of unit																																																																			$ 0.25
Number of PPO units due to conversion of Bridge notes																																																																		7,700,120
Number of Investor warrants due to conversion of Bridge Notes																																																																		7,700,120
Proceeds from private offering																																																																		125,000			31,000	409,980	125,000	20,000	150,000	50,000	25,000	50,000
Number of PPO units sold																																																																		500,000			124,000	1,639,920	500,000	80,000	600,000	200,000	100,000	200,000
Description of private placement offering																																																																		If at any time during the two year period following the closing date the Company issues additional shares of Common Stock for a consideration per share less than $0.25 (the "Reduced Price"), then the Company will issue to the purchasers in the Offering, concurrently with such issue and without any additional consideration from the purchasers, the number of additional shares of the Company's common stock and Investor Warrants equal to the difference between (A) the purchase price of the PPO Units being subscribed for divided by the Reduced Price and (B) the number of shares of the Company's common stock included in the units being subscribed for in the Offering.
Number of common stock consisting due to PPO																																																																					124,000	1,639,920	500,000	80,000	600,000	200,000	100,000	200,000
Number of investor warrants consisting due to PPO																																																															150,000	1,200,000					124,000	1,639,920	500,000	80,000	600,000	200,000	100,000	200,000
Exercise price of investor warrants																													$ 0.13																																					$ 1.00			$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00
Warrant issued during period																													2,500,000							11,664,040								16,000	72,000	656,010		72,000	72,000	187,514	187,514	187,514	187,514					1,600,000		9,058,824		752,126
Number of notes																																																																1	2
Exercise price of broker warrants																																												$ 0.25	$ 0.25	$ 0.25		$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25
Principal amount of note																																																																300,000
Fair value of the warrants					113,091		7,252,283																				42,625	3,788,687	210,349	1,067,196	297,716	888,596	113,091	7,252,283					491,051	663,528	25,827																686,192	57,143	60,886				9,482
Convertible Note Warrants	9,058,824																																																							13,520,000		137,238	1,912,195	85,293	2,704,000
Convertible Note Warrants exercisable at $0.50																																																									4,000,000
Share price of 4,000,000 Convertible Note Warrants																																																									$ 0.50
Convertible note warrants issued																																																									8,000,000
Expected volatility rate					80.00%																						65.00%	70.00%	55.00%	55.00%	55.00%	60.00%							55.00%	60.00%	1.90%																60.00%		55.00%	65.00%		55.00%	70.00%
Risk free interest rate					2.10%																						1.57%	0.83%	1.685%	1.685%	1.005%	0.95%							1.685%	0.95%	65.00%																0.95%		1.685%	1.90%		1.685%	0.83%
Expected term									5 years	18 months	24 days	14 months						10 years	10 years	5 years	10 years						5 years		5 years		5 years								18 months																				5 years	5 years		5 years	5 years
Expected dividend rate																												0.00%	0.00%	0.00%	0.00%	0.00%							0.00%	0.00%																			0.00%	0.00%		0.00%	0.00%
Derivative liability			527,606		527,606		1,660,440	0																						1,660,440			527,606	1,660,440	0
Derivative liability (gain) / loss			$ (375,334)	$ 406,803	$ (1,245,925)	$ 346,627																												$ 5,411,959
Increase in warrants exercise price							0.25
Broker warrants issued shares																																															851,549

XML

Factoring Agreements and Short - Term Loans

6 Months Ended

Dec. 31, 2013

Factoring Agreements and Short Term Loans [Abstract]

FACTORING AGREEMENTS AND SHORT - TERM LOANS

NOTE 4.                         FACTORING AGREEMENTS AND SHORT - TERM LOANS

Factoring Agreements

Effective as of November 21, 2012, each of BLBK and BLB entered into a one-year Factoring Agreement (the “Factoring Agreements”) and Supply Agreement (the “Supply Agreements”) with Star Funding, Inc. Under the terms of the Factoring Agreements, the Company sells most of its trade receivables to the factor without recourse as to credit risk but with recourse for any claims by customers for adjustments in the normal course of business. The Company is able to borrow up to 80% of its factored receivables. Under the terms of the Supply Agreements, the Company is able to finance the purchases of its inventory.

For the six months ended December 31, 2013 and December 31, 2012, interest and commissions totaled approximately $59,907 and $36,765, respectively, under the Factoring Agreements and Supply Agreements. For the three months ended December 31, 2013 and December 31, 2012, interest and commissions totaled approximately $32,912 and $36,765, respectively, under the Factoring Agreements and Supply Agreements. Balances due from factor include outstanding accounts receivables from customers net of allowances for discounts and chargebacks, advances and interest due to factor. The Factoring Agreements and Supply Agreements limit the Company’s ability to: (i) incur additional debt, (ii) pay dividends or make distributions to its stockholders, (iii) incur liens that would rank senior in priority to, or pari passu with, the obligations under the Company’s the Factoring Agreements and Supply Agreements, (iv) sell certain assets, and (v) sell or otherwise dispose of any assets or rights of the Company or any of its subsidiaries, subject to certain exceptions. Substantially all of the Company’s assets are collateralized against the Factoring Agreements and Supply Agreements. The Company is continuing to operate under the existing Factoring Agreements and Supply Agreements until their renewal or cancellation, which automatically renewed on November 21, 2013 for an additional one-year period.

Outstanding Factored Receivables	$	507,700
Less:
Advances and Deductions		(262,730	)
Unapplied Customer Credits		0
Due from Factor, Net	$	244,970

Short - Term Loans

During the six months ended December 31, 2012, the Company issued secured bridge loan promissory notes totaling in the aggregate $300,000 bearing interest at a rate of 10% per annum.

The promissory notes were issued in two installments:

· September 7, 2012 - $150,000, due by December 7, 2012

· September 25, 2012 - $150,000, due by December 25, 2012

As of March 28, 2013, the Company had re-paid the principal and accrued interest on all of the bridge loan promissory notes.

On November 9, 2012, the Company issued a short-term note in the principal amount of $60,000 to a stockholder of the Company bearing interest at an annual rate of 10%. As of December 21, 2012, the Company had re-paid the principal plus accrued interest on this promissory note.

On December 7, 2012, the Company issued a secured bridge loan promissory note totaling $100,000 bearing interest at a rate of 10% per annum. As of December 21, 2012, the Company has re-paid the principal plus interest on this promissory note.

On October 4, 2012, the Company entered into a Purchase Order Sale Agreement (the “PO Agreement”) with Solops LLC, under which it financed certain of its contracts of orders (or purchase orders) (the “Orders”), which represent amounts due from bona fide contracts for the sale and delivery of the Company’s goods to certain merchants, in the principal amount of $1,125,000. Pursuant to the PO Agreement, the Company sold the Orders to Solops for a purchase price of $875,000. Under the terms of the PO Agreement, Solops will receive $1,065,000 through a combination of the merchants’ payments under the Orders directly to Solops, the Company’s collection of accounts receivable under the Orders and resulting payments to Solops and/or any other payments made by the Company to Solops under the PO Agreement. Upon the full payment to Solops of $1,065,000, the PO Agreement will immediately terminate and Solops will convey, assign and deliver back to the Company the Orders and all of its rights thereunder. After such full payment is made, the Company will regain sole ownership of the Orders and it will not have any further obligations to Solops, and Solops will not have any further rights, with respect to the Orders or under the PO Agreement. As of November 21, 2012, the Company has re-paid its obligation under the PO Agreement.

XML

Income Taxes (Details 1) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Summary of principal components of deferred tax assets and (liabilities)
Net operating losses carryforward	$ 2,159,286	$ 2,002,842
Start-up costs and fixed assets, net of amortization	120,011	60,005
Property and equipment	126,955	56,270
Stock based compensation	340,217	192,786
Gross deferred taxes	2,746,569	2,311,903
Valuation allowance	(2,746,569)	(2,311,903)
Net deferred taxes

XML

Prepaid Royalties (Details) (USD $)	Dec. 31, 2013
Schedule of contractual commitment [Abstract]
Less than 1 year	$ 1,185,278
1-3 years	3,389,722
3-5 years	2,842,125
More than 5 years	0
Total	7,417,125
License agreement obligations [Member]
Schedule of contractual commitment [Abstract]
Less than 1 year	1,185,278
1-3 years	3,389,722
3-5 years	2,842,125
More than 5 years	0
Total	7,417,125
Operating lease obligation [Member]
Schedule of contractual commitment [Abstract]
Less than 1 year	0
1-3 years	0
3-5 years	0
More than 5 years	0
Total	$ 0

XML

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 Customer	Dec. 31, 2012	Jun. 30, 2013
Summary of Significant Accounting Policies (Textual)
Sales discount expenses	$ 499,861	$ 227,543	$ 782,521	$ 227,543
Estimated useful lives of assets			Two years
Property, plant and equipment, net	617,414		617,414		669,033
Depreciation expense	126,598	11,652	234,969	11,652
Advertising expenses	53,394	100,181	88,024	290,762
Selling expenses	253,513	341,778	350,516	341,778
Selling commission expenses	48,002	74,451	74,056	74,451
Deferred financing costs, net	133,059		133,059		328,893
Amortization of deferred financing costs	69,075	62,523	130,659	62,523
Deferred financing costs amortization date			Mar. 01, 2015
Unamortized on debt discount	1,214,181		1,214,181		281,716
Inventory write-offs			200,000		365,722
Amortization of debt discount	255,443	52,704	495,559	52,704
Number of customer			3
Accounts receivable percentage by one customer			69.00%		94.00%
License acquisition costs	20,298		20,298		24,504
Amortization of license acquisition costs	3,535	671	4,206	1,342
Impairment losses of long-lived assets or intangible assets recognized
Inventory, net	2,049,503		2,049,503		1,948,908
Shipping expenses	$ 43,458	$ 262,527	$ 74,578	$ 262,527
Customer Concentration Risk [Member] | Suppliers One [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk			33.00%
Customer Concentration Risk [Member] | Suppliers Two [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk			15.00%
Customer Concentration Risk [Member] | Suppliers Three [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk			14.00%
Customer Concentration Risk [Member] | Net revenues [Member] | Major Customer One [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk	30.00%	36.00%	33.00%	36.00%
Customer Concentration Risk [Member] | Net revenues [Member] | Major Customer Two [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk	29.00%	20.00%	25.00%	20.00%
Customer Concentration Risk [Member] | Net revenues [Member] | Major Customer Three [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk	18.00%	17.00%	24.00%	17.00%
Customer Concentration Risk [Member] | Net revenues [Member] | International Customers [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk	47.00%	2.00%	46.00%	2.00%
Customer Concentration Risk [Member] | Net revenues [Member] | Domestic Customers [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk	53.00%	98.00%	54.00%	98.00%
Customer Concentration Risk [Member] | Accounts receivable [Member] | Major Customer One [Member]
Summary of Significant Accounting Policies (Textual)
Customer concentration risk			69.00%		94.00%

XML

Income Taxes (Details Textual) (USD $)	6 Months Ended
	Dec. 31, 2013	Jun. 30, 2013
Income Taxes (Textual)
Gross deferred taxes of federal and state	$ 2,746,569	$ 2,311,903
Operating loss carryforwards, expiration date	Dec. 31, 2033
Valuation reserve	100.00%
Federal statutory income tax rate	34.00%

XML

Prepaid Royalties (Details Textual) (USD $)	6 Months Ended		6 Months Ended				6 Months Ended				6 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013 Royalty Agreements Two [Member]	Dec. 31, 2013 Royalty Agreements Two Period One [Member]	Dec. 31, 2013 Royalty Agreements Two Period Two [Member]	Dec. 31, 2013 Royalty Agreements Two Period Three [Member]	Dec. 31, 2013 Royalty Agreements Three [Member]	Dec. 31, 2013 Royalty Agreements Three Period One [Member]	Dec. 31, 2013 Royalty Agreements Three Period Two [Member]	Dec. 31, 2013 Royalty Agreements Three Period Three [Member]	Dec. 31, 2013 Royalty Agreement One [Member]	Jun. 30, 2012 Royalty Agreement One [Member]	Dec. 31, 2013 Royalty Agreement One [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreement One [Member] Maximum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period One [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Two [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Two [Member] Maximum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Three [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Three [Member] Maximum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Four [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Four [Member] Maximum [Member]
Prepaid Royalties [Line Items]
Licensing agreement expiration date			Feb. 29, 2016				Apr. 16, 2016				Nov. 30, 2016
Guaranteed royalty payment under agreements			$ 600,000	$ 100,000	$ 225,000	$ 275,000	$ 100,000	$ 33,333	$ 33,333	$ 33,334			$ 4,686,125	$ 4,985,000	$ 1,000,000	$ 925,000	$ 1,000,000	$ 1,285,000	$ 1,188,625	$ 1,572,500	$ 1,700,000
Prepaid royalty	8,055	378,960	100,000				10,000					1,000,000
Net of amortization prepaid royalty			$ 100,000				$ 1,945
Warrants granted to purchase common stock	10,000,000

XML

Factoring Agreements and Short - Term Loans (Details) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Factoring Agreements and Short Term Loans [Abstract]
Outstanding Factored Receivables	$ 507,700
Less:
Advances and Deductions	(262,730)
Unapplied Customer Credits	0
Due from factor, net	$ 244,970	$ 164,090

XML

Prepaid Royalties

6 Months Ended

Dec. 31, 2013

Prepaid Royalties [Abstract]

PREPAID ROYALTIES

NOTE 3.                         PREPAID ROYALTIES

On July 11, 2012, the Company entered into a license agreement with an individual pursuant to which the Company (i) acquired the exclusive right to use the licensor’s image in connection with the development, production, distribution, advertisement, promotion and sale of products and (ii) the licensor agreed to provide certain ancillary services in connection with the marketing and promotion of the licensed products. The license agreement remains in effect through February 29, 2016.

During the term of the license agreement and as consideration for the grant of the license the Company has agreed to pay the licensor a royalty rate depending on the product sold on all net sales of all products during the contract term. In addition the Company has agreed to pay a guaranteed minimum royalty payment of $600,000 depending on the launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $100,000

· Contract period two: $225,000

· Contract period three: $275,000

As part of the license agreement, $100,000 was prepaid and is presented net of amortization of $100,000 under prepaid royalty as of December 31, 2013.

On April 25, 2013, the Company entered into a license agreement with an entity pursuant to which the Company (i) acquired the exclusive right to use the licensor’s image in connection with the development, production, distribution, advertisement, promotion and sale of products and (ii) the licensor agreed to provide certain ancillary services in connection with the marketing and promotion of the licensed products. The license agreement remains in effect through April 16, 2016.

During the term of the license agreement and as consideration for the grant of the license the Company has agreed to pay the licensor a royalty rate depending on the product sold on all net sales of all products during the contract term. In addition the Company has agreed to pay a guaranteed minimum royalty payment of $100,000 depending on the launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $33,333

· Contract period two: $33,333

· Contract period three: $33,334

As part of the license agreement, $10,000 was prepaid and is presented net of amortization of $1,945 under prepaid royalty as of December 31, 2013.

On May 9, 2012, the Company entered into a license agreement with three individuals pursuant to which the Company (i) acquired the exclusive right to use the licensors’ images in connection with the development, production, distribution, advertisement, promotion and sale of products and (ii) the licensors agreed to provide certain ancillary services in connection with the marketing and promotion of the licensed products. The license agreement remains in effect through November 30, 2016. The Company has the option to extend the term of the license agreement for an additional period of eighteen months.

During the term of the license agreement and as consideration for the grant of the license the Company has agreed to pay the licensors a single digit royalty depending on the product sold on all wholesale sales of all products during the contract term. In addition the Company has agreed to pay a guaranteed minimum royalty payment of $4,686,125 or $4,985,000 depending on the launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $1,000,000

· Contract period two: $925,000 or $1,000,000

· Contract period three: $1,188,625 or $1,285,000

· Contract period four: $1,572,500 or $1,700,000

In addition to the royalty payments and guaranteed minimum royalty payments, the Company granted the licensors warrants to purchase 10,000,000 common shares of the Company’s common stock on a cashless exercise basis.

As part of the license agreement, $1,000,000 was prepaid during period ended June 30, 2012 and is presented net of amortization of $1,000,000 under prepaid royalty as of December 31, 2013.

Contractual Obligations and Commitments:

The table below provides information concerning obligations of our contractual commitment as of December 31, 2013:

		Total			Less than 1 year			1 – 3 years			3 - 5 years			More than 5 years
License agreement obligations		$	7,417,125		$	1,185,278		$	3,389,722		$	2,842,125		$	0
Operating lease obligation	$	0		$	0		$	0		$	0		$	0
Total		$	7,417,125		$	1,185,278		$	3,389,722		$	2,842,125		$	0

XML

Factoring Agreements and Short - Term Loans (Details Textual) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended		0 Months Ended
	Nov. 21, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Sep. 07, 2012 Secured Bridge Loan Promissory Notes [Member]	Dec. 07, 2012 Short Term Note [Member]	Nov. 09, 2012 Short Term Note [Member]	Sep. 25, 2012 Short Term Note [Member]	Oct. 04, 2012 Solops LLC [Member]
Short Term Loans and Factoring Agreement (Textual)
Promissory notes issued					$ 1,335,000	$ 150,000	$ 60,000	$ 100,000	$ 150,000
Secured bridge loan promissory notes, interest rate						10.00%	10.00%	10.00%
Promissory notes, maturity date						Dec. 07, 2012			Dec. 25, 2012
Factoring line of credit, principal amount										1,125,000
Factoring line of credit, purchase price of receivable		507,700		507,700						875,000
Factoring line of credit, amount collected by factor										1,065,000
Factoring Agreements and Supply Agreements, Term of agreement	1 year
Percentage of borrowing under factoring line of credit	80.00%
Accrued interest and commissions		$ 32,912	$ 36,765	$ 59,907	$ 36,765

XML

Stock Compensation Expense and Fair Value Measurement (Details)		0 Months Ended			1 Months Ended	0 Months Ended
	Dec. 31, 2013	Jul. 12, 2012 Stock options [Member]	Aug. 15, 2012 Stock options one [Member]	Nov. 21, 2012 Stock options two [Member]	Mar. 28, 2013 Stock option three [Member]	Apr. 08, 2013 Stock option four [Member]	Jun. 28, 2013 Stock option five [Member]	Jul. 12, 2013 Stock option six [Member]	Aug. 15, 2013 Stock option seven [Member]
Summary of relevant inputs used to determine the value of the stock option grants
Number of options outstanding	17,780,000	3,600,000	397,500	500,000	0	500,000	25,000	11,400,000	1,357,500
Weighted average risk-free rate		0.83%	0.83%	0.95%	1.005%	1.685%	1.685%	1.715%	1.86%
Expected life in years		3 years 6 months	6 years	6 years	6 years	6 years	6 years	3 years 6 months	6 years
Expected volatility		70.00%	70.00%	60.00%	55.00%	55.00%	55.00%	65.00%	65.00%
Expected dividends		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

XML

Condensed Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Jun. 30, 2013
Current assets:
Cash and cash equivalents	$ 26,431	$ 388,892
Accounts receivable	9,199	100,087
Due from factor, net	244,970	164,090
Inventory (net of reserve of $200,000 and $365,772, as of December 31, 2013 and June 30, 2013, respectively)	2,049,503	1,948,908
Prepaid inventory	307,376	258,531
Prepaid expenses and other current assets	78,449	89,786
Current portion of prepaid royalty	8,055	378,960
Current portion of deferred financing costs, net	157,138	29,899
Total current assets	2,881,121	3,359,153
Property, plant and equipment, net	617,414	669,033
Deferred financing costs, net	133,059	328,893
License acquisition costs	20,298	24,504
Total assets	3,651,892	4,381,583
Current liabilities:
Accounts payable	3,642,532	2,481,852
Accrued expenses and other current liabilities	1,067,818	806,553
Current portion of convertible debt, net of debt discount ($596,021 and $116,524, as of December 31, 2013 and June 30, 2013, respectively)	589,312	23,476
Due to Gold Grenade, LLC	234,550
Total current liabilities	5,534,212	3,311,881
Long-Term Liabilities
Convertible debt, net of debt discount ($485,798 and $1,281,760, as of December 31, 2013 and June 30, 2013, respectively)	624,869	258,240
Derivative liability	527,606	1,660,440
Total Long-Term Liabilities	1,152,475	1,918,680
Total Liabilities	6,686,687	5,230,561
Commitments and Contingencies (Note 7)
Shareholders' deficit:
Preferred stock, $.001 par value, 10,000,000 shares authorized, zero issued and outstanding
Common stock, $.001 par value, 300,000,000 shares authorized, 155,829,276 and 155,301,468 shares issued as of December 31, 2013 and June 30, 2013 respectively	155,829	155,301
Treasury stock, at cost - 999,680 and 999,680 shares as of December 31, 2013 and June 30, 2013, respectively	(228,284)	(228,284)
Additional paid in capital	7,211,525	6,841,822
Accumulated deficit	(10,173,865)	(7,617,817)
Total shareholders' deficit	(3,034,795)	(848,978)
Total liabilities and shareholders' deficit	$ 3,651,892	$ 4,381,583

XML

Related Party Transactions (Details) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Related Party Transactions (Textual)
Due to Gold Grenade	$ 234,550	$ 149,898	$ 234,550	$ 149,898
Product development fees payable to Gold Grenade	$ 230,000	$ 210,000	$ 500,000	$ 412,700

XML

Formation and Nature of Business

6 Months Ended

Dec. 31, 2013

Formation and Nature of Business [Abstract]

FORMATION AND NATURE OF BUSINESS

NOTE 1.                         FORMATION AND NATURE OF BUSINESS

Organization

BOLDFACE Group, Inc. (“BLBK”) together with its wholly owned subsidiary BOLDFACE Licensing + Branding (“BLB” and collectively, the “Company”) was incorporated under the laws of the State of Nevada on July 9, 2007. On July 12, 2012, BOLDFACE Acquisition Corp., the Company’s wholly owned subsidiary, merged with and into BLB, with BLB remaining as the surviving entity (the “Merger”). As a result of the Merger, the Company acquired the business of BLB and has continued the existing business operations of BLB as the Company’s wholly owned subsidiary. In connection with the Merger, on August 14, 2012, the Company’s Board of Directors approved a change of the Company’s fiscal year end from September 30 to June 30.

For financial reporting purposes, the Merger represented a capital transaction of BLB or a “reverse merger” rather than a business combination, because the sellers of BLB effectively controlled the combined company immediately following the completion of the Merger. As such, BLB was deemed to be the accounting acquirer in the transaction and, consequently, the transaction was treated as a recapitalization of BLB.

BLB was incorporated under the laws of the State of Nevada on April 26, 2012. BLB was founded by Ms. Nicole Ostoya, the Company’s Chief Executive Officer, President and a director, and Ms. Robin Coe-Hutshing, a principal shareholder of the Company. Ms. Ostoya and Ms. Coe-Hutshing are beauty industry veterans with over 40 years combined experience in the industry. BLB’s focus is on licensing top tier entertainment and designer brands for opportunities in the beauty, fragrance and personal care markets. BLB contracts to design, manufacture and sell branded color cosmetics, hair preparations, fragrances, home fragrances, skin care, beauty tools, and other beauty and personal care products in multiple channels of distribution.

To date, the Company has devoted its efforts to developing, marketing and selling its Kardashian Beauty™ brand in multiple retail channels, developing a line of products that will be marketed under its licenses with Mario Lopez and UGLYDOLL®, evaluating additional license agreements with additional celebrities and brands, and raising additional capital.

Basis of Presentation

The accompanying condensed consolidated financial statements as of December 31, 2013 and for the three and six month period ended December 31, 2012 are unaudited, but include all adjustments, consisting of normal recurring entries, which the Company’s management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of June 30, 2013 have been derived from the Company’s audited financial statements included in its Form 10-K for the year ended June 30, 2013 filed with the Securities and Exchange Commission (“SEC”) on October 15, 2013.

The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company’s audited financial statements in its Form 10-K for the year ended June 30, 2013. The Company’s operating results will continue to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

Going Concern and Liquidity

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  However, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to generate sufficient cash flow from its planned operations to meet its obligations on a timely basis, to raise additional equity and/or debt financing and through its factoring arrangements. In connection with the execution of its business plan, the Company anticipates additional increases in operating expenses and capital expenditures relating to: (i) payments under existing licenses, (ii) investments in inventory for our Kardashian Beauty™ brand; (iii) research and development costs associated with new product offerings, and (iv) management and consulting costs, as well as general administrative expenses, including the costs of being a public company. The Company intends to finance these expenses by raising additional capital and generating sufficient revenues to meet short-term and long-term operating requirements. If additional financings are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict its business operations. The Company currently does not have a specific plan of how it will obtain such funding; however, it anticipates that additional funding will be in the form of equity and/or debt financings and/or additional short-term borrowings. As such, these factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company continues to operate within its factoring agreement, which automatically renewed on November 21, 2013 for an additional one-year period.

The Company’s condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s auditors expressed substantial doubt about its ability to continue as a going concern in their audit report dated October 15, 2013, for the period ending June 30, 2013.

XML

Convertible Debt Offering (Details Textual) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		6 Months Ended			0 Months Ended	6 Months Ended		6 Months Ended	12 Months Ended		6 Months Ended			6 Months Ended	1 Months Ended	12 Months Ended									0 Months Ended
	Dec. 21, 2012	Aug. 29, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013	Dec. 21, 2012 Convertible Note Warrants [Member]	Dec. 31, 2013 Convertible Note Warrants [Member]	Dec. 31, 2013 Aegis Capital Corporation [Member]	Dec. 31, 2013 Third Party [Member]	Jun. 30, 2013 Gottbetter Capital Markets (GCM) [Member]	Jun. 30, 2012 Gottbetter Capital Markets (GCM) [Member]	Dec. 31, 2013 Gottbetter & Partners and Loeb & Loeb [Member]	Dec. 31, 2013 Convertible Note Broker Warrants [Member] Aegis Capital Corporation [Member]	Dec. 31, 2013 Convertible Note [Member]	Dec. 31, 2013 August Convertible Note Offering [Member]	Jun. 20, 2013 June Convertible Debt Offering [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] Gottbetter Capital Markets (GCM) [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] Debt Instrument, Redemption, Period One [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] Debt Instrument, Redemption, Period Two [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] Debt Instrument, Redemption, Period Three [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] Debt Instrument, Redemption, Period Four [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] Debt Instrument, Redemption, Period Five [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] December 1, 2014 [Member]	Jun. 30, 2013 June Convertible Debt Offering [Member] November 1, 2014 [Member]	Jun. 20, 2013 April Convertible Note [Member]
Convertible Debt (Textual) [Abstract]
Senior secured convertible notes issued		$ 616,000																$ 1,500,000
Original Issue Discount		12.00%								10.00%
Deferred financing costs			133,059		133,059		328,893			406,900	1,156,000					62,065	365,179
Period for cashless exercise warrants																	5 years		5 years
Debt Instrument, Interest Rate Terms		The August Convertible Notes bear interest at a rate of 8% per annum, which is paid quarterly. Interest is payable in cash or at the Company's option in shares of common stock, provided certain conditions are met, based on a share value equal to the lesser of (a) 90% of the average of the volume weighted average price (the "VWAP") for the 20 consecutive trading days prior to the applicable interest payment date and (b) 100% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date less $0.01. Upon any Event of Default (as defined in the August Convertible Notes), the outstanding principal amount of each August Convertible Note, plus liquidated damages, interest, a premium of 30% and other amounts owing in respect thereof through the date of acceleration, shall become, at the noteholders' election, immediately due and payable in cash. Commencing five days after the occurrence of any Event of Default, the interest rate on each August Convertible Note shall accrue at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law. The August Conversion Price is subject to "full ratchet" and other customary anti-dilution protections.																The June Convertible Notes bear interest at 8% per annum, which is paid quarterly beginning on November 1, 2013. Interest is payable in cash or at the Company's option in shares of the Company's common stock, provided certain conditions are met, based on a share value equal to the lesser of (a) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date and (b) 100% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date less $0.01. Upon any Event of Default (as defined in the June Convertible Notes), the outstanding principal amount of the June Convertible Notes plus liquidated damages, interest, a premium of 30% and other amounts owing in respect thereof through the date of acceleration, shall become, at the holders' election, immediately due and payable in cash. Commencing five days after the occurrence of any Event of Default, the interest rate on the June Convertible Notes shall accrue at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law. The June Conversion Price is subject to "full ratchet" and other customary anti-dilution protections.
Warrants ,exercise price		0.082													0.25			0.082
Number of common stock purchase due to issuance of warrants													1,900,000		1,600,000
Percentage of funds raised in convertible notes offering paid as commission																				7.20%
Term of Convertible Notes	The term of the Convertible Notes include an eight month maturity period and an annual interest rate of 12% which is accrued until payment or until the Convertible Notes are converted into equity.	The term of the August Convertible Notes include an eighteen-month maturity period, with partial redemption beginning on September 1, 2014. The August Convertible Notes bear interest at a rate of 8% per annum, which is paid quarterly.																The term of the June Convertible Notes includes an eighteen-month maturity period, with partial redemptions beginning on June 1, 2014.										The Convertible Notes were converted at a per share price of $0.07, as the Company's stock price was less than $0.30 on the Reset Date, for 30,276,190 shares. The Convertible Note Warrants were converted into 7,000,000 shares of the Company's common stock.
Convertible note redemption description		On each of September 1, 2014, October 1, 2014, November 1, 2014, December 1, 2014, January 1, 2015 and February 1, 2015, the Company is obligated to redeem an amount equal to $51,333 and on March 1, 2015, the Company is obligated to redeem an amount equal to $308,000, (plus accrued but unpaid interest, liquidated damages and any other amounts then owing in respect of the August Convertible Notes) (collectively, the "Periodic Redemption Amount"). In lieu of a cash redemption and subject to the Company meeting certain equity conditions described in the August Convertible Notes, the Company may elect to pay the Periodic Redemption Amount in shares of its common stock based on a conversion price equal to the lesser of (a) $0.068 per share, subject to adjustments upon certain events, and (b) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable redemption date.																	In lieu of a cash redemption and subject to the Company meeting certain equity conditions described in the June Convertible Notes, the Company may elect to pay the June Periodic Redemption Amount in shares of its common stock based on a conversion price equal to the lesser of (a) $0.068 per share, subject to adjustments upon certain events, and (b) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable redemption date.
Convertible notes annual interest rate	12.00%	8.00%																8.00%
Value of convertible note															137,238
Convertible notes per unit issued price	200,000
Gross proceeds from secured notes payable	2,000,000	616,000																1,680,000
Percentage of original issue discount	0.20%	12.00%																12.00%	12.00%
Convertible note redemption amount																					140,000	140,000	140,000	140,000	140,000	840,000	140,000
Convertible notes, conversion price per share		$ 0.068	$ 0.25		$ 0.25													$ 0.068
Convertible Notes Conversion Price , description					The Conversion Price Reset will be available on the earlier of: (i) the date of maturity of the 12% Notes or (ii) the completion of a subsequent financing by the Company of at least $5,000,000, (the "Reset Date"), if the closing price of the Company's stock is less than $0.30 on the Reset Date. The conversion price after the reset will be equal to 70% of the 5-day VWAP immediately preceding the Reset Date.
Convertible Note Warrants		9,058,824						13,520,000											24,705,882									30,276,190
Number of Convertible note warrants exercisable at $0.25					5,000,000
Per share price of convertible note warrants		$ 0.082																	$ 0.082
Fair value of the Convertible Note Warrants and Debt Conversion Feature	1,353,720	113,091																	1,423,177
Warrants converted in to number of common stock															1,440,000													7,000,000
Additional fees for legal and escrow agent					96,556
Number of free Trading shares sold by non-affiliated. third party shareholders											4,000,000
Funds raised in convertible notes offering paid as commission																				100,000
Broker Warrants Period												5 years
Common Stock Exercise Price												$ 0.082
Legal Fees												117,446		12,065
Professional Fees			$ 245,443	$ 571,326	$ 667,705	$ 608,723						$ 85,207		$ 50,000
Convertible note warrants issued									8,000,000
Share price of 4,000,000 Convertible Note Warrants									$ 0.50
Convertible Note Warrants exercisable at $0.50									4,000,000

XML

Convertible Debt Offering (Tables) (Convertible Note [Member])

6 Months Ended

Dec. 31, 2013

Convertible Note [Member]

Schedule of convertible debt discount

August Convertible Note Face Value	$	616,000
Debt Discount
August Convertible Notes – Issued Warrant Derivative		87,264
Conversion Feature Derivative		25,827
Original Issue Discount		66,000
Total Debt Discount	$	179,091
Amortization of Debt Discount, as of December 31, 2013		(38,933	)
Debt Discount, Net	$	140,158
August Convertible Notes Carrying Value at December 31, 2013	$	475,842

June Convertible Notes Face Value	$	1,680,000
Debt Discount
June Convertible Notes – Issued Warrant Derivative		752,126
Conversion Feature Derivative		491,051
Original Issue Discount		180,000
Total Debt Discount	$	1,423,177
Amortization of Debt Discount, as of December 31, 2013		(481,516	)
Debt Discount, Net	$	941,661
June Convertible Notes Carrying Value at December 31, 2013	$	738,339

Schedule of deferred financing cost

Legal fees and other fees associated with the August Convertible Notes offering	$	62,065
Total Deferred Financing Costs	$	62,065
Amortization of Deferred Financing Costs, as of December 31, 2013		(13,493	)
Deferred Financing Costs, Net, as of December 31, 2013	$	48,572

Placement agent and other fees associated with the June Convertible Notes offering	$	304,293
June Convertible Note Broker Warrants		60,886
Total Deferred Financing Costs	$	365,179
Amortization of Deferred Financing Costs, as of December 31, 2013		(123,554	)
Deferred Financing Costs, Net, as of December 31, 2013	$	241,625

XML

Derivative Liability (Details) (USD $)	6 Months Ended	12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013
Summary of roll forward of fair value of warrant liability
Beginning Balance	$ 1,660,440	$ 0
Issuance of Warrants	113,091	7,252,283
Repurchase / Exercise / Cancellation of Warrants	0	(179,884)
Change in fair value	(1,245,925)	(5,411,959)
Ending Balance	$ 527,606	$ 1,660,440

XML

Stock Compensation Expense and Fair Value Measurement (Tables)

6 Months Ended

Dec. 31, 2013

Stock Compensation Expense and Fair Value Measurement [Abstract]

Summary of relevant inputs used to determine the value of the stock option grants

	Number of options outstanding		Weighted average risk-free rate			Expected life in years		Expected volatility			Expected dividends
July 12, 2012		3,600,000		0.83	%		3.5		70	%		0	%
August 15, 2012		397,500		0.83	%		6.0		70	%		0	%
November 21, 2012		500,000		0.95	%		6.0		60	%		0	%
March 28, 2013		0		1.005	%		6.0		55	%		0	%
April 8, 2013		500,000		1.685	%		6.0		55	%		0	%
June 28, 2013		25,000		1.685	%		6.0		55	%		0	%
July 12, 2013		11,400,000		1.715	%		3.5		65	%		0	%
August 15, 2013		1,357,500		1.860	%		6.0		65	%		0	%
Total		17,780,000

XML

Summary of Significant Accounting Policies

6 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2.                         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary BLB. All significant intercompany balances and transactions are eliminated in consolidation.

Method of Accounting

The Company maintains its accounting records on the accrual method of accounting in conformity with GAAP. As of September 30, 2013, the Company reclassified the presentation of freight-out from cost of sales and has included the expense as a selling expense in the accompanying condensed consolidated statements of operations. As of December 31, 2013, the Company reclassified the presentation of commissions and fees from general and administrative expense and has included the expense as a selling expense in the accompanying condensed consolidated statements of operations.

Use of Estimates

In preparing the financial statements in conformity with GAAP, management makes estimates and assumptions that affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates on certain assumptions that it believes to be reasonable as of the reporting period, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most subjective and intricate estimates include inventory obsolescence reserves, certain accruals, returns and allowances and fair value calculations, including derivative liabilities and stock option expense.

Revenue Recognition

As required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable and collection is probable.

For the six months ended December 31, 2013, the Company achieved 46% of net revenues from international customers and 54% of net revenues from its domestic customers. For the three and six months ended December 31, 2012, the Company achieved 2% of net revenues from international customers and 98% of net revenues from its domestic customers.

For the three months ended December 31, 2013, the Company achieved 47% of net revenues from international customers and 53% of net revenues from its domestic customers.

The Company offers its customers a variety of sales and incentive programs, including discounts, allowances, coupons, slotting fees, and co-op advertising; such amounts are recorded as a reduction of revenue over the period in which revenue is recognized.

The Company reduced revenue in the amount of $782,520 and $227,543 for the six months ended December 31, 2013 and December 31, 2012, respectively, and such amounts are included in discounts in the accompanying condensed consolidated statement of operations.

The Company reduced revenue in the amount of $499,681 and $227,543 for the three months ended December 31, 2013 and December 31, 2012, respectively, and such amounts are included in discounts in the accompanying condensed consolidated statement of operations.

Fair Value Measurements

The Company’s financial instruments are primarily composed of cash, accounts receivable, factoring line of credit, accounts payable, and its convertible notes and warrants. The fair value of cash, restricted cash, accounts receivable, factoring line of credit, accounts payable and convertible notes closely approximates their carrying value due to their short maturities.

The valuation techniques utilized for the warrants and beneficial conversion feature of its convertible notes are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

The Company’s warrants and the beneficial conversion feature for its convertible notes are categorized within Level 3 of the fair value hierarchy. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company's accounting and finance department.

As of December 31, 2013, there were no transfers in or out of Level 3 from other levels.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

 Accounts Receivable

Accounts receivable balances represent payments due to the Company for previously recognized net sales, reduced by an allowance for doubtful accounts for balances, which are estimated to be uncollectible at December 31, 2013 and June 30, 2013, respectively. The Company grants credit terms in the normal course of business to its customers. The Company does not require collateral or other security to support credit sales. The allowance for doubtful accounts is determined based on historical experience and ongoing evaluations of the Company’s receivables and evaluations of the risks of payment. The allowance for doubtful accounts is recorded against accounts receivable balances when they are deemed uncollectible. When accounts are deemed significantly past due and uncollectible, the accounts receivable balances are written down for the amount deemed to be uncollectible. Recoveries of accounts receivable previously reserved are recorded in the consolidated statements of operations when received. As of December 31, 2013, all of the Company’s accounts receivable were deemed to be collectible. One customer accounted for 69% and 94% of outstanding accounts receivable as of December 31, 2013 and June 30, 2013, respectively.

Inventories

Inventories, which consist primarily of finished goods, include items which are considered salable or usable in future periods, and are stated at the lower of cost or market value, with cost being based on standard cost which approximates actual cost on a first-in, first-out basis. Costs include direct materials, direct labor and overhead (e.g., indirect labor, rent and utilities, depreciation, purchasing, receiving, inspection and quality control), and in-bound freight costs. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. During the six months ended December 31, 2013 and the twelve months ended June 30, 2013, the Company reserved $200,000 and $365,722, respectively, for write-offs. The inventory write-off as of June 30, 2013 was primarily due to the name change of its Kardashian Beauty™ brand, which forced the Company to destroy or mark for destruction finished goods and work-in-process. The inventory write-off reserve as of December 31, 2013 was for allowances related to liquidation of slower moving items and write-offs for obsolete inventory. Total inventories as of December 31, 2013 and June 30, 2013 were $2.050 million and $1.949 million, respectively.

Property and Equipment

Property and equipment as of December 31, 2013 consists of costs incurred by the Company in connection with installing display fixtures at certain key customer display rooms and retail stores. The display fixtures are being depreciated on a straight-line basis over two years, which approximates the estimated useful lives of such assets. Display fixtures maintained at customer display rooms and retail stores amounted to $617,414, net of accumulated depreciation, at December 31, 2013.

Depreciation expense amounted to $234,969 and $11,652 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is included in depreciation & amortization expense in the accompanying condensed consolidated statements of operations.

Depreciation expense amounted to $126,598 and $11,652 for the three months ended December 31, 2013 and December 31, 2012, respectively, and is included in depreciation & amortization expense in the accompanying condensed consolidated statements of operations.

Advertising

Advertising costs are expensed as incurred. Total advertising expenses amounted to $88,024 and $290,762 for the six months ended December 31, 2013 and December 31, 2012, respectively, and are included in general and administrative expenses in the accompanying condensed consolidated statements of operations. Total advertising expenses amounted to $53,394 and $100,181 for the three months ended December 31, 2013 and December 31, 2012, respectively, and are included in general and administrative expenses in the accompanying condensed consolidated statements of operations.

Selling Expenses and Commissions

Selling expenses are expensed as incurred. Total selling expenses amounted to $350,516 and $341,778 for the six months ended December 31, 2013 and 2012, respectively, and are included in operating expenses in the accompanying statements of operations. Total selling expenses amounted to $253,513 and $341,778 for the three months ended December 31, 2013 and 2012.

As of September 30, 2013, the Company reclassified the presentation of freight-out from cost of sales and has included the expense as a selling expense under operating expenses in the accompanying condensed consolidated statements of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Shipping expense is included in selling expense under operating expenses and amounted to $74,578 and $262,527 during the six months ended December 31, 2013 and December 31, 2012, respectively. Total shipping expense was $43,458 and $262,527 for the three months ended December 31, 2013 and 2012, respectively.

Selling commissions are expensed as incurred. As of December 31, 2013, the Company reclassified the presentation of commissions and fees from general and administrative expenses and has included the expense as a selling expense under operating expenses in the accompanying condensed consolidated statements of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Total selling commissions amounted to $74,056 and $74,451 for the six months ended December 31, 2013 and 2012, respectively, and are included in selling expenses in the accompanying condensed consolidated statements of operations.  Total selling commissions amounted to $48,002 and $74,451 for the three months ended December 31, 2013 and 2012, respectively.

Deferred Financing Costs

Deferred financing costs represent fees paid in connection with obtaining short-term loans and convertible notes (see Notes 4, 5 and 6). These fees are amortized using a method that approximates the effective interest method over the term of the related financing.

As of December 31, 2013 and June 30, 2013, deferred financing costs of $290,197 and $358,792, respectively, net of accumulated amortization, are presented on the accompanying condensed consolidated balance sheets.

Amortization expense for deferred financing costs was $130,659 and $62,523 for the six months ended December 31, 2013 and 2012, respectively, is included in interest expense in the accompanying condensed consolidated statements of operations. Amortization expense for deferred financing costs was $69,075 and $62,523 for the three months ended December 31, 2013 and 2012, respectively, is included in interest expense in the accompanying condensed consolidated statements of operations.  The remaining deferred financing costs will be fully amortized by March 1, 2015.

Debt Discount

The Company records debt discounts in connection with raising funds through the issuance of convertible debt (see Note 5). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is charged to the statement of operations.

As of December 31, 2013 and June 30, 2013, convertible debt, net of unamortized debt discounts, was $1,214,181 and $281,716, respectively.

Amortization expense for debt discounts was $495,559 and $52,704 is included in interest expense in the accompanying condensed consolidated statements of operations for the six months ended December 31, 2013 and 2012, respectively. Amortization expense for debt discounts was $255,443 and $52,704 is included in interest expense in the accompanying condensed consolidated statements of operations for the three months ended December 31, 2013 and 2012, respectively. The remaining debt discounts will be fully amortized by March 1, 2015 (see Note 5).

Derivative Financial Instruments

GAAP requires derivative instruments embedded in convertible debt or equity instruments, to be bifurcated and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model, which management estimates to approximate the fair value using the Binomial Lattice Model. In assessing the debt instruments with characteristics of liability and equity, management determines if the convertible debt host instrument is conventional convertible debt and if there is a beneficial conversion feature. If the instrument is not considered conventional convertible debt, the Company will estimate the fair value of the embedded derivative instruments. The warrant liability is measured at fair value on a recurring basis using level 3 inputs (see Notes 5 and 6).

Financial Instruments and Concentrations of Business and Credit Risk

The Company’s financial instruments include cash and cash equivalents, convertible debt, a factoring line of credit, short-term loans, accounts payable and other current assets and liabilities.  The fair value of these instruments approximates their carrying value due to their relatively short maturities.  Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Customer concentrations also subject the Company to concentrations of credit risk.  The Company maintains cash balances that at times exceed amounts insured by the Federal Deposit Insurance Corporation.

Three customers accounted for approximately 33%, 25% and 24% of the Company’s net revenues for the six months ended December 31, 2013. Three customers accounted for approximately 30%, 29% and 18% of the Company’s net revenues for the three months ended December 31, 2013. Three customers accounted for approximately 36%, 20% and 17% of the Company’s net revenues for the three and six months ended December 31, 2012.  

Accounts receivable for one customer represented 69% of the Company’s accounts receivable balance, prior to accrued discounts, as of December 31, 2013. Accounts receivable for one customer represented 94% of the Company’s accounts receivable balance as of June 30, 2013.

Three suppliers represented 33%, 15%, and 14% of the Company’s inventory purchases as of December 31, 2013.

The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area.

License Acquisition Costs

License acquisition costs represent legal fees paid in connection with obtaining the Company’s license agreements (see Note 3). These fees are amortized using the straight-line method over the term of each license agreement.

As of December 31, 2013 and June 30, 2013, license acquisition costs, net of amortization, were $20,298 and $24,504, respectively on the accompanying condensed consolidated balance sheets.

Amortization of license acquisition costs of $4,206 and $1,342 is included in depreciation and amortization expense in the accompanying condensed consolidated statements of operations for the six months ended December 31, 2013 and December 31, 2012. Amortization of license acquisition costs was $3,535 and $671 for the three months ended December 31, 2013 and December 31, 2012.

Estimated future license acquisition cost amortization expense is as follows:

Twelve month periods ending December 31,
2014	$	7,793
2015		7,793
2016		4,712
	$	20,298

Impairment of Long-Lived Assets

The Company evaluates long-lived assets and certain identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset.  In such cases, the carrying value of these assets are adjusted to their estimated fair value and assets held for sale are adjusted to their estimated fair value less selling expenses.  No impairment losses of long-lived assets or intangible assets were recognized for the six and three months ended December 31, 2013 and December 31, 2012.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date. The Company provides a valuation allowance against its deferred tax assets when circumstances indicate that it is no longer more likely than not that such assets will be realized.

Net Loss Per Share

Basic net income / (loss) per share is computed by dividing net income / (loss) by the weighted average number of shares of common stock outstanding for the period. The Company’s potential dilutive shares, which include common stock options, common stock warrants and convertible debt have not been included in the computation of diluted net loss per share for all periods where there was a net loss as the result would be antidilutive. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share. Such potential shares of common stock consist of the following:

	As of December 31, 2013
Warrants		69,682,783
Stock options		17,780,000
Convertible Debt		33,764,706
		121,355,281

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Balance Sheets [Abstract]
Inventory net of reserve	$ 200,000	$ 365,772
Debt discount on convertible debt current	596,021	116,524
Debt discount on convertible debt non-current	$ 485,798	$ 1,281,760
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	155,829,276	155,301,468
Treasury stock at cost, shares	999,680	999,680

XML

Subsequent Events

6 Months Ended

Dec. 31, 2013

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 12.                      SUBSEQUENT EVENTS

None.

XML

Document and Entity Information	6 Months Ended
	Dec. 31, 2013	Feb. 14, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	BOLDFACE GROUP, INC.
Entity Central Index Key	0001423107
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-Q
Document Period End Date	Dec. 31, 2013
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2014
Entity Filer Category	Smaller Reporting Company
Entity Common Stock Shares Outstanding		154,929,596

XML

Summary of Significant Accounting Policies(Policies)

6 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Basis of Consolidation

Basis of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary BLB. All significant intercompany balances and transactions are eliminated in consolidation.

Method of Accounting

Method of Accounting

The Company maintains its accounting records on the accrual method of accounting in conformity with GAAP. As of December 31, 2013, the Company reclassified the presentation of freight-out from cost of sales as well as commissions and fees from general and administrative expenses and has included the expenses as a selling expense in the accompanying condensed consolidated statements of operations.

Use of Estimates

Use of Estimates

In preparing the financial statements in conformity with GAAP, management makes estimates and assumptions that affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates on certain assumptions that it believes to be reasonable as of the reporting period, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most subjective and intricate estimates include inventory obsolescence reserves, certain accruals, returns and allowances and fair value calculations, including derivative liabilities and stock option expense.

Revenue Recognition

Revenue Recognition

As required by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable and collection is probable.

For the six months ended December 31, 2013, the Company achieved 46% of net revenues from international customers and 54% of net revenues from its domestic customers. For the three and six months ended December 31, 2012, the Company achieved 2% of net revenues from international customers and 98% of net revenues from its domestic customers.

For the three months ended December 31, 2013, the Company achieved 47% of net revenues from international customers and 53% of net revenues from its domestic customers.

The Company offers its customers a variety of sales and incentive programs, including discounts, allowances, coupons, slotting fees, and co-op advertising; such amounts are recorded as a reduction of revenue over the period in which revenue is recognized.

The Company reduced revenue in the amount of $782,520 and $227,543 for the six months ended December 31, 2013 and December 31, 2012, respectively, and such amounts are included in discounts in the accompanying condensed consolidated statement of operations.

The Company reduced revenue in the amount of $499,681 and $227,543 for the three months ended December 31, 2013 and December 31, 2012, respectively, and such amounts are included in discounts in the accompanying condensed consolidated statement of operations.

Fair Value Measurements

Fair Value Measurements

The Company’s financial instruments are primarily composed of cash, accounts receivable, factoring line of credit, accounts payable, and its convertible notes and warrants. The fair value of cash, restricted cash, accounts receivable, factoring line of credit, accounts payable and convertible notes closely approximates their carrying value due to their short maturities.

The valuation techniques utilized for the warrants and beneficial conversion feature of its convertible notes are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

The Company’s warrants and the beneficial conversion feature for its convertible notes are categorized within Level 3 of the fair value hierarchy. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company's accounting and finance department.

As of December 31, 2013, there were no transfers in or out of Level 3 from other levels.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Accounts Receivable

Accounts Receivable

Accounts receivable balances represent payments due to the Company for previously recognized net sales, reduced by an allowance for doubtful accounts for balances, which are estimated to be uncollectible at December 31, 2013 and June 30, 2013, respectively. The Company grants credit terms in the normal course of business to its customers. The Company does not require collateral or other security to support credit sales. The allowance for doubtful accounts is determined based on historical experience and ongoing evaluations of the Company’s receivables and evaluations of the risks of payment. The allowance for doubtful accounts is recorded against accounts receivable balances when they are deemed uncollectible. When accounts are deemed significantly past due and uncollectible, the accounts receivable balances are written down for the amount deemed to be uncollectible. Recoveries of accounts receivable previously reserved are recorded in the consolidated statements of operations when received. As of December 31, 2013, all of the Company’s accounts receivable were deemed to be collectible. One customer accounted for 69% and 94% of outstanding accounts receivable as of December 31, 2013 and June 30, 2013, respectively.

Inventories

Inventories

Inventories, which consist primarily of finished goods, include items which are considered salable or usable in future periods, and are stated at the lower of cost or market value, with cost being based on standard cost which approximates actual cost on a first-in, first-out basis. Costs include direct materials, direct labor and overhead (e.g., indirect labor, rent and utilities, depreciation, purchasing, receiving, inspection and quality control), and in-bound freight costs. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. During the six months ended December 31, 2013 and the twelve months ended June 30, 2013, the Company reserved $200,000 and $365,722, respectively, for write-offs. The inventory write-off as of June 30, 2013 was primarily due to the name change of its Kardashian Beauty™ brand, which forced the Company to destroy or mark for destruction finished goods and work-in-process. The inventory write-off reserve as of December 31, 2013 was for allowances related to liquidation of slower moving items and write-offs for obsolete inventory. Total inventories as of December 31, 2013 and June 30, 2013 were $2.050 million and $1.949 million, respectively.

Property and Equipment

Property and Equipment

Property and equipment as of December 31, 2013 consists of costs incurred by the Company in connection with installing display fixtures at certain key customer display rooms and retail stores. The display fixtures are being depreciated on a straight-line basis over two years, which approximates the estimated useful lives of such assets. Display fixtures maintained at customer display rooms and retail stores amounted to $617,414, net of accumulated depreciation, at December 31, 2013.

Depreciation expense amounted to $234,969 and $11,652 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is included in depreciation & amortization expense in the accompanying condensed consolidated statements of operations.

Depreciation expense amounted to $126,598 and $11,652 for the three months ended December 31, 2013 and December 31, 2012, respectively, and is included in depreciation & amortization expense in the accompanying condensed consolidated statements of operations.

Advertising

Advertising

Advertising costs are expensed as incurred. Total advertising expenses amounted to $88,024 and $290,762 for the six months ended December 31, 2013 and December 31, 2012, respectively, and are included in general and administrative expenses in the accompanying condensed consolidated statements of operations. Total advertising expenses amounted to $53,394 and $100,181 for the three months ended December 31, 2013 and December 31, 2012, respectively, and are included in general and administrative expenses in the accompanying condensed consolidated statements of operations.

Selling Expenses and Commissions

Selling Expenses and Commissions

Selling expenses are expensed as incurred. Total selling expenses amounted to $350,516 and $341,778 for the six months ended December 31, 2013 and 2012, respectively, and are included in operating expenses in the accompanying statements of operations. Total selling expenses amounted to $253,513 and $341,778 for the three months ended December 31, 2013 and 2012.

As of September 30, 2013, the Company reclassified the presentation of freight-out from cost of sales and has included the expense as a selling expense under operating expenses in the accompanying condensed consolidated statements of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Shipping expense is included in selling expense under operating expenses and amounted to $74,578 and $262,527 during the six months ended December 31, 2013 and December 31, 2012, respectively. Total shipping expense was $43,458 and $262,527 for the three months ended December 31, 2013 and 2012, respectively.

Selling commissions are expensed as incurred. As of December 31, 2013, the Company reclassified the presentation of commissions and fees from general and administrative expenses and has included the expense as a selling expense under operating expenses in the accompanying condensed consolidated statements of operations. Accordingly, the prior periods have been updated to reflect such reclassification. Total selling commissions amounted to $74,056 and $74,451 for the six months ended December 31, 2013 and 2012, respectively, and are included in selling expenses in the accompanying condensed consolidated statements of operations.  Total selling commissions amounted to $48,002 and $74,451 for the three months ended December 31, 2013 and 2012, respectively.

Deferred Financing Costs

Deferred Financing Costs

Deferred financing costs represent fees paid in connection with obtaining short-term loans and convertible notes (see Notes 4, 5 and 6). These fees are amortized using a method that approximates the effective interest method over the term of the related financing.

As of December 31, 2013 and June 30, 2013, deferred financing costs of $290,197 and $358,792, respectively, net of accumulated amortization, are presented on the accompanying condensed consolidated balance sheets.

Amortization expense for deferred financing costs was $130,659 and $62,523 for the six months ended December 31, 2013 and 2012, respectively, is included in interest expense in the accompanying condensed consolidated statements of operations. Amortization expense for deferred financing costs was $69,075 and $62,523 for the three months ended December 31, 2013 and 2012, respectively, is included in interest expense in the accompanying condensed consolidated statements of operations.  The remaining deferred financing costs will be fully amortized by March 1, 2015.

Debt Discount

Debt Discount

The Company records debt discounts in connection with raising funds through the issuance of convertible debt (see Note 5). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is charged to the statement of operations.

As of December 31, 2013 and June 30, 2013, convertible debt, net of unamortized debt discounts, was $1,214,181 and $281,716, respectively.

Amortization expense for debt discounts was $495,559 and $52,704 is included in interest expense in the accompanying condensed consolidated statements of operations for the six months ended December 31, 2013 and 2012, respectively. Amortization expense for debt discounts was $255,443 and $52,704 is included in interest expense in the accompanying condensed consolidated statements of operations for the three months ended December 31, 2013 and 2012, respectively. The remaining debt discounts will be fully amortized by March 1, 2015 (see Note 5).

Derivative Financial Instruments

Derivative Financial Instruments

GAAP requires derivative instruments embedded in convertible debt or equity instruments, to be bifurcated and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model, which management estimates to approximate the fair value using the Binomial Lattice Model. In assessing the debt instruments with characteristics of liability and equity, management determines if the convertible debt host instrument is conventional convertible debt and if there is a beneficial conversion feature. If the instrument is not considered conventional convertible debt, the Company will estimate the fair value of the embedded derivative instruments. The warrant liability is measured at fair value on a recurring basis using level 3 inputs (see Notes 5 and 6).

Financial Instruments and Concentrations of Business and Credit Risk

Financial Instruments and Concentrations of Business and Credit Risk

The Company’s financial instruments include cash and cash equivalents, convertible debt, a factoring line of credit, short-term loans, accounts payable and other current assets and liabilities.  The fair value of these instruments approximates their carrying value due to their relatively short maturities.  Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Customer concentrations also subject the Company to concentrations of credit risk.  The Company maintains cash balances that at times exceed amounts insured by the Federal Deposit Insurance Corporation.

Three customers accounted for approximately 33%, 25% and 24% of the Company’s net revenues for the six months ended December 31, 2013. Three customers accounted for approximately 30%, 29% and 18% of the Company’s net revenues for the three months ended December 31, 2013. Three customers accounted for approximately 36%, 20% and 17% of the Company’s net revenues for the three and six months ended December 31, 2012.  

Accounts receivable for one customer represented 69% of the Company’s accounts receivable balance, prior to accrued discounts, as of December 31, 2013. Accounts receivable for one customer represented 94% of the Company’s accounts receivable balance as of June 30, 2013.

Three suppliers represented 33%, 15%, and 14% of the Company’s inventory purchases as of December 31, 2013.

           The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area.

License Acquisition Costs

License Acquisition Costs

License acquisition costs represent legal fees paid in connection with obtaining the Company’s license agreements (see Note 3). These fees are amortized using the straight-line method over the term of each license agreement.

As of December 31, 2013 and June 30, 2013, license acquisition costs, net of amortization, were $20,298 and $24,504, respectively on the accompanying condensed consolidated balance sheets.

Amortization of license acquisition costs of $4,206 and $1,342 is included in depreciation and amortization expense in the accompanying condensed consolidated statements of operations for the six months ended December 31, 2013 and December 31, 2012. Amortization of license acquisition costs was $3,535 and $671 for the three months ended December 31, 2013 and December 31, 2012.

Estimated future license acquisition cost amortization expense is as follows:

Twelve month periods ending December 31,
2014	$	7,793
2015		7,793
2016		4,712
	$	20,298

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company evaluates long-lived assets and certain identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future cash flows expected to be generated by the asset.  In such cases, the carrying value of these assets are adjusted to their estimated fair value and assets held for sale are adjusted to their estimated fair value less selling expenses.  No impairment losses of long-lived assets or intangible assets were recognized for the six and three months ended December 31, 2013 and December 31, 2012.

Income Taxes

Income Taxes

The Company uses the asset and liability method of accounting for income taxes.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date. The Company provides a valuation allowance against its deferred tax assets when circumstances indicate that it is no longer more likely than not that such assets will be realized.

Net Loss per Share

Net Loss Per Share

Basic net income / (loss) per share is computed by dividing net income / (loss) by the weighted average number of shares of common stock outstanding for the period. The Company’s potential dilutive shares, which include common stock options, common stock warrants and convertible debt have not been included in the computation of diluted net loss per share for all periods where there was a net loss as the result would be antidilutive. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share. Such potential shares of common stock consist of the following:

	As of December 31, 2013
Warrants		69,682,783
Stock options		17,780,000
Convertible Debt		33,764,706
		121,355,281

XML

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenues
Gross revenues	$ 1,968,962	$ 1,753,812	$ 3,520,976	$ 1,753,812
Discounts	499,861	227,543	782,521	227,543
Revenues, net of discounts	1,469,101	1,526,269	2,738,455	1,526,269
Cost of Goods Sold
Cost of goods sold	1,143,141	794,396	1,900,211	794,396
Gross Profit	325,960	731,873	838,244	731,873
Operating expenses:
Selling expenses	253,513	341,778	350,516	341,778
Research and development	5,747	3,473	11,189	23,012
Royalty expense	176,597	161,404	396,334	322,809
Professional fees	245,443	571,326	667,705	608,723
General and administrative expenses	1,015,521	731,830	1,697,022	1,392,179
Depreciation and amortization expense	126,598	74,176	234,969	74,176
Product development fee - related party	230,000	210,000	500,000	412,700
Total Operating Expense	2,053,419	2,093,987	3,857,735	3,175,377
Loss from operations	(1,727,459)	(1,362,114)	(3,019,491)	(2,443,504)
Other (income) / expenses:
Interest expense, net of interest income	413,016	296,135	782,482	296,135
Derivative liability (gain) / loss	(375,334)	406,803	(1,245,925)	346,627
Net loss	$ (1,765,141)	$ (2,065,052)	$ (2,556,048)	$ (3,086,266)
Net loss per share attributable to common shareholders - basic and diluted	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.04)
Weighted average number of common shares used in computing - basic and diluted	154,491,758	87,773,384	154,397,805	87,188,180

XML

Commitments and Contingencies

6 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7.                         COMMITMENTS AND CONTINGENCIES

License Agreements

On May 9, 2012, the Company entered into a licensing agreement with the Licensors (see Note 3 for further detail).

During the term of the licensing agreement the Company has agreed to pay a guaranteed minimum royalty payment of $4,686,125 or $4,985,000 depending on launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $1,000,000

· Contract period two: $925,000 or $1,000,000

· Contract period three: $1,188,625 or $1,285,000

· Contract period four: $1,572,500 or $1,700,000

On July 11, 2012, the Company entered into the Second License (see Note 3). The Company agreed to pay a guaranteed minimum royalty payment of $600,000 depending on launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $100,000

· Contract period two: $225,000

· Contract period three: $275,000

On April 25, 2013, the Company entered into a licensing agreement with the Third Licensor (see Note 3). The Company agreed to pay a guaranteed minimum royalty payment of $100,000 depending on launch date of various products in accordance with the following schedule, but subject to adjustments:

· Contract period one: $33,333

· Contract period two: $33,333

· Contract period three: $33,334

Operating Lease

On May 8, 2012, the Company executed a one-year operating lease for its corporate office commencing on May 15, 2012 at a monthly rent payment of $1,785 per month. Total rent expense related to this operating lease was $10,710 and $10,620 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is included in general and administrative expenses in accompanying statement of operations. Total rent expense related to this operating lease was $5,355 for each of the three months ended December 31, 2013 and December 31, 2012. As of December 31, 2013, the lease has expired and the Company is renting the office space on a month-to-month basis.

On January 7, 2013, the Company executed a five-month operating lease for storage commencing on January 1, 2013 at a monthly rent payment of $1,500 per month. Total rent expense related to this operating lease was $9,000 and $0 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is included in general and administrative expenses in accompanying statement of operations. Total rent expense related to this operating lease was $4,500 and $0 for the three months ended December 31, 2013 and December 31, 2012, respectively. As of December 31, 2013, the storage space lease has expired and the Company is renting the space on a month-to-month basis.

Litigation

In the normal course of business, the Company may become involved in various legal proceedings. Except as described below, management knows of no pending or threatened legal proceeding to which they are or will be a party and which, if successful, might result in a material adverse change in our business, properties or financial condition.

On November 19, 2012, an action entitled Chroma Makeup Studio, LLC. v. BOLDFACE Group, Inc. and BOLDFACE Licensing + Branding was filed in the United States District Court for the Central District of California, Western Division (the “Court”). Chroma Makeup Studio, LLC (“Chroma”) alleged that the Company’s use of the term Khroma, including the marks Khroma Beauty and Khroma Beauty By Kourtney, Kim and Khloe (the “Khroma Beauty Marks”), for cosmetics is infringing upon Chroma's rights in its Chroma mark. The Complaint included claims for trademark infringement under the Lanham Act and unfair competition under applicable California law. The Court set a tentative trial date of April 22, 2014. The parties also agreed to pursue private mediation in an attempt to resolve the disputed issues in this case. On November 7, 2013, following private mediation, the parties agreed to settle the action and are currently negotiating the terms of a written settlement agreement. On December 11, 2013, the Company entered into a settlement agreement and mutual general release (the “Settlement Agreement”) with Chroma to settle any and all claims between the Company and Chroma. Pursuant to the terms of the Settlement Agreement, the parties have agreed that the terms of the Settlement Agreement are to remain confidential.  Pursuant to the terms of the Settlement Agreement, and with no admission of any liability, the Company has agreed to pay Chroma a cash amount over a period of one year commencing on December 31, 2013 and ending on December 31, 2014. The total cash amount that the Company has agreed to pay Chroma is lower than the amount the Company reserved for any payments to be made in connection the dispute.

On November 30, 2012, BLB filed a complaint for a declaratory judgment in the United States District Court for the Central District of California, Western Division entitled BOLDFACE Licensing + Branding v. By Lee Tillett, Inc. (“Tillett”). BLB’s complaint requests a declaration from the Court that (1) BLB’s use of the Khroma term, including the Khroma Beauty marks does not infringe on Tillett’s rights in its Kroma trademark, and (2) BLB’s two pending trademark applications for Khroma Beauty marks should be allowed to register with the USPTO. On January 9, 2013 Tillet filed an answer and counterclaims for (1) trademark infringement, (2) false designation of origin, (3) trademark infringement, and (4) unfair competition pursuant. In addition to BLB, Tillett's Counterclaims are made against the following additional parties: Kims a princess Inc., 2Die4Kourt Inc., Khlomoney Inc., and individuals Kim Kardashian, Kourtney Kardashian, and Khloe Kardashian (collectively, the "Kardashian Parties"). In March 2013, Tillet obtained a preliminary injunction enjoining BLB’s use of the Khroma Beauty mark. BLB appealed the injunction and moved for a stay in the Ninth Circuit. As a result, the injunction was stayed until May 31, 2013. The Ninth Circuit ruled on the Company’s motion on June 7, 2013 granting Tillett’s application and ruling that the preliminary injunction would be effective as of June 7, 2013. By the time the stay expired, BLB had already changed the name of its mark from Khroma Beauty by Kourtney, Kim and Khloe to Kardashian Beauty. On August 9, 2013, BLB and the Kardashian Parties filed a joint motion to dismiss the appeal. On August 2, 2013, the parties participated in mediation in an attempt to settle the case but were unable to do so. The Court set a tentative trial date of April 22, 2014.

On October 28, 2013, Tillett filed a motion to amend its counterclaim to add Gold Grenade, LLC as a counter-defendant and two additional claims: conspiracy and common law trademark infringement.  The Company and the Kardashian Parties have filed an answer to Tillett’s motion.  On November 18, 2013, the Court denied Tillett’s motion to amend its counterclaim.

The Company filed a motion for summary judgment, contending that Tillett could not prove that it suffered any damages based on the conduct of the BLB. On December 6, 2013, the Court issued an order to show cause re: contempt and sanctions against BLB based on allegations that BLB had distributed Khroma labeled product after the effective date of the preliminary injunction. As part of that order, the Court took off calendar the pending summary judgment motion and all remaining trial and pre-trial dates. The parties filed briefs regarding the alleged contempt and an evidentiary hearing was held on January 9, 2014, after which the Court took the matter under submission. As of the date of this filing, no ruling has been issued.

Based on the expressed willingness of BLB to settle the cases and the likely cost to continuing litigation, the Company has accrued for total settlement costs of less than $700,000 for any potential settlement offers.

Registration Agreement

As of December 31, 2013, the Company had 300,000,000 shares of common stock authorized. As of December 31, 2013, the Company had 155,829,276 shares issued and 155,591,438 shares outstanding.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are not entitled to receive dividends unless declared by the Company's Board of Directors.

PPO Offering Registration Rights

In connection with the Merger and Offering (as defined in Notes 1, 4 and 7), the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with each of the investors participating in the Offering. Under the Registration Rights Agreement, as amended, the Company committed to file a registration statement on Form S-1, or other applicable form (the “Registration Statement”), covering the resale of (i) the Company’s common stock underlying the Bridge Warrants (as defined in Note 6), (ii) common stock underlying the PPO Units (as defined in Note 6) sold or to be sold in the Offering, and (iii) common stock underlying the Investor Warrants (as defined in Note 6) (including securities issued in the Offering as a result of the conversion of the Bridge Notes (as defined in Note 6), but not common stock that is issuable upon exercise of the broker warrants issued to the placement agent for the Offering) (collectively, the “Registrable Securities”) no later than October 29, 2012 (the “Filing Date”), and to use commercially reasonable efforts to cause the Registration Statement to become effective no later than 150 days after it is filed (the “Effectiveness Date”). As of the date of this Quarterly Report the Company has not filed the Registration Statement with the SEC. The Company agreed to use its commercially reasonable efforts to maintain the effectiveness of the Registration Statement for at least one year from the date the Registration Statement is declared effective by the SEC or for such shorter period ending on the earlier to occur of (i) until Rule 144 of the Securities Act is available to investors with respect to all of their Registrable Securities or (ii) the date when all of the Registrable Securities registered thereunder shall have been sold.

The Company will be liable for liquidated damages at the rate of 1% of the purchase price per PPO Unit paid by each investor for the Registrable Securities then held by such investor for each full period of 30 days for which the Company fails to file the registration statement by the Filing Date or if the Company fails to have the Registration Statement declared effective by the Effectiveness Date (each, a “Registration Event”), until such failure is cured. The payment amount shall be prorated for partial 30-day periods. The aggregate penalty accrued with respect to each investor may not exceed 10% of the original purchase price paid by such investor. However, if a Registration Event occurs (or is continuing) on a date more than one year after July 12, 2012 or the final closing of the Offering, liquidated damages shall be paid only with respect to that portion of the Registrable Securities that cannot then be immediately resold in reliance on Rule 144. If the Company fails to pay any partial liquidated damages or refund pursuant in full within seven days after the date payable, the Company will pay interest thereon at a rate of 8% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the holder of the PPO Unit.

In December 2006, the FASB issued guidance on accounting for registration payment arrangements. This guidance specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement, should be separately recognized and measured in accordance with FASB guidance on accounting for contingencies. This guidance further clarifies that a financial instrument subject to a registration payment arrangement should be accounted for in accordance with GAAP without regard to the contingent obligation to transfer consideration pursuant to the registration payment arrangement. The Company applied the recognition and measurement provisions of the FASB guidance to the registration rights associated with the Registration Rights Agreement.

The Amendment Agreements also provided for a waiver of all penalties incurred by the Company under the terms of the PPO registration rights agreement as a result of the Company’s failure to timely file and effect the registration for resale of the private placement securities.

Aegis Convertible Note Offering Registration Rights

In connection with two closings of convertible note offerings in December 2012 and March 2013, the Company also entered into a registration rights agreement with the Investors (the “Convertible Note Registration Rights Agreement”). Under the terms of the Convertible Note Registration Rights Agreement, the Company committed to file a registration statement on Form S-1, or other applicable form, covering the resale of (i) the Common Stock underlying the Warrants and (ii) the Common Stock underlying the Notes (collectively, the “Convertible Note Registrable Securities”) within 45 days from the final closing of the Offering (the “Filing Date”), and to use its commercially reasonable efforts to cause the registration statement to become effective no later than 90 days after it is filed (the “Effectiveness Date”).

The Company agreed to use its commercially reasonable efforts to maintain the effectiveness of the registration statement for at least one year from the date the registration statement is declared effective by the SEC or for such shorter period ending on the earlier to occur of (i) until Rule 144 of the Securities Act of 1933, as amended (the “Securities Act”), is available to Investors with respect to all of their Convertible Note Registrable Securities or (ii) the date when all of the Convertible Note Registrable Securities registered thereunder shall have been sold. The Company will be liable for monetary penalties equal to 0.5% of the purchase price per Unit paid by such Investor for the Convertible Note Registrable Securities then held by each investor for each full period of period of 30 days if the Company fails to file the registration statement by the Filing Date or if the Company fails to use its reasonable efforts to have the registration statement declared effective by the Effectiveness Date until such failure is cured. The payment amount shall be prorated for partial 30-day periods. The maximum aggregate amount of payments to be made by the Company as the result of such failures, whether by reason of a filing deadline failure, effectiveness deadline failure or any combination thereof, shall be an amount equal to 6% of the purchase price per Unit paid by such Investor for the Convertible Note Registrable Securities held by such Investor at the time of the first occurrence of such failure to file with, or to have the registration statement be declared effective by, the United States Securities and Exchange Commission (the “SEC”).

Moreover, no such payments shall be due and payable with respect to any Convertible Note Registrable Securities that the Company is unable to register due to limits imposed by the SEC’s interpretation of Rule 415 under the Securities Act. The holders of any Convertible Note Registrable Securities removed from the registration statement as the result of a Rule 415 comment or other comment from the SEC shall have “piggyback” registration rights for the shares of Common Stock underlying the Convertible Note Registrable Securities, until such shares can be sold without limitation under Rule 144, with respect to any registration statement filed by the Company following the effectiveness of the registration statement which would permit the inclusion of these shares.

During the period ended December 31, 2013, the Company has recorded total liabilities of $206,381 in accrued expenses on the accompanying condensed consolidated balance sheet associated with the above registration rights.

XML

Derivative Liability

6 Months Ended

Dec. 31, 2013

Derivative Liability [Abstract]

DERIVATIVE LIABILITY

NOTE 6.                         DERIVATIVE LIABILITY

As of December 31, 2013, the Company had reserved 69,682,783 shares of common stock for issuance upon exercise of the Company’s outstanding warrants. The Company had reserved 33,764,706 shares of common stock for issuance upon exercise of the Company’s outstanding convertible debt as of December 31, 2013.

In connection with the June and August Convertible Notes offerings, the Company entered into an Amendment and Waiver Agreement (collectively, the “Amendment Agreement”) the holders of substantially all of the securities issued in connection with the Company’s Bridge Notes (as defined below), PPO Units (as defined below), short-term loans and PPO and Bridge Broker Warrants (as defined below) with the holders (collectively, the “Holders”) pursuant to which the Company reduced the exercise prices of all of its outstanding Series A, Series B, Series C, Series D and Series E common stock purchase warrants (collectively, the “Warrants”) as follows: the exercise price per share of the Series A warrants that had an initial exercise price of $0.25 was reduced to $0.01; the exercise price per share of the Series B warrants that had an initial exercise price of $0.50 was reduced to $0.015; the exercise price per share of the Series C warrants that had an initial exercise price of $1.00 was reduced to $0.03; and the exercise price per share of the Series D and Series E warrants that had an initial exercise price of $0.25 was reduced to $0.01. As the triggering event for the re-pricing of the warrants was the June Convertible Notes offering, the effect of the reduction in the respective exercise prices was reflected in the June 30, 2013 statement of operations and accompanying balance sheet.

In consideration of the exercise price reductions, the Holders agreed to permanently waive all past and future exercise price and share number anti-dilution adjustment provisions that would otherwise be triggered by share issuances by the Company at prices less than the purchase, exercise or conversion price of any securities acquired by the Holders in the offerings or underlying any of such securities.

Bridge Notes

Upon the completion of the Merger, $1,925,030 in bridge notes (the “Bridge Notes”) converted into PPO Units. The holders of the Bridge Notes received 7,700,120 five-year bridge warrants (the “Bridge Warrants”), each exercisable to purchase one share of the Company’s Common Stock. 3,850,060 of the Bridge Warrants were originally exercisable at $0.25 per share (the “Series A Warrants”) and 3,850,060 of the Bridge Warrants (the “Series B Warrants”) were originally exercisable at $0.50 per share. As of August 29, 2013, the Series A warrants were modified to be exercisable at $0.01 per share and the Series B warrants were modified to be exercisable at $0.015 per share. Except as to exercise price, the Bridge Warrants are identical, in all material respects to the Investor Warrants (as defined below).

Licensor Warrants

The Company also issued to the certain licensors warrants to purchase an aggregate of 10,000,000 shares of the Company’s common stock for a term of ten years at an original exercise price of $0.24 per share (the “Licensor Warrants”). The exercise price and number of shares of common stock issuable upon exercise of the Licensor Warrants may be adjusted in certain circumstances including stock splits and stock dividends (but excluding future issuances of the Company’s equity securities, regardless of whether or not such issuance is for no consideration or for consideration per share less than $0.24). The Licensor Warrants are exercisable on a cashless basis at any time prior to their expiration. Except as otherwise described herein, the Licensor Warrants are identical in all material respects to the Investor Warrants. On May 8, 2013, the Company reduced the exercise price of the Licensor Warrants to $0.12 in consideration of value received.

Private Placement Offering

Concurrently with the closing of the Merger, the Company completed an initial closing of a private placement offering (the “Offering”) wherein 500,000 units (the “PPO Units”) were sold, at a price of $0.25 per PPO Unit, for a total cash consideration of $125,000. Each PPO Unit consists of one share of the Company’s common stock and a warrant to purchase one share of the Company’s common stock (the “Investor Warrants”). The Investor Warrants are exercisable for a period of five years at a purchase price of $1.00 per share of the Company’s common stock. If at any time during the two year period following the closing of the Offering the Company issues additional shares of common stock for consideration per share of less than $0.25 (the “Reduced Price”), then the Company agreed to issue to the investors in the Offering, concurrently with such issue and without any additional consideration from the investors, a number of additional shares of the Company’s common stock and Investor Warrants equal to the difference between (A) the purchase price of the PPO Units being subscribed for divided by the Reduced Price and (B) the number of shares of the Company’s common stock included in the units being subscribed for in the subsequent offering. In addition, on July 12, 2012, the Company effected the conversion of $1,925,030 in Bridge Notes. The Bridge Notes were converted into 7,700,120 PPO Units and 7,700,120 five-year Investor Warrants each exercisable to purchase one share of the Company’s common stock. As of August 29, 2013, the Investor Warrants were modified to be exercisable at $0.03 per share.

On July 20, 2012, the Company completed the second closing of the Offering through the sale of 124,000 PPO Units (for aggregate gross proceeds of $31,000) consisting of 124,000 shares of common stock and 124,000 five-year Investor Warrants with an exercise price of $1.00.

On July 31, 2012, the Company completed the third closing of the Offering through the sale of 1,639,920 PPO Units (for aggregate gross proceeds of $409,980) consisting of 1,639,920 shares of common stock and 1,639,920 five-year Investor Warrants with an exercise price of $1.00.

On August 24, 2012, the Company completed the fourth closing of the Offering through the sale of 500,000 PPO Units (for aggregate gross proceeds of $125,000) consisting of 500,000 shares of common stock and 500,000 five-year Investor Warrants with an exercise price of $1.00.

On September 10, 2012, the Company completed the fifth closing of the Offering through the sale of 80,000 PPO Units (for aggregate gross proceeds of $20,000) consisting of 80,000 shares of common stock and 80,000 five-year Investor Warrants with an exercise price of $1.00.

On December 6, 2012, the Company completed the sixth closing of the Offering through the sale of 600,000 PPO Units (for aggregate gross proceeds of $150,000) consisting of 600,000 shares of common stock and 600,000 five-year Investor Warrants with an exercise price of $1.00.

On December 10, 2012, the Company completed the seventh closing of the Offering through the sale of 200,000 PPO Units (for aggregate gross proceeds of $50,000) consisting of 200,000 shares of common stock and 200,000 five-year Investor Warrants with an exercise price of $1.00.

On December 12, 2012, the Company completed the eighth closing of the Offering through the sale of 100,000 PPO Units (for aggregate gross proceeds of $25,000) consisting of 100,000 shares of common stock and 100,000 five-year Investor Warrants with an exercise price of $1.00.

On February 8, 2013, the Company completed the ninth closing of the Offering through the sale of 200,000 PPO Units (for aggregate gross proceeds of $50,000) consisting of 200,000 shares of common stock and 200,000 five-year Investor Warrants with an exercise price of $1.00.

As of August 29, 2013, the Investor Warrants, aggregating to 11,664,040 warrants, or the “Series C” Warrants, were modified to be exercisable at $0.03 per share.

In connection with the July 12, 2012 PPO closing, the Company issued an aggregate of 656,010 five year broker warrants with an exercise price of $0.25 per share. Effective as of December 31, 2013, 119,962 broker warrants have been cancelled with the repurchase of 999,680 shares. In connection with the July 20, 2012, July 31, 2012, August 24, 2012, and September 10, 2012 closings, the Company issued an aggregate of 187,514 five-year broker warrants with an exercise price of $0.25 per share. In connection with the December 6, 2012, December 10, 2012, and December 12, 2012 closings, the Company issued an aggregate of 72,000 five-year broker warrants with an exercise price of $0.25 per share. In connection with the February 8, 2013 closing, the Company issued 16,000 five-year broker warrants with an exercise price of $0.25 per share. As of August 29, 2013, the broker warrants, aggregating to 851,549 warrants, were modified to be exercisable at $0.01 per share.

Short - Term Loans

In connection with two short-term notes that were issued on September 7, 2012 and an additional short-term note that the Company issued on September 24, 2012, for an aggregate principal amount of $300,000, the Company issued 1,200,000 warrants to holders of these notes (the “Series D Warrants”). These warrants are exercisable for a period of five years at a purchase price of $0.25 per share of the Company’s common stock. These warrants contain certain anti-dilution and other customary terms.

On March 28, 2013, in connection with a repayment of a short-term shareholder note, the Company issued an additional 150,000 five-year warrants to the holder to compensate the holder as the shareholder note was past due. The fair value of the warrants was $9,482 using a Black-Scholes model with the following assumptions: expected volatility of 70%, risk free interest rate of 0.83%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and debt discount on the balance sheet.  These warrants are exercisable for a period of five years at a purchase price of $0.25 per share of the Company’s common stock. These warrants contain certain anti-dilution and other customary terms.

As of August 29, 2013, the Series D warrants were modified to be exercisable at $0.01 per share.

Convertible Note Warrants

In connection with the Convertible Note offering on December 21, 2012, the Company issued 8,000,000 Convertible Note Warrants. 4,000,000 Convertible Note Warrants were exercisable at $0.50 and 4,000,000 Convertible Note Warrants were exercisable at $1.00.

The fair value of the warrants at issuance was estimated at $686,192 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and debt discount on the balance sheet.

Convertible Note Broker Warrants

In connection with the Convertible Note offering, the Company issued 1,600,000 Convertible Note Broker Warrants. 800,000 Convertible Note Broker Warrants are exercisable at $0.50 and 800,000 Convertible Note Warrants are exercisable at $1.00.

The fair value of the warrants at issuance was estimated at $137,238 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

Debt Conversion Feature

The Convertible Note offering on December 21, 2012 included a Debt Conversion Feature (see Note 5).

The fair value of the Debt Conversion Feature was estimated, using Level 3 inputs, at $663,528 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry.  

June and August Convertible Note Warrants

In connection with the June Convertible Note offering on June 20, 2013, the Company issued 24,705,882 June Convertible Note Warrants, which are exercisable at $0.082 and contain weighted average anti-dilution protections.

The fair value of the warrants at issuance was estimated at $752,126 using a Black-Scholes valuation model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and debt discount on the balance sheet.

In connection with the August Convertible Note offering on August 29, 2013, the Company issued 9,058,824 August Convertible Note Warrants, which are exercisable at $0.082 and contain weighted average anti-dilution protections.

The fair value of the warrants at issuance was estimated at $85,293 using a Black-Scholes valuation model with the following assumptions: expected volatility of 65%, risk free interest rate of 1.9%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded as a debt discount on the balance sheet.

June Convertible Note Broker Warrants

In connection with the June Convertible Note offering on June 20, 2013, the Company issued 1,912,195 Convertible Note Broker Warrants. The Convertible Note Broker Warrants are exercisable at $0.082.

The fair value of the warrants at issuance was estimated at $60,886 using a Black-Scholes valuation model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

Founder Warrants

In connection with the acquisition of the Third License on April 17, 2013, the Company issued 2,500,000 warrants. The warrants are exercisable at $0.13.

The fair value of the warrants at issuance was estimated at $210,349 using a Black-Scholes valuation model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

Consultant Warrants

On April 8, 2013, the Company issued 500,000 five-year warrants with an exercise price of $0.25 to a consultant, engaged effective as of the same date for consulting services to the Company. The warrants shall vest ratably in arrears over six 30-day periods beginning on April 8, 2013, with one-sixth of the warrants vesting on each successive thirtieth day following April 8, 2013, subject to the termination of the consulting agreement prior thereto.

The fair value of the warrants at issuance was estimated at $42,625 using a Black-Scholes valuation model with the following assumptions: expected volatility of 65%, risk free interest rate of 1.57%, expected life of five years and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability and deferred financing cost on the balance sheet.

Debt Conversion Feature

The June and August Convertible Note offerings included a Debt Conversion Feature (see Note 5).

The fair value of the Debt Conversion Feature of the June 20, 2013 closing was estimated, using Level 3 inputs, at $491,051 using a Black-Scholes model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of eighteen months and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry.

The fair value of the Debt Conversion Feature of the August 29, 2013 closing was estimated, using Level 3 inputs, at $25,827 using a Black-Scholes model with the following assumptions: expected volatility of 65%, risk free interest rate of 1.9%, expected life of eighteen months and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry.

Fair Value Measurement

The fair value at issuance of those warrants granted during the quarter ended September 30, 2012 was estimated at $3,788,687 using a Black-Scholes model with the following assumptions: expected volatility of 70%, risk free interest rate of 0.83%, expected life of 5.0 – 10.0 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The fair value at issuance of those warrants granted during the quarter ended December 31, 2012 was $888,596 using a Black-Scholes model with the following assumptions: expected volatility of 60%, risk free interest rate of 0.95%, expected life of 0.8 - 5.0 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The fair value at issuance of those warrants granted during the quarter ended March 31, 2013 was estimated at $297,716 using a Black-Scholes model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.005%, expected life of 5.0 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The fair value at issuance of those warrants granted during the quarter ended June 30, 2013 was estimated at $1,067,196 using a Black-Scholes model with the following assumptions: expected volatility of 55%, risk free interest rate of 1.685%, expected life of eighteen months to 10 years, based upon the term of the warrant, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty and personal care industry. The fair value of the warrants was recorded in the long-term liability section of the balance sheet.

The Company’s warrant liability was valued at December 31, 2013 using a Black-Scholes valuation model with the following assumptions: expected volatility of 80%, risk free interest rate of 2.1%, expected life of fourteen months – 10 years, based upon the term of the warrant or convertible note, and no dividends. Expected volatility was based on the volatility of similar public entities in the beauty industry. The following table is a roll forward of the fair value of the warrant liability:

	December 31,  2013			June 30, 2013
Beginning Balance	$	1,660,440		$	0
Issuance of Warrants		113,091			7,252,283
Repurchase / Exercise / Cancellation of Warrants		0			(179,884	)
Change in fair value		(1,245,925	)		(5,411,959	)
Ending Balance	$	527,606		$	1,660,440

The fair value of the Company’s outstanding warrants and derivative instruments was estimated at $527,606 and $1,660,440 as of December 31, 2013 and June 30, 2013. The (gain) / loss in the fair value of the warrants of $(1,245,925) and $346,627 for the six months ended December 31, 2013 and December 31, 2012, respectively, was recognized as a (gain) / loss in the derivative liability section on the accompanying condensed consolidated statement of operations. The (gain) / loss in the fair value of the warrants was $(375,334) and $406,803 for the three months ended December 31, 2013 and December 31, 2012, respectively.

XML

Derivative Liability (Tables)

6 Months Ended

Dec. 31, 2013

Derivative Liability [Abstract]

Summary of roll forward of fair value of warrant liability

	December 31,  2013			June 30, 2013
Beginning Balance	$	1,660,440		$	0
Issuance of Warrants		113,091			7,252,283
Repurchase / Exercise / Cancellation of Warrants		0			(179,884	)
Change in fair value		(1,245,925	)		(5,411,959	)
Ending Balance	$	527,606		$	1,660,440

XML

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Summary of future license acquisition cost amortization expense

Twelve month periods ending December 31,
2014	$	7,793
2015		7,793
2016		4,712
	$	20,298

Summary of consists of potential common shares

	As of December 31, 2013
Warrants		69,682,783
Stock options		17,780,000
Convertible Debt		33,764,706
		121,355,281

XML

Income Taxes

6 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

INCOME TAXES

NOTE 10.                      INCOME TAXES

The Company did not incur any income tax expense for the three and six months ended December 31, 2013. At December 31, 2013, $2,746,569 of federal and state net operating losses were available to the Company to offset future taxable income, which will expire in 2033. Given the short history of the Company and the uncertainty as to the likelihood of future taxable income, the Company has recorded a 100% valuation reserve against the anticipated recovery from the use of the net operating losses created at the inception or generated thereafter. The Company will evaluate the appropriateness of the valuation allowance on an annual basis and adjust the allowance as considered necessary.

The Company’s effective tax rate differs from the federal statutory rate of 34% primarily due to the impact of state income taxes and the valuation allowance recorded against its deferred tax assets.

	December 31, 2013
Statutory rate		34.0	%
State income taxes		6.0	%
Permanent differences		(15.7	)%
Valuation allowance		(21.4	)%
Other		(2.7	)%
Total		0.0	%

The principal components of deferred tax assets and (liabilities) are as follows as of December 31, 2013 and June 30, 2013 on a tax effected basis:

	December 31, 2013			June 30, 2013
Net operating losses carryforward	$	2,159,286		$	2,002,842
Start-up costs and fixed assets, net of amortization		120,011			60,005
Property and equipment		126,955			56,270
Stock based compensation		340,217			192,786
Gross deferred taxes	$	2,746,569		$	2,311,903
Valuation allowance		(2,746,569	)		(2,311,903	)
Net deferred taxes	$	-		$	-

The Company follows the provisions of FASB ASC Subtopic 740-10-65-1, Income Taxes. As of December 31, 2013 and June 30, 2013, respectively, the Company did not recognize any liability for unrecognized tax benefits.

Section 382 of the Internal Revenue Code can limit the amount of net operating losses, which may be utilized if certain changes to a company’s ownership occur. While the Company underwent a shift in ownership in 2013 as defined by Section 382 of the Internal Revenue Code, the Company has not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code, it may incur limitations in the future if there is a change in ownership.

The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at December 31, 2013. There are no income tax examinations currently in process and as of the date of this report.

XML

Equity Transactions

6 Months Ended

Dec. 31, 2013

Equity Transactions [Abstract]

EQUITY TRANSACTIONS

NOTE 8.                         EQUITY TRANSACTIONS

On December 31, 2013, the Company issued 337,838 shares of common stock to a board member per the compensation package of said board member, fair valued at $6,250.

XML

Stock Compensation Expense and Fair Value Measurement

6 Months Ended

Dec. 31, 2013

Stock Compensation Expense and Fair Value Measurement [Abstract]

STOCK COMPENSATION EXPENSE AND FAIR VALUE MEASUREMENT

NOTE 9.                         STOCK COMPENSATION EXPENSE AND FAIR VALUE MEASUREMENT

In July 2012, the Company's Board of Directors adopted the 2012 Stock Option and Incentive Plan (the "2012 Equity Incentive Plan"). The 2012 Equity Incentive Plan provides for the grants of incentive and non-qualified stock options, restricted stock and other equity awards to employees, officers, directors, consultants and advisors of the Company. Provisions such as vesting, repurchase and exercise conditions, and limitations are determined by the Board of Directors on the grant date. There are 20,000,000 shares of the Company’s Common Stock reserved for issuance under its 2012 Equity Incentive Plan.

As of December 31, 2013, the Company has issued an aggregate of 17,780,000 common shares for future issuance upon exercise of outstanding and future grants of common stock options and future issuances of restricted stock awards pursuant to the Company's 2012 Equity Incentive Plan.

Effective as of July 12, 2012 the Company issued 4,600,000 stock options under its 2012 Equity Incentive Plan to the Company’s CEO, a consultant and the Chairman of the Board of Directors; 3,600,000 of which have a five-year term and 1,000,000 of which has a ten-year term. All of the options are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.24 per share. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the Merger, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date. As of December 31, 2013, 1,000,000 options have been forfeited.

Effective as of August 15, 2012 the Company issued 400,000 stock options under its 2012 Equity Incentive Plan to certain of the Company’s employees and consultants. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.24 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date. As of December 31, 2013, 2,500 options have been forfeited.

Effective as of November 21, 2012 the Company issued 500,000 stock options under its 2012 Equity Incentive Plan to the Company’s newly appointed director. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.24 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of March 28, 2013 the Company issued 500,000 stock options under its 2012 Equity Incentive Plan to the Company’s newly appointed director. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.17 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of April 8, 2013 the Company issued 500,000 stock options under its 2012 Equity Incentive Plan to the Company’s newly appointed director. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.14 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of June 28, 2013 the Company issued 50,000 stock options under its 2012 Equity Incentive Plan to two of the Company’s directors pursuant to the Company’s board compensation package, effective as of March 15, 2013. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.05 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of July 12, 2013 the Company issued 11,400,000 stock options under its 2012 Equity Incentive Plan to the Company’s CEO and a consultant. The options have a five-year term. All of the options are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.06 per share. Such options, which will vest annually at a rate of 33% beginning on the first anniversary of the grant date, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

Effective as of August 15, 2013 the Company issued 1,357,500 stock options under its 2012 Equity Incentive Plan to certain of the Company’s employees and consultants. All of the options have a ten-year term and are exercisable for the purchase of one share of the Company’s common stock at an exercise price of $0.05 per share. Vesting on these awards is a three-year period. Such options, which will vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case, if the grantee remains employed by the Company or any of its subsidiaries on each annual vesting date.

As of December 31, 2013, 1,527,500 stock options had been forfeited.

The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model. The expected life assumption is based on the estimated forfeiture rate. Expected volatility is based on a blend of the volatility of the Company and similar public entities in the beauty industry. The risk-free interest rate is the yield currently available on U.S. Treasury five-year and seven-year zero-coupon issues approximating the expected term used as the input to the Black-Scholes model. FASB accounting guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods as options vest, if actual forfeitures differ from those estimates. During the six months ended December 31, 2013, because substantially all of the Company's stock option grants vest annually, stock-based employee compensation expense includes the actual impact of forfeitures. No stock options are exercisable as of December 31, 2013. The relevant inputs used to determine the value of the stock option grants is as follows:

	Number of options outstanding		Weighted average risk-free rate			Expected life in years		Expected  volatility			Expected  dividends
July 12, 2012		3,600,000		0.83	%		3.5		70	%		0	%
August 15, 2012		397,500		0.83	%		6.0		70	%		0	%
November 21, 2012		500,000		0.95	%		6.0		60	%		0	%
March 28, 2013		0		1.005	%		6.0		55	%		0	%
April 8, 2013		500,000		1.685	%		6.0		55	%		0	%
June 28, 2013		25,000		1.685	%		6.0		55	%		0	%
July 12, 2013		11,400,000		1.715	%		3.5		65	%		0	%
August 15, 2013		1,357,500		1.860	%		6.0		65	%		0	%
Total		17,780,000

The fair value of the Company’s outstanding options issued to non-employees was $27,119 as of December 31, 2013. These options were valued at December 31, 2013 using a Black-Scholes model with Level 3 inputs. Expected volatility was based on the volatility of similar public entities in the beauty industry.

As a result, share-based compensation expense totaled $315,106 and $289,279 for the six months ended December 31, 2013 and December 31, 2012, respectively, and is recorded in general and administrative expenses. Share-based compensation expense totaled $161,803 and $159,131 for the three months ended December 31, 2013 and December 31, 2012, respectively.

XML

Related Party Transactions

6 Months Ended

Dec. 31, 2013

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 11.                      RELATED PARTY TRANSACTIONS

The Company entered into a consulting agreement with Gold Grenade, LLC (“Gold Grenade”), a related entity co-owned by two of the shareholders to receive product development services. As of December 31, 2013 and December 31, 2012, $234,550 and $149,898, respectively, was due to Gold Grenade. For the six months ended December 31, 2013 and December 31, 2012, the Company incurred approximately $500,000 and $412,700 respectively, in product development fees payable to Gold Grenade. For the three months ended December 31, 2013 and December 31, 2012, the Company incurred approximately $230,000 and $210,000 respectively, in product development fees payable to Gold Grenade. The agreement is to remain in effect unless either party desires to cancel the agreement.

XML

Convertible Debt Offering (Details 1) (USD $)	Dec. 31, 2013	Jun. 30, 2013
Schedule of deferred financing cost
Total Deferred Financing Costs	$ 133,059	$ 328,893
Deferred Financing Costs, Net, as of December 31, 2013	157,138	29,899
Convertible Note [Member]
Schedule of deferred financing cost
Legal fee, placement agent and other fees associated with the Convertible Notes offering	62,065
Total Deferred Financing Costs	62,065
Amortization of Deferred Financing Costs, as of December 31, 2013	(13,493)
Deferred Financing Costs, Net, as of December 31, 2013	48,572
June Convertible Note [Member]
Schedule of deferred financing cost
Legal fee, placement agent and other fees associated with the Convertible Notes offering	304,293
June Convertible Note Broker Warrants	60,886
Total Deferred Financing Costs	365,179
Amortization of Deferred Financing Costs, as of December 31, 2013	(123,554)
Deferred Financing Costs, Net, as of December 31, 2013	$ 241,625

XML

Factoring Agreements and Short - Term Loans (Tables)

6 Months Ended

Dec. 31, 2013

Factoring Agreements and Short Term Loans [Abstract]

Summary of Existing Factoring and Supply Agreement

Outstanding Factored Receivables	$	507,700
Less:
Advances and Deductions		(262,730	)
Unapplied Customer Credits		0
Due from Factor, Net	$	244,970

XML

Summary of Significant Accounting Policies (Details) (Licensing Agreements, USD $)	Dec. 31, 2013
Licensing Agreements
Estimated future license acquisition cost amortization expense
2014	$ 7,793
2015	7,793
2016	4,712
Estimated future license acquisition cost amortization expense	$ 20,298

XML

Stock Compensation Expense and Fair Value Measurement (Details Textual) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended								6 Months Ended		0 Months Ended	6 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Aug. 15, 2013 Equity Incentive Plan 2012 [Member]	Jul. 12, 2013 Equity Incentive Plan 2012 [Member]	Jun. 28, 2013 Equity Incentive Plan 2012 [Member]	Apr. 08, 2013 Equity Incentive Plan 2012 [Member]	Mar. 28, 2013 Equity Incentive Plan 2012 [Member]	Nov. 21, 2012 Equity Incentive Plan 2012 [Member]	Aug. 15, 2012 Equity Incentive Plan 2012 [Member]	Jul. 12, 2012 Equity Incentive Plan 2012 [Member]	Dec. 31, 2013 Equity Incentive Plan 2012 [Member]	Jul. 31, 2012 Equity Incentive Plan 2012 [Member]	Jul. 12, 2012 Equity Incentive Plan One 2012 [Member]	Dec. 31, 2013 Equity Incentive Plan One 2012 [Member]	Jul. 12, 2012 Equity Incentive Plan Two 2012 [Member]
Stock Compensation Expense (Textual)
Common stock reserved for future issuance													17,780,000	20,000,000
Stock options issued during period					1,357,500	11,400,000	50,000	500,000	500,000	500,000	400,000	4,600,000			3,600,000		1,000,000
Term of stock options					10 years	5 years	10 years	10 years	10 years	10 years	10 years	5 years			5 years		10 years
Exercise price of common stock					$ 0.05	$ 0.06	$ 0.05	$ 0.14	$ 0.17	$ 0.24	$ 0.24	$ 0.24
Option vesting period					3 years		3 years	3 years	3 years	3 years	3 years
Option vesting condition					which will vest annually at a rate of 33% beginning on the first anniversary date of the grant	which will vest annually at a rate of 33% beginning on the first anniversary of the grant date	Vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case.	Vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case.	Vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case.	Vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case.	Vest annually at a rate of 33% beginning on the first anniversary date of the grant, in each case.	which will vest annually at a rate of 33% beginning on the first anniversary date of the Merger, in each case.
Stock compensation expense	$ 161,803	$ 159,131	$ 327,606	$ 289,279
Fair value of the stock options	$ 27,119		$ 27,119
Stock option, Forfeited			1,527,500										1,000,000			2,500

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	$ (2,556,048)	$ (3,086,266)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation expense	327,606	289,279
Shares issued for services	42,625
Inventory reserves	200,000
Amortization of license acquisition costs	4,206	1,342
Amortization of deferred financing costs	130,659	62,523
Amortization of debt discount	495,559	52,704
Depreciation	234,969	11,652
Derivative liability gain	(1,245,925)	346,627
Change in operating assets and liabilities:
Accounts receivable	90,888	(905,496)
Due from factor, net	(80,880)
Prepaid royalty	370,905	272,808
License acquisition costs		(8,902)
Inventory	(300,595)	(626,677)
Prepaid expenses and other current assets	11,337	(98,528)
Prepaid inventory	(48,845)	(570,806)
Accounts payable	1,160,680	996,984
Customer deposits		13,470
Accrued expenses and other current liabilities	261,265	347,134
Due to Gold Grenade, LLC	234,550	(108,475)
Net cash used in operating activities	(667,044)	(3,010,626)
Cash flows from investing activities:
Acquisition of property and equipment	(183,351)	(139,829)
Net cash used in investing activities	(183,351)	(139,829)
Cash flows from financing activities:
Issuance of common stock, net of financing fees		771,235
Purchase of treasury stock and warrants
Proceeds from short term loans		1,335,000
Paydown of short term loans		(1,085,000)
Factoring line of credit, net		536,144
Issuance of convertible debt	550,000	2,000,000
Payments for deferred financing fees in relation to convertible debt issuance	(62,065)	(316,710)
Net cash provided by financing activities	487,935	3,240,669
Net change in cash and cash equivalents	(362,461)	90,214
Cash at beginning of period	388,892	71,532
Cash at end of period	26,431	161,746
Supplemental disclosures of cash flow information:
Interest	59,161	210,228
Income Taxes
Non-cash financing activities:
Conversion of bridge notes and convertible debt		1,925,030
Contribution from shareholder of deferred financing cost		1,156,000
Other non-cash deferred financing fees from issuance of convertible debt		137,238
Fair value of conversion features and warrants issued in connection with equity and debt financing	$ 113,091	$ 5,203,574

XML

Convertible Debt Offering (Convertible Note [Member])

6 Months Ended

Dec. 31, 2013

Convertible Note [Member]

CONVERTIBLE DEBT OFFERING

NOTE 5.                         CONVERTIBLE DEBT OFFERINGS

August Convertible Notes Offering

On August 29, 2013, the Company issued senior secured convertible notes (the “August Convertible Notes”) with an original issue discount of 12% and a conversion price of $0.068 per share (the “August Conversion Price”) for gross proceeds of $616,000.  The term of the August Convertible Notes include an eighteen-month maturity period, with partial redemption beginning on September 1, 2014. The August Convertible Notes bear interest at a rate of 8% per annum, which is paid quarterly. Interest is payable in cash or at the Company’s option in shares of common stock, provided certain conditions are met, based on a share value equal to the lesser of (a) 90% of the average of the volume weighted average price (the “VWAP”) for the 20 consecutive trading days prior to the applicable interest payment date and (b) 100% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date less $0.01. Upon any Event of Default (as defined in the August Convertible Notes), the outstanding principal amount of each August Convertible Note, plus liquidated damages, interest, a premium of 30% and other amounts owing in respect thereof through the date of acceleration, shall become, at the noteholders’ election, immediately due and payable in cash.  Commencing five days after the occurrence of any Event of Default, the interest rate on each August Convertible Note shall accrue at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law.  The August Conversion Price is subject to  “full ratchet” and other customary anti-dilution protections.

As of February 14, 2014, with the timely filing of its Form 10-Q, the Company is in compliance with the covenants of the August Convertible Notes which require the timely filing of the Company’s periodic reports with the SEC. The August Convertible Notes limit the Company’s ability to (i) incur additional indebtedness, (ii) pay dividends or make distributions to its shareholders, (iii) incur liens that would rank senior in priority or pari passu to the August Convertible Notes, or (iv) sell or otherwise dispose of any assets or rights of the Company or its subsidiaries.

In connection with the issuance of the August Convertible Notes, warrants to purchase 9,058,824 shares of the Company’s common stock (“August Convertible Note Warrants”) were issued.  The August Convertible Note Warrants are exercisable for five years on a cashless basis. The August Convertible Note Warrants are exercisable at $0.082 per share and are subject to “weighted average” and other customary anti-dilution protections (see Note 6).

August Convertible Note Redemption

On September 1, 2014, October 1, 2014, November 1, 2014, December 1, 2014, January 1, 2015 and February 1, 2015, the Company is obligated to redeem an amount equal to $51,333 and on March 1, 2015, the Company is obligated to redeem an amount equal to $308,000 (plus accrued but unpaid interest, liquidated damages and any other amounts then owing in respect of the August Convertible Notes) (collectively, the “Periodic Redemption Amount”).  In lieu of a cash redemption and subject to the Company meeting certain equity conditions described in the August Convertible Notes, the Company may elect to pay the Periodic Redemption Amount in shares of its common stock based on a conversion price equal to the lesser of (a) $0.068 per share, subject to adjustments upon certain events, and (b) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable redemption date.

Debt Discounts

The fair value of the August Convertible Note Warrants and the corresponding Debt Conversion Feature, issued on August 29, 2013, totaling $113,091 is recorded as a debt discount in the accompanying consolidated condensed balance sheet as of December 31, 2013 and is amortized as interest expense in the accompanying condensed statements of operations over the term of the August Convertible Notes using the effective interest method (see Note 6).

Original Issue Discount

For certain convertible debt issue, the Company may provide the debt holder with an original issue discount. The August Convertible Notes were issued with an original issue discount of 12%. The original issue discount is recorded as debt discount, reducing the face amount of each August Convertible Note and is amortized to interest expense over the term of the August Convertible Notes.

August Convertible Note Face Value	$	616,000
Debt Discount
August Convertible Notes – Issued Warrant Derivative		87,264
Conversion Feature Derivative		25,827
Original Issue Discount		66,000
Total Debt Discount	$	179,091
Amortization of Debt Discount, as of December 31, 2013		(38,933	)
Debt Discount, Net	$	140,158
August Convertible Notes Carrying Value at December 31, 2013	$	475,842

Deferred Financing Costs

Transaction Fees

The Company paid $12,065, collectively, in legal fees to Gottbetter & Partners and Loeb & Loeb, and $50,000 in professional fees to the lead investor in the August Convertible Notes offering.

Legal fees and other fees associated with the August Convertible Notes offering	$	62,065
Total Deferred Financing Costs	$	62,065
Amortization of Deferred Financing Costs, as of December 31, 2013		(13,493	)
Deferred Financing Costs, Net, as of December 31, 2013	$	48,572

June Convertible Notes Offering

On June 20, 2013, the Company issued $1,500,000 senior secured convertible notes (the “June Convertible Notes”) with an original issue discount of 12%, and a conversion price of $0.068 per share (the “June Conversion Price”), for gross proceeds of $1,680,000.  The term of the June Convertible Notes includes an eighteen-month maturity period, with partial redemptions beginning on June 1, 2014. The June Convertible Notes bear interest at 8% per annum, which is paid quarterly beginning on November 1, 2013. Interest is payable in cash or at the Company’s option in shares of the Company’s common stock, provided certain conditions are met, based on a share value equal to the lesser of (a) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date and (b) 100% of the average of the VWAP for the 20 consecutive trading days prior to the applicable interest payment date less $0.01.  Upon any Event of Default (as defined in the June Convertible Notes), the outstanding principal amount of the June Convertible Notes plus liquidated damages, interest, a premium of 30% and other amounts owing in respect thereof through the date of acceleration, shall become, at the holders’ election, immediately due and payable in cash.  Commencing five days after the occurrence of any Event of Default, the interest rate on the June Convertible Notes shall accrue at an interest rate equal to the lesser of 18% per annum or the maximum rate permitted under applicable law.  The June Conversion Price is subject to  “full ratchet” and other customary anti-dilution protections.

As of February 14, 2014, with the timely filing of its Form 10-Q, the Company is in compliance with the covenants of the June Convertible Notes which require the timely filing of the Company’s periodic reports with the SEC. The June Convertible Notes limit the Company’s ability to (i) incur additional indebtedness, (ii) pay dividends or make distributions to its shareholders, (iii) incur liens that would rank senior in priority or pari passu to the June Convertible Notes, or (iv) sell or otherwise dispose of any assets or rights of the Company or its subsidiaries.

In connection with the issuance of the June Convertible Notes, warrants to purchase 24,705,882 shares of the Company’s common stock (“June Convertible Note Warrants”) were issued. The June Convertible Note Warrants are exercisable for five years on a cashless basis. The June Convertible Note Warrants are exercisable at $0.082 per share and are subject to “weighted average” and other customary anti-dilution protections (see Note 6).

June Convertible Note Redemption

On June 1, 2014, July 1, 2014, August 1, 2014, September 1, 2014, October 1, 2014 and November 1, 2014, the Company is obligated to redeem an amount equal to $140,000 and on December 1, 2014, the Company is obligated to redeem an amount equal to $840,000 (plus accrued but unpaid interest, liquidated damages and any other amounts then owing in respect of the June Convertible Notes) (collectively, the “June Periodic Redemption Amount”).  In lieu of a cash redemption and subject to the Company meeting certain equity conditions described in the June Convertible Notes, the Company may elect to pay the June Periodic Redemption Amount in shares of its common stock based on a conversion price equal to the lesser of (a) $0.068 per share, subject to adjustments upon certain events, and (b) 90% of the average of the VWAP for the 20 consecutive trading days prior to the applicable redemption date.

Debt Discounts

The fair value of the June Convertible Note Warrants and the corresponding Debt Conversion Feature, issued on June 20, 2013, totaling $1,423,177 is recorded as a debt discount in the accompanying condensed consolidated balance sheet as of December 31, 2013 and is amortized as interest expense in the accompanying condensed consolidated statements of operations over the term of the June Convertible Notes using the effective interest method (see Note 6).

Original Issue Discount

For certain convertible debt issue, the Company may provide the debt holder with an original issue discount. The June Convertible Notes were issued with an original issue discount of 12%. The original issue discount is recorded to debt discount, reducing the face amount of each June Convertible Note and is amortized to interest expense over the term of the June Convertible Notes.

June Convertible Notes Face Value	$	1,680,000
Debt Discount
June Convertible Notes – Issued Warrant Derivative		752,126
Conversion Feature Derivative		491,051
Original Issue Discount		180,000
Total Debt Discount	$	1,423,177
Amortization of Debt Discount, as of December 31, 2013		(481,516	)
Debt Discount, Net	$	941,661
June Convertible Notes Carrying Value at December 31, 2013	$	738,339

Deferred Financing Costs

Transaction Fees

The Company paid Gottbetter Capital Markets (“GCM”) who acted as the sole placement agent for the June Convertible Notes offering a commission of 7.2% of the first $1,400,000 funds raised in the June Convertible Notes offering for a total payment of $100,000. In addition, GCM received five-year broker warrants to purchase approximately 1.9 million shares of the Company’s common stock at an exercise price of $0.082 per share (the “June Convertible Note Broker Warrants”). The June Convertible Note Broker Warrants are identical to the June Convertible Note Warrants in all material respects. The Company also paid $117,446 in legal fees to Gottbetter & Partners and $85,207 in professional fees to the lead investor in the June Convertible Notes offering.  The following table sets forth a summary of the fees and costs associated with the June Convertible Notes offering.

Placement agent and other fees associated with the June Convertible Notes offering	$	304,293
June Convertible Note Broker Warrants		60,886
Total Deferred Financing Costs	$	365,179
Amortization of Deferred Financing Costs, as of December 31, 2013		(123,554	)
Deferred Financing Costs, Net, as of December 31, 2013	$	241,625

December 2012 Convertible Notes Offering

On December 21, 2012 the Company issued senior secured convertible notes (the “Convertible Notes”).  The term of the Convertible Notes include an eight month maturity period and an annual interest rate of 12% which is accrued until payment or until the Convertible Notes are converted into equity. The Convertible Notes were issued at a price of $200,000 per unit, for total gross proceeds of $2,000,000 with an original issue discount of 0.2%.

The Convertible Notes are convertible at a per share conversion price of $0.25, which is subject to a one-time reset right (“Conversion Price Reset”) as well as “weighted average” and other customary anti-dilution protections (“Debt Conversion Feature”). The Conversion Price Reset will be available on the earlier of (the “Reset Date”) (i) the date of maturity of the 12% Notes or (ii) the completion of a subsequent financing by the Company of at least $5,000,000, if the closing price of the Company’s stock is less than $0.30 on the Reset Date. For (i) the conversion price after the reset will be equal to 70% of the 5-day VWAP immediately preceding the Reset Date. For (ii) the Conversion Price after the reset will be equal to 70% of 5-day VWAP immediately after the Reset Date.

In connection with the issuance of Convertible Notes, 8,000,000 five-year cashless exercise warrants (“Convertible Note Warrants”) were issued with “weighted average” and other customary anti-dilution protections. 4,000,000 Convertible Note Warrants are exercisable at $0.50 and 4,000,000 Convertible Note Warrants are exercisable at $1.00 (see Note 6 for further detail).

As of June 20, 2013, the Convertible Notes and the Convertible Note Warrants were converted into equity. The Convertible Notes were converted at a per share price of $0.07, as the Company’s stock price was less than $0.30 on the Reset Date, for 30,276,190 shares. The Convertible Note Warrants were converted into 7,000,000 shares of the Company’s common stock.

Debt Discounts

Convertible Note Warrants and Debt Conversion Feature

The fair value of the Convertible Note Warrants and the Debt Conversion Feature, issued as of December 21, 2012, totaling $1,353,720 was recorded as a debt discount in the accompanying balance sheet and was amortized as interest expense in the accompanying statement of operations over the term of the Convertible Note using the effective interest method (see Note 6 for further detail). As of June 30, 2013, the full value of this debt discount had been amortized as a result of the conversion of the Convertible Notes and Convertible Note Warrants into equity.

Deferred Financing Costs

Transaction Fees

The Company paid Aegis Capital Corp. (“Aegis”), who acted as the sole placement agent for the Convertible Notes Offering a commission of 10% of the funds raised in the Convertible Notes Offering and a 3% non-accountable reimbursement of its expenses, for a total payment of $406,900, which is recorded as a deferred financing cost in the accompanying balance sheet.

The Company incurred additional fees of $96,556 for legal and escrow agent fees in connection with the Convertible Notes Offering, which are recorded as a deferred financing cost in the accompanying balance sheet.

Convertible Note Broker Warrants

In addition, Aegis received five-year warrants (the “Convertible Note Broker Warrants”) to purchase 1,600,000 shares of the Company’s common stock. The Convertible Note Broker Warrants were issued with “weighted average” and other customary anti-dilution protections. The Convertible Note Broker Warrants are identical to the Convertible Note Warrants in all material respects, except that they are exercisable at $0.25. As of June 20, 2013, the Convertible Note Broker Warrants were considered converted into 1,440,000 shares of common stock based on the same conversion terms as the Convertible Note Warrants. The Convertible Note Broker Warrants were valued at approximately $137,238 based on a Black-Scholes model (see Note 6 for further detail).

Third Party Share Sale

The Convertible Note holders were sold 4,000,000 free trading shares by non-affiliated, third party shareholders of the Company at par value. Although the Company was not a party to the sale of these shares by third party shareholders, per FASB ASC Topic 718, the fair value of this non-affiliated third party transaction is recognized by the Company as a deferred financing cost of the Convertible Note transaction. Additionally, the Company will provide no reimbursement or compensation to the selling shareholders of the 4,000,000 free trading shares. As such, the Company does not anticipate recognizing any further expenses in relation to this third-party transaction. The fair value of this third party transaction of $1,156,000 is recorded under deferred financing costs in the accompanying balance sheet.

XML

Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Dec. 31, 2013
Summary of consists of potential common shares
Total Shares	121,355,281
Warrant [Member]
Summary of consists of potential common shares
Total Shares	69,682,783
Stock options [Member]
Summary of consists of potential common shares
Total Shares	17,780,000
Convertible Debt [Member]
Summary of consists of potential common shares
Total Shares	33,764,706

XML

Commitments and Contingencies (Details Textual) (USD $)	6 Months Ended		6 Months Ended			6 Months Ended															3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013 PPO Offering Registration Rights [Member]	Dec. 31, 2013 Convertible Note Registration Rights Agreement [Member]	Dec. 31, 2013 Registration Agreement [Member]	Dec. 31, 2013 Minimum [Member]	Dec. 31, 2013 Maximum [Member]	Dec. 31, 2013 Royalty Agreement One [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreement One [Member] Maximum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period One [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Two [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Two [Member] Maximum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Three [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Three [Member] Maximum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Four [Member] Minimum [Member]	Dec. 31, 2013 Royalty Agreements One Contract Period Four [Member] Maximum [Member]	Dec. 31, 2013 Royalty Agreements Two [Member]	Dec. 31, 2013 Royalty Agreements Two Period One [Member]	Dec. 31, 2013 Royalty Agreements Two Period Two [Member]	Dec. 31, 2013 Royalty Agreements Two Period Three [Member]	Dec. 31, 2013 Operating Lease Agreement One [Member]	Dec. 31, 2012 Operating Lease Agreement One [Member]	Dec. 31, 2013 Operating Lease Agreement One [Member]	Dec. 31, 2012 Operating Lease Agreement One [Member]	Dec. 31, 2013 Operating Lease Agreement Two [Member]	Dec. 31, 2012 Operating Lease Agreement Two [Member]	Dec. 31, 2013 Operating Lease Agreement Two [Member]	Dec. 31, 2012 Operating Lease Agreement Two [Member]	Dec. 31, 2013 Royalty Agreements Three [Member]	Dec. 31, 2013 Royalty Agreements Three Period One [Member]	Dec. 31, 2013 Royalty Agreements Three Period Two [Member]	Dec. 31, 2013 Royalty Agreements Three Period Three [Member]
Commitments and Contingencies (Textual)
Guaranteed royalty payment under agreements								$ 4,686,125	$ 4,985,000	$ 1,000,000	$ 925,000	$ 1,000,000	$ 1,285,000	$ 1,188,625	$ 1,572,500	$ 1,700,000	$ 600,000	$ 100,000	$ 225,000	$ 275,000									$ 100,000	$ 33,333	$ 33,333	$ 33,334
Term of operating lease																							1 year				5 months
Operating lease monthly rent payment																							1,785				1,500
Number of days in which bond amount need to deposit on entry of injunction	7 days
Operating lease rent expense included in general and administrative expenses																					5,355	5,355	10,710	10,620	4,500	0	9,000	0
Common stock, shares authorized	300,000,000	300,000,000			300,000,000
Common stock, shares issued	155,829,276	155,301,468			155,829,276
Common stock, shares outstanding	155,491,438	155,301,468			155,591,438
Common stock, Voting rights	Each share of common stock entitles the holder to one vote on all matters submitted to a vote.
Description of registration payment arrangement			(i) The Company's common stock underlying the Bridge Warrants (as defined in Note 6), (ii) common stock underlying the PPO Units (as defined in Note 6) sold or to be sold in the Offering, and (iii) common stock underlying the Investor Warrants (as defined in Note 6) (including securities issued in the Offering as a result of the conversion of the Bridge Notes (as defined in Note 6), but not common stock that is issuable upon exercise of the broker warrants issued to the placement agent for the Offering) (collectively, the "Registrable Securities") no later than October 29, 2012 (the "Filing Date").	(i) The Common Stock underlying the Warrants and (ii) the Common Stock underlying the Notes (collectively, the "Convertible Note Registrable Securities") within 45 days from the final closing of the Offering (the "Filing Date"), and to use its commercially reasonable efforts to cause the registration statement to become effective no later than 90 days after it is filed (the "Effectiveness Date").
Liquidated damages maximum liability rate	1.00%
Penalty accrued as percentage of original purchase price paid by investor	10.00%
Percentage of interest rate payable to investor	8.00%
Accrued expenses	206,381
Registration payment arrangement default penalty percentage						0.50%	6.00%
Accrued settlement costs	$ 700,000

XML

Prepaid Royalties (Tables)

6 Months Ended

Dec. 31, 2013

Prepaid Royalties [Abstract]

Schedule of contractual commitment

	Total		Less than 1 year		1 – 3 years		3 - 5 years		More than 5 years
License agreement obligations	$	7,417,125	$	1,185,278	$	3,389,722	$	2,842,125	$	0
Operating lease obligation	$	0	$	0	$	0	$	0	$	0
Total	$	7,417,125	$	1,185,278	$	3,389,722	$	2,842,125	$	0